0001683168-19-003653.txt : 20191114 0001683168-19-003653.hdr.sgml : 20191114 20191114172512 ACCESSION NUMBER: 0001683168-19-003653 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191114 DATE AS OF CHANGE: 20191114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37937 FILM NUMBER: 191221717 BUSINESS ADDRESS: STREET 1: 40 SPEEN STREET, SUITE 102 CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 40 SPEEN STREET, SUITE 102 CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 10-Q 1 xenetic_10q-093019.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q



x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 or

¨ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to

Commission File Number: 001-37937

XENETIC BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)


Nevada (State or other jurisdiction of incorporation or organization)	45-2952962 (IRS Employer Identification No.)

40 Speen Street, Suite 102 Framingham, Massachusetts 01701 (Address of principal executive offices and zip code) 781-778-7720 (Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	XBIO	The NASDAQ Stock Market LLC

Purchase Warrants	XBIOW	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days): Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2): Yes ¨ No x

As of November 8, 2019, the number of outstanding shares of the registrant’s common stock was 5,755,141.

XENETIC BIOSCIENCES, INC.

FORM 10-Q

QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019

PART I	FINANCIAL INFORMATION

Item 1	Condensed Consolidated Financial Statements:	3

	Condensed Consolidated Balance Sheets as of September 30, 2019 (Unaudited) and December 31, 2018	3

	Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2019 and 2018	4

	Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the three and nine months ended September 30, 2019 and 2018	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2019 and 2018	8

	Notes to Condensed Consolidated Financial Statements	9

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3	Quantitative and Qualitative Disclosures About Market Risk	30

Item 4	Controls and Procedures	30

PART II	OTHER INFORMATION

Item 1	Legal Proceedings	31

Item 1A	Risk Factors	31

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	31

Item 3	Defaults Upon Senior Securities	31

Item 4	Mine Safety Disclosures	31

Item 5	Other Information	31

Item 6	Exhibits	32

Signatures		34

PART I – FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2019			December 31, 2018
	(Unaudited)
ASSETS
Current assets:
Cash	$	12,044,472		$	571,605
Restricted cash		–			66,510
Prepaid expenses and other		876,816			555,856
Total current assets		12,921,288			1,193,971
Property and equipment, net		1,590			4,956
Goodwill		–			3,283,379
Indefinite-lived intangible assets		9,243,128			9,243,128
Other assets		709,113			705,660
Total assets	$	22,875,119		$	14,431,094

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	1,158,555		$	934,147
Accrued expenses and other current liabilities		538,734			665,641
Total current liabilities		1,697,289			1,599,788

Deferred tax liability		2,918,518			2,918,518
Total liabilities		4,615,807			4,518,306

Commitments (Note 11)
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized
Series B, $0.001 par value: 1,804,394 shares issued and outstanding as of September 30, 2019 and December 31, 2018		1,804			1,804
Series A, $0.001 par value: 970,000 shares issued and outstanding as of September 30, 2019 and December 31, 2018		970			970
Common stock, $0.001 par value; 12,500,000 shares authorized as of September 30, 2019 and December 31, 2018; 5,660,481 and 810,856 shares issued as of September 30, 2019 and December 31, 2018, respectively; 5,633,490 and 783,865 shares outstanding as of September 30, 2019 and December 31, 2018, respectively		5,660			811
Additional paid in capital		188,116,697			168,170,244
Accumulated deficit		(164,838,373	)		(153,233,595	)
Accumulated other comprehensive income		253,734			253,734
Treasury stock		(5,281,180	)		(5,281,180	)
Total stockholders' equity		18,259,312			9,912,788
Total liabilities and stockholders' equity	$	22,875,119		$	14,431,094

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	THREE MONTHS ENDED SEPTEMBER 30,						NINE MONTHS ENDED SEPTEMBER 30,
	2019			2018			2019			2018
Operating costs and expenses:
Research and development	$	(3,520,638	)	$	(735,879	)	$	(4,471,939	)	$	(2,369,219	)
General and administrative		(2,142,505	)		(1,079,008	)		(3,896,657	)		(3,267,597	)
Goodwill impairment (Note 6)		(3,283,379	)		–			(3,283,379	)		–
Loss from operations		(8,946,522	)		(1,814,887	)		(11,651,975	)		(5,636,816	)

Other income (expense):
Other income (expense)		(223	)		2,292			267			(24,838	)
Interest income		46,617			59			46,930			424
Total other income (expense)		46,394			2,351			47,197			(24,414	)

Net loss	$	(8,900,128	)	$	(1,812,536	)	$	(11,604,778	)	$	(5,661,230	)

Deemed dividend		(1,404,932	)		–			(5,284,379	)		–

Net loss applicable to common stockholders	$	(10,305,060	)	$	(1,812,536	)	$	(16,889,157	)	$	(5,661,230	)

Basic and diluted loss per share	$	(2.67	)	$	(2.31	)	$	(9.07	)	$	(7.58	)

Weighted-average shares of common stock outstanding, basic and diluted		3,862,936			783,865			1,861,867			746,629

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

THREE MONTHS ENDED SEPTEMBER 30, 2019

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity
Balance as of June 30, 2019		2,774,394	$	2,774		949,218	$	948	$	171,352,760		$	(155,938,245	)	$	253,734	$	(5,281,180	)	$	10,390,791

Issuance of common stock and warrants in July 2019 public offering, net of issuance costs		–		–		1,746,666		1,747		13,420,203			–			–		–			13,421,950
Issuance of common stock in connection with purchase of in-process research and development		–		–		624,995		625		3,030,601			–			–		–			3,031,226
Exercise of pre-funded warrants		–		–		450,000		450		4,050			–			–		–			4,500
Exercise of purchase warrants		–		–		1,889,602		1,890		(1,890	)		–			–		–			–
Issuance of warrants in connection with reverse stock split		–		–		–		–		63,536			–			–		–			63,536
Deemed dividend related to Series B Preferred Stock down round provision		–		–		–		–		1,404,932			–			–		–			1,404,932
Accretion of deemed dividend related to Series B Preferred Stock down round provision		–		–		–		–		(1,404,932	)		–			–		–			(1,404,932	)
Share-based expense		–		–		–		–		232,437			–			–		–			232,437
Common stock awards to vendors		–		–		–		–		15,000			–			–		–			15,000
Net loss		–		–		–		–		–			(8,900,128	)		–		–			(8,900,128	)
Balance as of September 30, 2019		2,774,394	$	2,774		5,660,481	$	5,660	$	188,116,697		$	(164,838,373	)	$	253,734	$	(5,281,180	)	$	18,259,312

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

NINE MONTHS ENDED SEPTEMBER 30, 2019

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity

Balance as of January 1, 2019		2,774,394	$	2,774		810,856	$	811	$	168,170,244		$	(153,233,595	)	$	253,734	$	(5,281,180	)	$	9,912,788

Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs		–		–		86,667		87		2,698,963			–			–		–			2,699,050
Issuance of common stock and warrants in July 2019 public offering, net of issuance costs		–		–		1,746,666		1,747		13,420,203			–			–		–			13,421,950
Issuance of common stock in connection with purchase of in-process research and development		–		–		624,995		625		3,030,601			–			–		–			3,031,226
Exercise of pre-funded warrants		–		–		492,417		492		4,517			–			–		–			5,009
Exercise of purchase warrants		–		–		1,889,602		1,890		(1,890	)		–			–		–			–
Issuance of common stock to vendor		–		–		7,836		7		(7	)		–			–		–			–
Issuance of warrants in connection with reverse stock split		–		–		–		–		63,536			–			–		–			63,536
Issuance of common stock to adjust for reverse split rounding		–		–		1,442		1		(1	)		–			–		–			–
Deemed dividend related to Series B Preferred Stock down round provision		–		–		–		–		5,284,379			–			–		–			5,284,379
Accretion of deemed dividend related to Series B Preferred Stock down round provision		–		–		–		–		(5,284,379	)		–			–		–			(5,284,379	)
Share-based expense		–		–		–		–		683,104			–			–		–			683,104
Common stock awards to vendors		–		–		–		–		47,427			–			–		–			47,427
Net loss		–		–		–		–		–			(11,604,778	)		–		–			(11,604,778	)
Balance as of September 30, 2019		2,774,394	$	2,774		5,660,481	$	5,660	$	188,116,697		$	(164,838,373	)	$	253,734	$	(5,281,180	)	$	18,259,312

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

THREE MONTHS ENDED SEPTEMBER 30, 2018

	Preferred Stock				Common Stock									Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital		Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity
Balance as of June 30, 2018		2,774,394	$	2,774		810,856	$	811	$	167,590,260	$	(149,781,831	)	$	253,734	$	(5,281,180	)	$	12,784,568

Share-based expense		–		–		–		–		306,051		–			–		–			306,051
Common stock awards to vendors		–		–		–		–		17,427		–			–		–			17,427
Net loss		–		–		–		–		–		(1,812,536	)		–		–			(1,812,536	)
Balance as of September 30, 2018		2,774,394	$	2,774		810,856	$	811	$	167,913,738	$	(151,594,367	)	$	253,734	$	(5,281,180	)	$	11,295,510

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

NINE MONTHS ENDED SEPTEMBER 30, 2018

	Preferred Stock						Common Stock									Accumulated Other
	Number of Shares			Par Value ($0.001)			Number of Shares		Par Value ($0.001)		Additional Paid in Capital		Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity

Balance as of January 1, 2018		3,090,742		$	3,090			753,659	$	754	$	165,258,198	$	(145,933,137	)	$	253,734	$	(5,281,180	)	$	14,301,459

Exercise of warrants		–			–			30,834		31		1,479,969		–			–		–			1,480,000
Conversion of Series B preferred stock to shares of common stock		(316,348	)		(316	)		26,363		26		290		–			–		–			–
Share-based expense		–			–			–		–		1,123,000		–			–		–			1,123,000
Common stock awards to vendors		–			–			–		–		52,281		–			–		–			52,281
Net loss		–			–			–		–		–		(5,661,230	)		–		–			(5,661,230	)
Balance as of September 30, 2018		2,774,394		$	2,774			810,856	$	811	$	167,913,738	$	(151,594,367	)	$	253,734	$	(5,281,180	)	$	11,295,510

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	NINE MONTHS ENDED SEPTEMBER 30,
	2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(11,604,778	)	$	(5,661,230	)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development		3,031,226			–
Goodwill impairment		3,283,379			–
Depreciation		3,366			12,540
Amortization of right of use asset		16,629			–
Gain on sale of property and equipment		(2,000	)		(15,437	)
Share-based expense		683,104			1,123,000
Issuance of warrants in connection with reverse stock split		63,536			–
Vendor share-based expense		47,427			52,281
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(297,712	)		(310,239	)
Accounts payable, accrued expenses and other liabilities		54,171			(623,992	)
Net cash used in operating activities		(4,721,652	)		(5,423,077	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment		2,000			22,500
Net cash provided by investing activities		2,000			22,500

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants in July 2019 public offering		13,421,950			–
Net proceeds from issuance of common stock and warrants in March 2019 registered direct offering		2,699,050			–
Proceeds from exercise of warrants		5,009			1,480,000
Net cash provided by financing activities		16,126,009			1,480,000

Net change in cash and restricted cash		11,406,357			(3,920,577	)
Cash and restricted cash at beginning of period		638,115			5,599,572

Cash and restricted cash at end of period	$	12,044,472		$	1,678,995

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	8		$	599

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right of use asset acquired in exchange for lease liability	$	43,330		$	–
Issuance of common stock to vendor	$	7		$	–
Issuance of common stock to acquire in-process research and development	$	3,031,226		$	–
Issuance of common stock to adjust for Reverse Stock Split	$	1		$	–
Issuance of common stock from cashless exercise of purchase warrants	$	1,890		$	–
Conversion of Series B preferred stock to common stock	$	–		$	316

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1.	The Company

Background

Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART™, a personalized Chimeric Antigen Receptor (“CAR”) T cell platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (the “Institute”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (“IBCH”), is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. On March 1, 2019, the Company entered into agreements with Hesperix S.A. (“Hesperix”) and Opko Pharmaceuticals LLC (“OPKO”) to acquire the XCART technology (the “Transaction”) and closed the Transaction on July 19, 2019 concurrent with the completion of an approximate $15 million public offering (the “Offering”). For additional information regarding the Transaction, see Note 4 – “Acquisitions.”

Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen^™, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid (“PSA”) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics.

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.

The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various U.S. federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated.

Going Concern and Management’s Plan

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On March 7, 2019, the Company closed on a $3.1 million registered direct common stock offering resulting in $2.7 million of net proceeds to the Company. On July 19, 2019, the Company completed the Offering resulting in $13.4 million of net proceeds to the Company. The Company believes that these financings, coupled with the Company’s existing resources, will be adequate to fund the Company’s operations as a going concern. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives and continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

2.	Summary of Significant Accounting Policies

Preparation of Interim Financial Statements

The accompanying condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 and amended on April 30, 2019.

These condensed consolidated financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As a result, the financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

On June 25, 2019, the Company effected a reduction, on a 1 for 12 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every 12 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock were proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1 for 12 basis; and (iv) the number of shares of common stock into which each share of preferred stock could be converted were proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this Reverse Stock Split.

Certain prior period amounts have been reclassified to conform to the presentation for the current period.

Principles of Consolidation

The condensed consolidated financial statements of the Company include the accounts of Hesperix and Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share

The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during each period, except where such non-participating securities would be anti-dilutive.

For the three and nine months ended September 30, 2019 and 2018, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, and that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 Revenue from Contracts with Customers. ASU 2018-07 was effective for the Company in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04: Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment that eliminated the requirement to calculate implied fair value of goodwill to measure a goodwill impairment charge. Instead, the new guidance requires entities to take an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company no later than 2020. The Company adopted ASU 2017-04 in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

In February 2016, FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Subsequently, in July 2018, the FASB issued ASU 2018-11, Lease (Topic 842): Targeted Improvements, which provides a number of practical expedients in transition. The Company adopted ASU 2016-02 effective January 1, 2019 and elected a package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of lease, classification of a lease or any initial direct costs. The Company has also elected to use the hindsight practical expedients. The adoption did not have a material impact on the Company’s condensed consolidated financial statements, resulted in an approximate $43,000 increase in total assets and total liabilities in our condensed consolidated balance sheet and did not have any effect on accumulated deficit at the beginning of 2019. See Note 11 for further information.

3.	Significant Strategic Collaborations – Related Parties

The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd. (“Takeda”), Serum Institute of India (“Serum Institute”), Pharmsynthez and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through September 30, 2019. No amounts were recognized as revenue related to these agreements during the three and nine months ended September 30, 2019 or 2018. The related party ownership interest in the Company materially changed in connection with the Offering.

4.	Acquisitions

On March 1, 2019 (the “Signing Date”) the Company entered into agreements with Hesperix and Opko to acquire the XCART technology. The Company entered into a Share Purchase Agreement, as amended (the “Share Purchase Agreement”), with Hesperix, the owners of Hesperix (each, a “Seller” and collectively, the “Sellers”), and Alexey Andreevich Vinogradov, as the representative of each Seller, pursuant to which the Company purchased from Sellers all of the issued and outstanding shares of capital stock of Hesperix.

Under the terms of the Share Purchase Agreement, the Company issued to Sellers an aggregate of Four Hundred Six Thousand Two Hundred Forty-Six (406,246) shares of the Company’s common stock (the “Transaction Shares”) at the time of the closing. In addition, the Share Purchase Agreement contains customary representations and warranties relating to each Seller and about the condition of the Company and Hesperix. The Company issued the Transaction Shares pursuant to a registration statement on Form S-4.

On the Signing Date and in connection with the Transaction, Hesperix entered into an assignment agreement (the “Hesperix Assignment Agreement”) with IBCH, Pharmsynthez, and certain other parties thereto (collectively, the “Assignors”), pursuant to which, the Assignors have agreed, among other things, to sell, assign, transfer, and convey unto Hesperix all of their individual right, title, and interest throughout the world in and to patents related to “Articles And Methods Directed To Personalized Therapy Of Cancer,” and the related know-how. Hesperix has agreed to pay each of IBCH and Pharmsynthez a royalty rate in the low single digit range based on the net sales of products in each country in which, in the absence of the Hesperix Assignment Agreement, the manufacture, use, offer for sale, sale, or importation of such product would infringe a valid claim of a patent.

Also on the Signing Date, the Company entered into an assignment agreement with OPKO (the “OPKO Assignment Agreement”), pursuant to which the Company will acquire and accept, all of OPKO’s right, title and interest in and to that certain Intellectual Property License Agreement (the “IP License Agreement”), entered into between the Institute and OPKO regarding certain patents related to “Articles And Methods Directed To Personalized Therapy Of Cancer” and in which the Institute agreed to grant an exclusive royalty-bearing license, to the patent rights owned by the Institute to OPKO, and OPKO has agreed to pay the Institute a royalty rate in the low single digit range based on the net sales of products in each country in which, in the absence of the IP License Agreement, the manufacture, use, offer for sale, sale, or importation of such product would infringe a valid claim of a patent or pending application.

Under the terms of the OPKO Assignment Agreement and the IP License Agreement, the Company issued One Hundred Sixty Four Thousand Sixty Two (164,062) shares of the Company’s common stock to OPKO and Fifty-Four Thousand Six Hundred Eighty Seven (54,687) shares of the Company’s common stock to the Institute at the time of the closing. In addition, the OPKO Assignment Agreement contains customary representations and warranties relating to OPKO and the IP License Agreement.

On July 19, 2019, the Company closed the Transaction (the “Closing Date”), acquiring in-process research and development (“IPR&D”) related to certain intellectual property rights with respect to the XCART technology. The acquisition did not meet the business combination requirements and, as a result, was accounted for as an asset acquisition. The total consideration for the IPR&D was approximately $4.1 million, which represented the value of the common shares issued of $3.0 million utilizing the market price of the Company’s stock price at the Closing Date and approximately $1.1 million of transaction costs. As there was no future alternative use for the IPR&D, the Company recorded expense of $3.0 million to Research and development expense and $1.1 million to General and administrative expense for the transaction costs in the three and nine months ended September 30, 2019.

5.	Property and Equipment, net

Property and equipment, net consists of the following:

	September 30, 2019			December 31, 2018
Office and computer equipment	$	42,289		$	42,289
Leasehold improvements		–			26,841
Furniture and fixtures		14,738			20,263
Property and equipment – at cost		57,027			89,393
Less accumulated depreciation		(55,437	)		(84,437	)
Property and equipment – net	$	1,590		$	4,956

Depreciation expense was approximately $1,000 for the three months ended September 30, 2019 and 2018, respectively, and approximately $3,000 and $13,000 for the nine months ended September 30, 2019 and 2018, respectively.

6.	Goodwill and Indefinite-Lived Intangible Assets

Goodwill

Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired and is not amortized. The Company assesses goodwill for impairment at least annually, or when events or changes in the business environment indicate that the carrying value may not be fully recoverable. The Company performs its annual impairment review during the fourth quarter at the reporting unit level. Goodwill may be considered impaired if the carrying value of the reporting unit, including goodwill, exceeds the reporting unit’s fair value. The Company is comprised of one reporting unit. The Company experienced a significant decline in its stock price during the three months ended September 30, 2019 resulting in a drop in its market capitalization indicating potential impairment. The Company determined the fair value of the reporting unit using its market capitalization, concluding that the fair value of the reporting unit is less than the carrying amount in excess of Goodwill, therefore fully impairing Goodwill. Goodwill impairment is presented within continuing operations in the condensed consolidated statements of operations. A reconciliation of the change in the carrying value of Goodwill is as follows:

Balance as of January 1, 2018	$	3,283,379
No changes		–
Balance as of December 31, 2018		3,283,379
Impairment		(3,283,379	)
Balance as of September 30, 2019	$	–

Indefinite-Lived Intangible Assets

The Company’s indefinite-lived intangible asset, OncoHist, is IPR&D relating to the Company’s business combination with SymbioTec in 2012. The carrying value of the IPR&D was approximately $9.2 million as of September 30, 2019 and December 31, 2018, respectively. IPR&D is required to be tested annually until the project is completed or abandoned. The IPR&D is not yet commercialized and, therefore, has not yet begun to be amortized as of September 30, 2019. The Company assesses IPR&D for impairment at least annually as of October 1 or when events or changes in circumstances indicate that the carrying value may be impaired. No impairment was recorded during the nine months ended September 30, 2019 nor during the year ended December 31, 2018.

7.	Fair Value Measurements

Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. The carrying amounts of certain of the Company’s financial instruments approximates fair value due to their short maturities.

8.	Stockholders’ Equity

The Offering

On July 17, 2019, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Maxim Group LLC (the “Underwriter”), relating to the Company’s Offering of 1,730,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), Prefunded Warrants to purchase 570,000 shares of Common Stock (the “Prefunded Warrants”), and warrants to purchase 2,300,000 shares of the Common Stock (the “Purchase Warrants,” and together with the Shares and the Prefunded Warrants, the "Firm Securities"). Each Share was sold together with one Purchase Warrant at a combined public offering price of $6.50 per Share and Purchase Warrant. Each Pre-funded Warrant purchased was sold together with one Purchase Warrant at a combined public offering price of $6.49 per Prefunded Warrant and Purchase Warrant. The Prefunded Warrants were exercisable beginning on July 17, 2019 at an exercise price of $0.01 per share. The holders of the Prefunded Warrants will not have the right to exercise any portion of the Prefunded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Prefunded Warrants. The Prefunded Warrants had an intrinsic value of approximately $3.1 million. Pursuant to the Underwriting Agreement, the Company also granted the Underwriter a 45-day option to purchase up to an additional 345,000 shares of Common Stock and/or Purchase Warrants to purchase up to 345,000 shares of Common Stock (the "Additional Securities," and together with the Firm Securities, the "Securities"), at the public offering price less discounts and commissions.

The Securities were offered, issued, and sold pursuant to an effective Registration Statement on Form S-1 (Reg. No. 333-231508) and accompanying prospectus filed with the SEC under the Securities Act of 1933, as amended.

On the Closing Date, the Company completed the Offering resulting in gross proceeds to the Company of approximately $15.0 million before deducting the underwriting discount and offering fees and expenses payable by the Company. In addition, on the Closing Date, the Underwriter exercised its overallotment option with respect to 160,000 Purchase Warrants, resulting in additional gross proceeds of $1,600. The Company intends to use the net proceeds from the Offering of approximately $13.4 million to fund its research, development and clinical programs, including the development of the XCART technology acquired in the Transaction, and for other general corporate purposes. Prefunded Warrants to purchase 450,000 shares of Common Stock were exercised during the three and nine months ended September 30, 2019 resulting in $4,500 of net proceeds to the Company.

The Purchase Warrants are immediately exercisable at a price of $13.00 per share of Common Stock and expire five years from the date of issuance. The warrants began trading on NASDAQ on July 23, 2019 under the symbol “XBIOW.” The Purchase Warrants also provide that if the weighted-average price of Common Stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each Purchase Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $4.61 per share, for a total of approximately $11.3 million. The fair value of these warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 1.83%, an expected life of 5 years and an expected volatility of 141.89%. Purchase Warrants to purchase approximately 1.9 million shares of Common Stock were exercised on a cashless one-for-one basis during the three and nine months ended September 30, 2019.

Common Stock

On July 16, 2019, the Company, in connection with the Offering, entered into a consent agreement with certain holders of warrants to purchase shares of the Company’s Common Stock whose consent was sought in connection with the Offering. In consideration of the holders’ consent, the Company agreed to (i) issue such holders an aggregate of 16,666 shares of the Company’s Common Stock (“Consent Shares”) and (ii) adjust the exercise price of those certain warrants issued to each holder in connection with the Company’s Reverse Stock Split on June 25, 2019. The Consent Shares and incremental cost associated with the warrant modification were determined to be direct costs of the Offering and, as a result, have been included within net proceeds from the Offering.

On June 21, 2019, the Company filed a Certificate of Change to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., eastern Time, on June 25, 2019. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in 1,442 new shares of Common Stock being issued to existing holders of the Company’s common stock.

On June 19, 2019, shareholders of the Company voted to approve an amendment to the Company’s Articles of Incorporation to increase the authorized shares of Common Stock to 150,000,000 shares on a pre-Reverse Stock Split basis (the “Authorized Share Increase”). On June 24, 2019, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of the State of Nevada to effect the Authorized Share Increase as of June 25, 2019. As a result of the Authorized Share Increase and after giving effect to the Reverse Stock Split, the Company had 12,500,000 authorized shares of Common Stock.

As a result of the Reverse Stock Split, the number of outstanding shares of our Common Stock held by non-affiliates was approximately 475,000. On June 28, 2019, the Company received a notice from the Nasdaq Capital Market ("NASDAQ") that it no longer met the minimum 500,000 publicly held shares requirement for continued listing. On July 19, 2019, the Company received a notice from NASDAQ that the Company had regained compliance with the publicly held shares requirement as a result of the Offering.

On March 5, 2019, the Company entered into a Securities Purchase Agreement with certain purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of (i) 86,667 shares of Common Stock, par value $0.001 per share and (ii) prefunded warrants to purchase 42,417 shares of Common Stock. The prefunded warrants were exercisable beginning on March 7, 2019 at an exercise price of $0.012 per share. The shares were sold at a price of $24.00 per share and the prefunded warrants were sold at a price of $23.988 per prefunded warrant, which represents the per share purchase price for the shares less the $0.012 per share exercise price for each such prefunded warrant. The holders of the prefunded warrants will not have the right to exercise any portion of the prefunded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the prefunded warrants. The net proceeds to the Company from this offering were approximately $2.7 million, after deducting expenses related to the offering, including dealer-manager fees and expenses. In a concurrent private placement, the Company issued to the purchasers a warrant to purchase one share of the Company’s Common Stock for each share and prefunded warrant purchased in the offering. These warrants have an exercise price of $27.00 per share, were exercisable beginning on September 8, 2019 and expire seven years from such date. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $22.74 per share, for a total of approximately $2.9 million. The fair value of the warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 2.56%, an expected life of 7.5 years and an expected volatility of 111.3%. The prefunded warrants had an intrinsic value of approximately $1.1 million. In June 2019, the prefunded warrants were exercised in full resulting in $509 of net proceeds to the Company.

Series B Preferred Stock

As of September 30, 2019 and December 31, 2018 there were approximately 1.8 million shares of Series B Preferred Stock issued and outstanding which were convertible on a 1.625 preferred shares to one share of common stock basis. The number of shares of Common Stock that, when aggregated with any shares of Common Stock that may be issued in connection with any conversion of Series B Preferred Stock and the exercise of warrants issued in connection with the Series B Preferred Stock, is subject to an Issuable Maximum, subject to adjustment, as set forth in the Second Amended and Restated Certificate of Designation of the Company’s Series B Preferred Stock. As of September 30, 2019, the Issuable Maximum is 0.6 million shares of Common Stock that can be issued upon the conversion of the currently outstanding Series B Preferred Stock and the exercise of warrants, issued in connection with the Series B Preferred Stock, that are currently outstanding.

The March 2019 registered direct offering triggered the down-round provision in the Company’s Series B Preferred Stock resulting in an adjustment to the conversion ratio and the recording of a deemed dividend of $3.9 million increasing the net loss attributable to common shareholders for the nine months ended September 30, 2019. In addition, the Offering triggered the down-round provision in the Company’s Series B Preferred Stock, resulting in a further adjustment to the conversion ratio and the recording of a deemed dividend of $1.4 million during the third quarter increasing the net loss attributable to common shareholders for the three and nine months ended September 30, 2019. There were no Series B Preferred Stock conversions during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, the holders of Series B Preferred Stock converted approximately 316,000 shares into approximately 26,000 shares of common stock.

Warrants

On July 17, 2019, in connection with the Offering, the Company offered to the purchasers Prefunded Warrants to purchase 570,000 shares of common stock. The Prefunded Warrants were exercisable beginning on July 17, 2019 at an exercise price of $0.01 per share. The Prefunded Warrants were sold at a price of $6.49 per Prefunded Warrant, which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such Prefunded Warrant. The holders of the Prefunded Warrants did not have the right to exercise any portion of the Prefunded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Prefunded Warrants. Prefunded Warrants to purchase 450,000 shares were exercised during the three and nine months ended September 30, 2019 resulting in net proceeds to the Company of $4,500. Also in connection with the Offering, the Company issued to the purchasers the Purchase Warrants. These Purchase Warrants have an exercise price of $13.00 per share, were exercisable beginning on July 17, 2019 and expire five years from such date. The warrants began trading on NASDAQ on July 23, 2019 under the symbol “XBIOW.” The Purchase Warrants also provide that if the weighted-average price of Common Stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each Purchase Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. Purchase Warrants to purchase approximately 1.9 million shares of common stock were exercised on a cashless one-for-one basis during the three and nine months ended September 30, 2019. As of September 30, 2019, there were approximately 120,000 Prefunded Warrants and 0.6 million Purchase Warrants outstanding. Subsequent to quarter end, the remaining outstanding Prefunded Warrants were exercised resulting in $1,200 of net proceeds to the Company.

On June 24, 2019, the Company entered into a consent agreement with certain holders of warrants to purchase shares of the Company’s common stock whose consent was required to effect the Reverse Stock Split. In consideration of the holders’ consent, the Company agreed to issue the holders warrants (the “Consent Warrants”) to purchase 8,335 shares of the Company’s common stock, at an exercise price per share based on a volume weighted average price for the five trading days following the effectiveness of the Reverse Stock Split. The Consent Warrants were issued on July 3, 2019 at an exercise price of $10.63. The Company evaluated the terms of the Consent Warrants and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $7.62 per share, for a total of approximately $64,000. The fair value of the Consent Warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 1.83%, an expected life of 7 years and an expected volatility of 114.53%. The Company recorded approximately $64,000 as general and administrative expense during the three and nine months ended September 30, 2019. The Consent Warrants were subsequently modified to reflect an exercise price of $2.91 price per share in connection with the Offering. As a result of this modification, the Company recognized a $2,000 expense that was netted against the proceeds of the Offering.

In March 2019, in connection with its registered direct offering, the Company offered to the purchasers prefunded warrants to purchase 42,417 shares of common stock. The prefunded warrants were exercisable beginning on March 7, 2019 at an exercise price of $0.012 per share. The prefunded warrants were sold at a price of $23.988 per prefunded warrant, which represents the per share purchase price for the shares less the $0.012 per share exercise price for each such prefunded warrant. The holders of the prefunded warrants did not have the right to exercise any portion of the prefunded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the prefunded warrants. All of these prefunded warrants were exercised in June 2019 resulting in net proceeds to the Company of $509. In a concurrent private placement, the Company issued to the purchasers a warrant to purchase one share of the Company’s common stock for each share and prefunded warrant (129,084 shares) purchased in the offering. These warrants have an exercise price of $27.00 per share, are exercisable beginning on September 8, 2019 and expire seven years from such date. As of September 30, 2019, all of these warrants were outstanding.

In addition to the prefunded and purchase warrants issued in the March 2019 registered direct offering and the Offering, the Company has outstanding warrants to purchase an aggregate of 262,690 shares of common stock in connection with debt and equity financing arrangements as of September 30, 2019 at a weighted average exercise price of $51.97 and expiration dates ranging from July 2020 through November 2021. There were no debt and equity financing warrants granted or exercised during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, debt and equity financing warrants to purchase approximately 31,000 shares of common stock were exercised resulting in approximately $1.5 million of net proceeds to the Company.

9.	Share-Based Expense

Total share-based expense related to stock options, restricted stock units (“RSUs”), common stock awards, and non-financing warrants were approximately $0.2 million and $0.3 million during the three months ended September 30, 2019 and 2018, respectively, and approximately $0.7 million and $1.2 million for the nine months ended September 30, 2019 and 2018, respectively.

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development expenses	$	38,843	$	9,155	$	81,921	$	178,926
General and administrative expenses		208,594		314,323		648,610		996,355
	$	247,437	$	323,478	$	730,531	$	1,175,281

Employee Stock Options

During the nine months ended September 30, 2019, the Company granted 50,000 stock option awards. The weighted average grant date fair value per option share was $1.18. Key assumptions used in the Black-Scholes option pricing model for options granted during the nine months ending September 30, 2019 were the Company’s stock price, a risk free rate of 1.60%, an expected life of 5.5 years and an expected volatility of 119.11%. There were no employee stock options exercised during the nine months ended September 30, 2019. No employee stock options or RSUs were granted nor exercised during the nine months ended September 30, 2018. The Company recognized a total of $0.2 million and $0.3 million of compensation expense related to employee stock options during the three months ended September 30, 2019 and 2018, respectively, and $0.7 million and $1.1 million during the nine months ended September 30, 2019 and 2018, respectively.

Non-Employee Stock Options

The Company did not grant any non-employee stock options during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, the Company granted 834 non-employee stock options. There were no non-employee stock options exercised during the nine months ended September 30, 2019 and 2018, respectively. The Company did not recognize any expense related to non-employee stock options during the three and nine months ended September 30, 2019, respectively, as all options were fully vested in 2018. The Company recognized approximately $1,000 and $36,000 of expense during the three and nine months ended September 30, 2018, respectively.

Common Stock Awards

During the three months ended September 30, 2019 and 2018, the Company granted 7,153 and 375 common stock awards, respectively, and 9,026 and 1,627 common stock awards during the nine months ended September 30, 2019 and 2018, respectively, based on the value of the professional services provided and the average stock price during each respective quarter. As all services were rendered in each respective quarter, approximately $15,000 and $17,000 of expense related to common stock awards was recognized during the three month periods ended September 30, 2019 and 2018, respectively, and approximately $47,000 and $52,000 of expense during the nine months ended September 30, 2019 and 2018, respectively. Other than 7,836 shares of Common Stock issued in June 2019, which represented common stock awards authorized but not issued as of March 31, 2019, all common stock awards were authorized but not issued as of September 30, 2019.

Warrants

In connection with certain of the Company’s collaboration agreements and consulting arrangements, the Company has issued warrants to purchase shares of common stock as payment for services. As of September 30, 2019 and December 31, 2018, collaboration warrants to purchase 44,944 shares of common stock were outstanding, respectively. The fair value of these warrants was determined at each issuance date using the Black-Scholes option pricing model. The warrants are subject to re-measurement at each reporting period until the measurement date is reached. Expense is recognized on a straight-line basis over the expected service period or at the date of issuance, if there is not a service period. These warrants have an average weighted exercise price of $124.90 and expiration dates ranging from December 2019 through May 2021. No collaboration warrants were granted or exercised in connection with collaboration or consulting services during the three and nine months ended September 30, 2019 and 2018, respectively.

10.

Income Taxes

During the nine months ended September 30, 2019 and 2018, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $26.2 million and $23.5 million as of September 30, 2019 and December 31, 2018, respectively.

As of September 30, 2019, and December 31, 2018, the net deferred tax liability of $2.9 million on the condensed consolidated balance sheets is related to book and tax basis differences for intangible assets with indefinite lives that were acquired in the Company’s January 2012 acquisition of SymbioTec. In accordance with ASC 740-10-30-18, the deferred tax liability related to the intangible assets cannot be used to offset deferred tax assets when determining the amount of the valuation allowance for deferred tax assets which are not more-likely-than-not to be realized. This results in a net deferred tax liability, even though the Company has a full valuation allowance on its other net deferred tax assets. This net deferred tax liability will continue to be reflected on the balance sheet until the related intangible assets are no longer held by the Company.

As of September 30, 2019 and December 31, 2018, the Company did not record any unrecognized tax positions.

11.

Commitments

Leases

The Company determines whether an arrangement is a lease at inception. In January 2019, the Company entered into a sublease and relocated its corporate headquarters from Lexington, Massachusetts to Framingham, Massachusetts. This sublease calls for total future minimum rent payments of approximately $52,000 and has a termination date of September 30, 2020, which corresponds to the underlying base lease. The Company does not have options to extend, termination options or material residual value guarantees. The Company recorded a right-of-use (“ROU”) asset and corresponding lease liability on the condensed consolidated balance sheet. The Company recognized a ROU asset and a lease liability of approximately $43,000 during the nine months ended September 30, 2019. As the sublease does not provide an implicit rate, we used our incremental borrowing rate (10.2%) based on the information available at the lease’s commencement date in determining the present value of lease payments.

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

	Nine Months Ended September 30,
	2019
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	16,629
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	$	43,330

Supplemental balance sheet information related to our operating leases is as follows:

	Balance Sheet Classification	September 30, 2019
Right-of-use assets	Prepaid expenses and other	$	26,701
Current lease liabilities	Accrued expenses and other current liabilities	$	26,701
Non-current lease liabilities	Other liabilities	$	–

The Company did not apply the provisions of ASU 2016-02 to the lease of its former headquarters in Lexington, Massachusetts or its office space lease in Miami, Florida as they did not have a material impact on our condensed consolidated financial statements. The leases would have resulted in a combined increase in total assets of approximately $3,000 and a combined increase in total liabilities of approximately $3,000 in our September 30, 2019 condensed consolidated balance sheet, respectively, and would not have a material impact on our accumulated deficit as of the beginning of 2019. The lease of the Company’s former headquarters expired on January 31, 2019 and the Miami office space lease expires in November 2019. As of September 30, 2019, total minimum lease payments on these leases were approximately $3,000.

12.

Related Party Transactions

The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (as well as SynBio, a wholly owned subsidiary of Pharmsynthez), each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the years ended December 31, 2018 filed with the SEC on March 29, 2019 as amended on April 30, 2019. In connection with the Offering, Serum Institute’s and Pharmsynthez’ ownership significantly changed. As of September 30, 2019, Serum Institute owned less than 1% and Pharmsynthez owned approximately 7.9% of the total outstanding common stock of the Company.

During the third quarter, the Company entered into a sponsored research agreement with Pharmsynthez related to experiments identified by the Company to support its efforts as it prepares for initial tech transfer of the XCART methods to a future academic collaborator. Under the agreement, the Company made a $350,000 payment to Pharmsynthez during the third quarter of 2019, which is refundable on pro rata basis if the project is terminated prematurely as a result of Pharmsynthez failing to perform the work. The Company expensed approximately $40,000 related to this agreement during the three months ended September 30, 2019. As of September 30, 2019, approximately $310,000 was recorded as an advanced payment and included in Prepaid expenses and other on the September 30, 2019 condensed consolidated balance sheet.

On July 19, 2019, the Company acquired the XCART technology platform from Hesperix and OPKO. Dr. Genkin is a director and significant shareholder of Hesperix. In addition, the Company agreed to repay an approximate $225,000 loan that Dr. Genkin entered into with Hesperix. Mr. Adam Logal, one of our directors, is Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer of OPKO Health, Inc., the parent company of OPKO.

Subsequent to quarter end, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company shall advance Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the August 2011 Stock Subscription and Collaborative Development of Pharmaceutical Products Agreement between the Company and SynBio. The Pharmsynthez Loan has a term of 15-months and shall accrue interest at a rate of 10% per annum. The Pharmsynthez Loan is guaranteed by SynBio and AS Kevelt, which are the operating entities of Pharmsynthez, and is secured by all of the equity interests of the Company owned by Pharmsynthez and SynBio.

13.

Subsequent Events

The Company performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined that there were no such events requiring recognition or disclosure in the financial statements other than as discussed above.

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, future revenues, projected costs, prospects and our objectives for future operations, are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning our plans to develop our proposed drug candidates; our expectations regarding the nature, timing and extent of clinical trials and proposed clinical trials including the timing of generating clinical data from these trials; our expectations regarding the timing for proposed submissions of regulatory filings, including but not limited to any Investigational New Drug (“IND”) filing or any New Drug Application; the nature, timing and extent of collaboration arrangements; the expected results pursuant to collaboration arrangements including the receipts of future payments that may arise pursuant to collaboration arrangements; the outcome of our plans to obtain regulatory approval of our drug candidates; the outcome of our plans for the commercialization of our drug candidates; our plans to address certain markets, engage third party manufacturers, and evaluate additional drug candidates for subsequent commercial development, and the likelihood and extent of competition to our drug candidates; the development of the Chimeric Antigen Receptor (“CAR”) T cell technology; our plans to initially apply the XCART technology to advance cell-based therapeutics by targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas; our beliefs regarding the expected results of the XCART technology, including its potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells; and our anticipation that our primary focus will now be on advancing the XCART technology through regulatory approval and commercialization.

In some cases, these statements may be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, or “continue”, or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, we cannot guarantee future results, the levels of activity, performance or achievements. These statements involve known and unknown risks and uncertainties that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from those expressed or implied by forward-looking statements.

The Management’s Discussion and Analysis of Financial Condition and Results of Operations (the “MD&A”) should be read together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report. This Quarterly Report, including the MD&A, contains trend analysis and other forward-looking statements. Any statements in this Quarterly Report that are not statements of historical facts are forward-looking statements. These forward-looking statements made herein are based on our current expectations, involve a number of risks and uncertainties and should not be considered as guarantees of future performance.

Some factors that could cause actual results to differ materially include without limitation:

	·	our need to raise additional working capital in the future for the purpose of further developing our CAR T technology and to continue as a going concern;
	·	our ability to finance our business;
	·	our ability to successfully execute, manage and integrate key acquisitions and mergers, including integration of the acquisition of the CAR T technology;
	· ·	product development and commercialization risks; including our ability to successfully develop the CAR T technology; our ability to successfully commercialize our current and future drug candidates;
	·	our ability to obtain a strategic academic collaborator for the CAR T technology;
	·	our ability to achieve milestone and other payments associated with our co-development collaborations and strategic arrangements;
	·	the impact of new technologies on our drug candidates and our competition;
	·	changes in laws or regulations of governmental agencies;
	·	interruptions or cancellation of existing contracts;
	·	impact of competitive products and pricing;
	·	product demand and market acceptance and risks;
	·	the presence of competitors with greater financial resources;
	·	continued availability of supplies or materials used in manufacturing at the current prices;
	·	the ability of management to execute plans and motivate personnel in the execution of those plans;
	·	our ability to attract and retain key personnel;
	·	adverse publicity related to our products or the Company itself;
	·	adverse claims relating to our intellectual property;
	·	the adoption of new, or changes in, accounting principles;
	·	the costs inherent with complying with statutes and regulations applicable to public reporting companies, such as the Sarbanes-Oxley Act of 2002;
	·	other new lines of business that the Company may enter in the future; and
	·	other factors set forth in the Risk Factors section of our Annual Report on Form 10-K and in subsequent filings with the SEC.

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in the forward-looking statements in this Quarterly Report. Other unknown or unpredictable factors also could have material adverse effects on our future results, including, but not limited to, those discussed in the section titled “Risk Factors.” The forward-looking statements in this Quarterly Report are made only as of the date of this Quarterly Report, and we do not undertake any obligation to publicly update any forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

BUSINESS OVERVIEW

We are a biopharmaceutical company focused on progressing XCART, a personalized CAR T cell platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (the “Institute”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (“IBCH”), is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. On March 1, 2019, the Company agreed to acquire the XCART technology (the “Transaction”) and closed the Transaction on July 19, 2019 concurrent with the completion of an approximate $15 million public offering (the “Offering”).

The XCART technology platform was designed by its originators to utilize an established screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor (“BCR”) on the surface of an individual patient’s malignant tumor cells. The peptide is then inserted into the antigen-binding domain of a CAR T cell, and a subsequent transduction/transfection process is used to engineer the patient’s T cells into a CAR T format which redirects the patient’s T cells to attack the tumor. Essentially, the XCART screening platform is the inverse of a typical CAR T screening protocol wherein libraries of highly specific antibody domains are screened against a given target. In the case of XCART screening, the target is itself an antibody domain, and hence highly specific by its nature. The XCART technology creates the possibility of personalized treatment of lymphomas utilizing a CAR with an antigen-binding domain that should only recognize, and only be recognized by, the unique BCR of a particular patient’s B-cell lymphoma. An expected result for XCART is limited off-tumor toxicities, such as B-cell aplasia. Our clinical development program will seek to confirm the early preclinical results, and to demonstrate a more attractive safety profile than existing therapies. We anticipate that our primary focus will now be on advancing this technology through regulatory approval and commercialization.

We also have oncology therapeutic investigational drug candidate XBIO-101 (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. We have exclusive rights to develop and commercialize XBIO-101 worldwide, except for specified countries in the Commonwealth of Independent States. XBIO-101 has been granted orphan drug designation by the United States (“U.S.”) Food and Drug Administration (“FDA”) for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy. We commenced a Phase II trial under an IND in 2017, with first patient dosed in October 2017. We closed patient enrollment in the trial in March 2019 as a result of slower than expected progress on the trial resulting from patient enrollment and retention challenges and have suspended further development of XBIO-101.

Additionally, our proprietary drug development platform, PolyXen, enables next-generation biological drugs by modifying their half-life and other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer prolonged half-life on biotherapeutics such as recombinant human erythropoietin and recombinant Factor VIII (“rFVIII”). We believe this technology may be applied to a variety of drug candidates to enhance the properties of the therapeutic, potentially providing advantages over competing products.

Our drug candidates have resulted from our research activities or that of our collaborators and are in the development stage. As a result, we continue to commit a significant amount of our resources to our research and development activities and anticipate continuing to do so for the near future. To date, none of our drug candidates have received regulatory marketing authorization in the U.S. by the FDA nor in any other territories by any applicable agencies. Although we hold a broad patent portfolio, the focus of our internal development efforts was limited in the first nine months of 2019 to research and development of XBIO-101 and preliminary development efforts associated with the XCART technology.

Going Concern

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. We have incurred substantial losses since our inception, and we expect to continue to incur operating losses in the near-term. These factors raise substantial doubt about our ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On March 7, 2019, the Company closed on a $3.1 million registered direct common stock offering resulting in $2.7 million of net proceeds to the Company. On July 19, 2019, the Company completed the Offering resulting in approximately $13.4 million of net proceeds to the Company. The Company believes that these financings, coupled with the Company’s existing resources, will be adequate to fund the Company’s operations as a going concern. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives and continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

Critical Accounting Estimates

The preparation of our financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue, costs and expenses during the reporting period. On an ongoing basis, we evaluate management’s estimates that are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results and outcomes could differ materially from our estimates, judgments and assumptions.

There has been no material change to our critical accounting estimates since those critical accounting estimates described in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 as amended on April 30, 2019.

RESULTS OF OPERATIONS

Comparison of Quarter Ended September 30, 2019 and 2018

The comparison of our historical results of operations for the fiscal quarter ended September 30, 2019 to the fiscal quarter ended September 30, 2018 is as follows:

Description	Quarter Ended September 30, 2019			Quarter Ended September 30, 2018			Increase (Decrease)		Percentage Change
Research and development expenses	$	(3,520,638	)	$	(735,879	)	$	2,784,759		378.4
General and administrative expenses		(2,142,505	)		(1,079,008	)		1,063,497		98.6
Goodwill impairment		(3,283,379	)		–			3,283,379		n/a
Loss from operations		(8,946,522	)		(1,814,887	)		7,131,635		393.0
Other income (expense):
Other income (expense)		(223	)		2,292			2,515		109.7
Interest income		46,617			59			46,558		78,911.9

Net loss	$	(8,900,128	)	$	(1,812,536	)	$	7,087,592		391.0

Research and Development Expenses

Overall, Research & development (“R&D”) expenses for the three months ended September 30, 2019 increased by $2.8 million, or 378.4% to $3.5 million from $0.7 million in the comparable quarter in 2018 primarily due to in-process research and development (“IPR&D”) expense of $3.0 million. During the three months ended September 30, 2019, the Company expensed $3.0 million of IPR&D associated with the Company’s acquisition of the XCART technology. There was no similar expense in 2018. Excluding the $3.0 million of IPR&D expense from total R&D expense of $3.5 million, R&D expense for the three months ended September 30, 2019 was $0.5 million, a decrease of $0.2 million, or 33.5% from $0.7 million in the comparable period in 2018.

The table below sets forth the R&D costs incurred by the Company by category of expense for the quarters ended September 30, 2019 and 2018:

	Quarter Ended,
Category of Expense	September 30, 2019		September 30, 2018
IPR&D expense	$	3,031,226	$	–
Outside services and contract research organizations		313,957		572,547
Salaries and wages		72,809		70,552
Share-based expense		38,843		9,155
Other		63,803		83,625
Total research and development expense	$	3,520,638	$	735,879

The decrease in outside services and contract research organizations was primarily due to decreased spending on our XBIO-101 phase 2 clinical trial during the three months ended September 30, 2019 as compared to the same period in the prior year. Costs related to the trial were generally lower as we closed patient enrollment during the first quarter of 2019 and suspended further development of XBIO-101. Share-based expense increased during the three months ended September 30, 2019 as compared to the same period in the prior year primarily due to the revaluation of warrants issued to Serum Institute in 2016. Other expense decreased during the three months ended September 30, 2019 as compared to the same period in the prior year primarily due to lower rent costs as we relocated our corporate headquarters in January 2019.

General and Administrative Expenses

General and administrative (“G&A”) expenses for the three months ended September 30, 2019 was $2.1 million, increasing by approximately $1.1 million for the quarter ended September 30, 2019 compared to the same period in the prior year, primarily due to $1.1 million of transaction costs associated with the XCART acquisition. There was no similar expense in 2018. Excluding the $1.1 million of transaction costs, associated with the XCART acquisition from the total G&A expense of $2.1 million, G&A expenses for the three months ended September 30, 2019 was $1.0 million, a decrease of approximately $39,000, or 3.6% from $1.1 million in the comparable quarter in 2018. This decrease was primarily due to lower consulting and share-based expense during the three months ended September 30, 2019 compared to the same period in the prior year, partially offset by an increase in investor relations activities during the third quarter of 2019.

Goodwill Impairment

Goodwill impairment was $3.3 million for the three months ended September 30, 2019 compared to no impairment for the same period in the prior year. During the third quarter of 2019, we experienced a significant decline in our stock price. As a result, our market capitalization fell significantly below the recorded value of our consolidated net assets and our analysis determined that Goodwill was fully impaired.

Other Income (Expense)

Other expense was $223 for the three months ended September 30, 2019 compared to approximately $2,300 of other income for the same period in 2018. This increase in expense was primarily related to changes in foreign currency exchange rates during the third quarter of 2019 as compared to the same period in 2018.

Interest Income

Interest income increased to approximately $47,000 during the three months ended September 30, 2019 as compared to $59 in same period in the prior year. This increase is due to the increase in cash in the third quarter of 2019 as compared to the third quarter of 2018 due to the receipt of net proceeds of $13.4 million from our Offering.

Comparison of Nine Months Ended September 30, 2019 and 2018

The comparison of our historical results of operations for the nine months ended September 30, 2019 to the nine months ended September 30, 2018 is as follows:

Description	Nine Months Ended September 30, 2019			Nine Months Ended September 30, 2018			Increase (Decrease)			Percentage Change
Research and development expenses	$	(4,471,939	)	$	(2,369,219	)	$	2,102,720			88.8
General and administrative expenses		(3,896,657	)		(3,267,597	)		629,060			19.3
Goodwill impairment		(3,283,379	)		–			3,283,379			n/a
Loss from operations		(11,651,975	)		(5,636,816	)		6,015,159			106.7
Other income (expense):
Other income (expense)		267			(24,838	)		(25,105	)		(101.1	)
Interest income		46,930			424			46,506			10,968.4

Net loss	$	(11,604,778	)	$	(5,661,230	)	$	5,943,548			105.0

Research and Development Expenses

Overall, R&D expenses for the nine months ended September 30, 2019 increased by $2.1 million, or 88.8% to $4.5 million from $2.4 million in the comparable period in 2018 primarily due to IPR&D expense of $3.0 million. During the nine months ended September 30, 2019, the Company expensed $3.0 million of IPR&D associated with the Company’s acquisition of the XCART technology. There was no similar expense in 2018. Excluding the $3.0 million of IPR&D expense from total R&D expense of $4.5 million, R&D expense for the nine months ended September 30, 2019 was $1.4 million, a decrease of $0.9 million, or 39.2%, from $2.4 million in the comparable period in 2018.

The table below sets forth the R&D costs incurred by us, by category of expense, for the nine months ended September 30, 2019 and 2018:

	Nine Months Ended,
Category of Expense	September 30, 2019		September 30, 2018
IPR&D expense	$	3,031,226	$	–
Outside services and contract research organizations		986,369		1,765,209
Salaries and wages		227,257		207,794
Share-based expense		115,253		178,926
Other		111,834		217,290
Total research and development expense	$	4,471,939	$	2,369,219

The decrease in outside services and contract research organizations expense was primarily due to decreased spending on our XBIO-101 phase 2 clinical trial during the nine months ended September 30, 2019 as compared to same period in the prior year. Costs related to the trial were generally lower as we closed patient enrollment during the first quarter of 2019 and suspended further development of XBIO-101. Other expense decreased during the nine months ended September 30, 2019 as compared to the same period in the prior year primarily due to lower rent costs as we relocated our corporate headquarters in January 2019. Share-based expense decreased during the nine months ended September 30, 2019 as compared to the same period in the prior year primarily due to the revaluation of warrants issued to Serum Institute in 2016.

General and Administrative Expenses

G&A expenses was $3.9 million for the nine months ended September 30, 2019, increasing by approximately $0.6 million for the nine months ended September 30, 2019 compared to the same period in the prior year primarily due to $1.1 million of transaction costs associated with the XCART acquisition. There was no similar expense in 2018. Excluding the $1.1 million of transaction costs associated with the XCART acquisition from total G&A expenses of $3.9 million, G&A expenses for the nine months ended September 30, 2019 was $2.8 million, a decrease of $0.5 million, or 14.5%, from $3.3 million in the comparable period in 2018. Payroll and share-based expense decreased due to lower headcount during the nine months ended September 30, 2019 compared to the same period in the prior year, and consulting costs decreased as we reduced spending due to capital constraints. These decreases were partially offset by an increase in investor relations activities during the nine months ended September 30, 2019 compared to the same period in the prior year.

Goodwill Impairment

Goodwill impairment was $3.3 million for the nine months ended September 30, 2019 compared to no impairment for the same period in the prior year. During the third quarter of 2019, we experienced a significant decline in our stock price. As a result, our market capitalization fell significantly below the recorded value of our consolidated net assets and our analysis determined that Goodwill was fully impaired.

Other Income (Expense)

Other income was $267 for the nine months ended September 30, 2019 compared to $24,838 of other expense for the same period in 2018. This decrease in expense was primarily related to a reduction in foreign currency transactions and related changes in foreign currency exchange rates during the nine months ended September 30, 2019 as compared to the same period in 2018.

Interest Income

Interest income increased to approximately $47,000 during the nine months ended September 30, 2019 as compared to $424 in same period in the prior year. This increase is due to the increase in cash during the nine months ended September 30, 2019 as compared to the same period in the prior year due to the receipt of net proceeds of $13.4 million from the Offering.

Non-GAAP Measures

In the Company’s narrative discussion of operations above, we exclude the impact of the Company’s acquisition of the XCART technology from certain operating measures, which narrative discussion includes reconciliation of such adjusted financial measures to the directly comparable GAAP financial measure. We believe these adjusted operating measures may provide investors with useful information regarding our underlying performance from period to period and allow investors to better understand our results of operations. Management uses these adjusted measures when assessing the performance of the business.

Liquidity and Capital Resources

We incurred a net loss of approximately $11.6 million for the nine months ended September 30, 2019. We had an accumulated deficit of approximately $164.8 million at September 30, 2019 as compared to an accumulated deficit of approximately $153.2 million at December 31, 2018. Working capital was approximately $11.2 million at September 30, 2019 and $(0.4) million at December 31, 2018, respectively. During the nine months ended September 30, 2019, our working capital increased by $11.6 million due to the Offering and our March 2019 registered direct offering resulting in $16.1 million in combined net proceeds to us. This increase in working capital was partially offset by our net loss for the nine months ended September 30, 2019 and transaction costs incurred in connection with the acquisition of the IPR&D. We expect to continue incurring losses for the foreseeable future and may need to raise additional capital or pursue other strategic alternatives in the long-term in order to continue the pursuit of our business plan.

Our principal source of liquidity consists of cash. At September 30, 2019, we had approximately $12.0 million in cash and $1.7 million in current liabilities. At December 31, 2018, we had approximately $0.6 million in cash and $1.6 million in current liabilities.

We have historically relied upon sales of our equity securities to fund our operations. From 2005 until September 30, 2019 we have raised approximately $76.0 million in proceeds from offerings of our common and preferred stock and received approximately $20.0 million from revenue producing activities. More than 90% of the milestone and sublicense revenue received to date has been from a single collaborator, Takeda Pharmaceuticals Co. Ltd. We expect the majority of our funding through equity or equity-linked instruments, debt financings, corporate collaborations, related party funding and/or licensing agreements to continue as a trend for the foreseeable future.

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. We have incurred substantial losses since our inception, and we expect to continue to incur operating losses in the near-term. These factors raise substantial doubt about our ability to continue as a going concern. We believe that we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On March 7, 2019, we closed on a $3.1 million registered direct common stock offering resulting in $2.7 million of net proceeds to us. On July 19, 2019, we completed the Offering resulting in approximately $13.4 million of net proceeds to us. We believe that these financings, coupled with our existing resources, will be adequate to fund our operations as a going concern. However, we anticipate we may need additional capital in the long-term to pursue our business initiatives and continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Cash Flows from Operating Activities

Cash flows used in operating activities for the nine months ended September 30, 2019 totaled approximately $4.7 million, which was primarily due to our net loss for the period, offset by non-cash charges associated with acquired IPR&D, goodwill impairment and share-based expense.

Cash flows used in operating activities for the nine months ended September 30, 2018 totaled approximately $5.4 million, which was primarily due to our $5.7 million net loss for the period offset by non-cash charges of $1.2 million, and approximately $0.9 million of cash used to reduce accounts payable and accrued expenses.

Cash Flows from Investing Activities

Cash flows provided by investing activities for the nine months ended September 30, 2019 totaled $2,000, which represented proceeds from the sale of property and equipment.

Cash flows provided by investing activities for the nine months ended September 30, 2018 totaled approximately $23,000 which represented proceeds from the sale of lab equipment.

Cash Flow from Financing Activities

Cash flows from financing activities for the nine months ended September 30, 2019 totaled approximately $16.1 million representing net proceeds from our registered direct offering in March 2019 and the Offering in July 2019.

Cash flows from financing activities for the nine months ended September 30, 2018 totaled approximately $1.5 million representing proceeds from the exercise of warrants.

Contractual Obligations and Commitments

As of September 30, 2019, there were no material changes in our contractual obligations and commitments from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 29, 2019 as amended on April 30, 2019. See Note 11 to our condensed consolidated financial statements for a summary of our lease commitments.

Off Balance Sheet Arrangements

We do not have any off-balance sheet financing arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, change in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Recent Accounting Standards

See Note 2 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report and Note 2 in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 29, 2019 as amended on April 30, 2019 for a discussion of recent accounting standards.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. There have been no material changes in our critical accounting policies from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 as amended on April 30, 2019.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this Item because we are a “smaller reporting company” (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)).

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report.

Based on this evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report that would have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

ITEM 1A – RISK FACTORS

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 as amended on April 30, 2019.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 – MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5 – OTHER INFORMATION

None.

ITEM 6 – EXHIBITS

The following exhibits are incorporated herein by reference or filed as part of this report.

EXHIBIT NUMBER	DESCRIPTION
2.1***#	Share Purchase Agreement (incorporated by reference to Exhibit 2.1 of the Registrant's Form 8-K filed with the SEC on March 4, 2019, as amended on the Form 8-K/A filed with the SEC on May 20, 2019).
2.2	First Amendment to Share Purchase Agreement (incorporated by reference to Exhibit 2.1 of the Registrant's Form 8-K filed with the SEC on June 13, 2019).
2.3	Second Amendment to Share Purchase Agreement (incorporated by reference to Exhibit 2.1 of the Registrant's Form 8-K filed with the SEC on June 24, 2019).
2.4	Third Amendment to Share Purchase Agreement (incorporated by reference to Exhibit 2.1 of the Registrant's Form 8-K filed with the SEC on July 16, 2019).
3.1	Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-178082) filed with the SEC on November 21, 2011).
3.2	Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 333-178082) filed with the SEC on February 12, 2013).
3.3	Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 333-178082) filed with the SEC on February 27, 2013).
3.4	Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 333-178082) filed with the SEC on January 10, 2014).
3.5	Certificate of Change Pursuant to NRS 78.209 (incorporated by reference to Exhibit 3.2 to the Registrant' s Quarterly Report on Form 10-Q (File No. 333-178082) filed with the SEC on January 10, 2014).
3.6	Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 333-178082) filed with the SEC on September 30, 2015).
3.7	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37937) filed with the SEC on February 27, 2017).
3.8	Form of Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock (incorporated by reference to Exhibit 3.8 of the Registrant's Registration Statement on Form S-1/A (File No. 333-211249) filed with the SEC on October 27, 2016).
3.9	Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (incorporated by reference to Exhibit A of the Company’s Information Statement on Schedule 14C (File No. 001-37937) filed with the SEC on May 2, 2017.
3.10	Certificate of Change (incorporated by reference to Exhibit 3.1 of the Registrant's Form 8-K filed with the SEC on June 24, 2019).
3.11	Certificate of Amendment (incorporated by reference to Exhibit 3.2 of the Registrant's Form 8-K filed with the SEC on June 24, 2019).
4.1	Form of Pre-Funded Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.18 of the Registrant's Form S-1/A filed with the SEC on July 12, 2019).
4.2	Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.19 of the Registrant's Form S-1/A filed with the SEC on July 12, 2019).
4.3	Form of Warrant (incorporated by reference to Exhibit 4.1 of the Registrant's Form 8-K filed with the SEC on June 25, 2019).
4.4	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant's Form 8-K filed with the SEC on July 22, 2019).
4.5	Form of Purchase Warrant (incorporated by reference to Exhibit 4.2 of the Registrant's Form 8-K filed with the SEC on July 22, 2019).
10.1	Third Amendment to OPKO Assignment Agreement (incorporated by reference to Exhibit 10.1 of the Registrant's Form 8-K filed with the SEC on July 16, 2019).
10.2	Consent Agreement (incorporated by reference to Exhibit 10.1 of the Registrant's Form 8-K filed with the SEC on July 16, 2019).
10.3	Warrant Agency Agreement (incorporated by reference to Exhibit 10.1 of the Registrant's Form 8-K filed with the SEC on July 22, 2019).
31.1*	Certification of Jeffrey F. Eisenberg, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of James Parslow, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certifications of Jeffrey F. Eisenberg, Principal Executive Officer, and James Parslow, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT NUMBER	DESCRIPTION
101.INS*	Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	The cover page of this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, formatted in Inline XBRL (included within the Exhibit 101 attachments).
*	Filed herewith.
**	Exhibit 32.1 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except as otherwise stated in such filing.
***	Schedules and similar attachments to the Share Purchase Agreement, dated as of March 1, 2019, have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby undertakes to furnish on a supplemental basis a copy of any omitted schedules and similar attachments to the Securities and Exchange Commission upon request.
#	Certain portions of the exhibit have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Xenetic Biosciences, Inc.


November 14, 2019	By:	/S/ JEFFREY F. EISENBERG
		Jeffrey F. Eisenberg
		Chief Executive Officer (Principal Executive Officer)

	By:	/S/ JAMES PARSLOW
		James Parslow Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 xenetic_ex3101.htm CERTIFICATION

EXHIBIT 31.1

I, Jeffrey F. Eisenberg, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2019

By: /s/ JEFFREY F. EISENBERG

Jeffrey F. Eisenberg
Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 xenetic_ex3102.htm CERTIFICATION

EXHIBIT 31.2

I, James Parslow, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2019

By: /s/ JAMES PARSLOW

James Parslow
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)

EX-32.1 4 xenetic_ex3201.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic Biosciences, Inc. (the “Company”), and James Parslow, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2019

In Witness Whereof, the undersigned have set their hands hereto as of the 14th day of November, 2019.

/s/ Jeffrey F. Eisenberg	/s/James Parslow
Jeffrey F. Eisenberg	James Parslow
Chief Executive Officer	Chief Financial Officer

“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xenetic Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”

EX-101.INS 5 xbio-20190930.xml XBRL INSTANCE FILE 0001534525 2019-09-30 0001534525 2018-12-31 0001534525 2019-01-01 2019-09-30 0001534525 2018-01-01 2018-09-30 0001534525 2019-11-08 0001534525 us-gaap:SeriesAMember 2019-09-30 0001534525 us-gaap:SeriesBMember 2019-09-30 0001534525 us-gaap:SeriesAMember 2018-12-31 0001534525 us-gaap:SeriesBMember 2018-12-31 0001534525 2017-12-31 0001534525 2018-09-30 0001534525 2019-07-01 2019-09-30 0001534525 2018-07-01 2018-09-30 0001534525 us-gaap:PreferredStockMember 2018-01-01 2018-09-30 0001534525 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0001534525 us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001534525 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0001534525 us-gaap:PreferredStockMember 2017-12-31 0001534525 us-gaap:PreferredStockMember 2018-09-30 0001534525 us-gaap:PreferredStockMember 2018-06-30 0001534525 us-gaap:PreferredStockMember 2018-12-31 0001534525 us-gaap:PreferredStockMember 2019-09-30 0001534525 us-gaap:PreferredStockMember 2019-06-30 0001534525 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001534525 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001534525 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001534525 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001534525 us-gaap:CommonStockMember 2017-12-31 0001534525 us-gaap:CommonStockMember 2018-09-30 0001534525 us-gaap:CommonStockMember 2018-06-30 0001534525 us-gaap:CommonStockMember 2018-12-31 0001534525 us-gaap:CommonStockMember 2019-09-30 0001534525 us-gaap:CommonStockMember 2019-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001534525 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001534525 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001534525 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001534525 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001534525 us-gaap:RetainedEarningsMember 2017-12-31 0001534525 us-gaap:RetainedEarningsMember 2018-09-30 0001534525 us-gaap:RetainedEarningsMember 2018-06-30 0001534525 us-gaap:RetainedEarningsMember 2018-12-31 0001534525 us-gaap:RetainedEarningsMember 2019-09-30 0001534525 us-gaap:RetainedEarningsMember 2019-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001534525 us-gaap:TreasuryStockMember 2018-01-01 2018-09-30 0001534525 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001534525 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0001534525 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001534525 us-gaap:TreasuryStockMember 2017-12-31 0001534525 us-gaap:TreasuryStockMember 2018-09-30 0001534525 us-gaap:TreasuryStockMember 2018-06-30 0001534525 us-gaap:TreasuryStockMember 2018-12-31 0001534525 us-gaap:TreasuryStockMember 2019-09-30 0001534525 us-gaap:TreasuryStockMember 2019-06-30 0001534525 2018-06-30 0001534525 2019-06-30 0001534525 xbio:OfficeAndComputerEquipmentMember 2019-09-30 0001534525 xbio:OfficeAndComputerEquipmentMember 2018-12-31 0001534525 us-gaap:LeaseholdImprovementsMember 2019-09-30 0001534525 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001534525 us-gaap:FurnitureAndFixturesMember 2019-09-30 0001534525 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001534525 2018-01-01 2018-12-31 0001534525 xbio:OncoHistMember 2019-09-30 0001534525 xbio:OncoHistMember 2018-12-31 0001534525 xbio:OncoHistMember 2019-01-01 2019-09-30 0001534525 us-gaap:FairValueInputsLevel3Member 2019-09-30 0001534525 xbio:UnderwritingAgreementMember xbio:PreFundedWarrantsMember 2019-01-01 2019-07-17 0001534525 xbio:UnderwritingAgreementMember us-gaap:CommonStockMember 2019-01-01 2019-07-17 0001534525 xbio:SecuritiesPurchaseAgreementMember 2019-01-01 2019-03-05 0001534525 xbio:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2019-01-01 2019-03-05 0001534525 xbio:SecuritiesPurchaseAgreementMember xbio:PreFundedWarrantsMember 2019-01-01 2019-03-05 0001534525 xbio:SecuritiesPurchaseAgreementMember xbio:PreFundedWarrantsMember 2019-03-05 0001534525 xbio:PreFundedWarrantsMember 2019-01-01 2019-09-30 0001534525 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-09-30 0001534525 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-09-30 0001534525 us-gaap:SeriesBPreferredStockMember 2019-07-01 2019-09-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001534525 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001534525 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001534525 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001534525 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001534525 xbio:NonEmployeeStockOptionsMember 2019-07-01 2019-09-30 0001534525 xbio:NonEmployeeStockOptionsMember 2018-07-01 2018-09-30 0001534525 xbio:NonEmployeeStockOptionsMember 2019-01-01 2019-09-30 0001534525 xbio:NonEmployeeStockOptionsMember 2018-01-01 2018-09-30 0001534525 xbio:CommonStockAwardsMember 2019-07-01 2019-09-30 0001534525 xbio:CommonStockAwardsMember 2018-07-01 2018-09-30 0001534525 xbio:CommonStockAwardsMember 2019-01-01 2019-09-30 0001534525 xbio:CommonStockAwardsMember 2018-01-01 2018-09-30 0001534525 us-gaap:WarrantMember xbio:CollaborationAgreementsMember 2019-09-30 0001534525 us-gaap:WarrantMember xbio:CollaborationAgreementsMember 2018-12-31 0001534525 us-gaap:WarrantMember xbio:CollaborationAgreementsMember 2019-01-01 2019-09-30 0001534525 us-gaap:WarrantMember xbio:CollaborationAgreementsMember 2018-01-01 2018-09-30 0001534525 us-gaap:OtherAssetsMember 2019-09-30 0001534525 xbio:AccruedExpensesMember 2019-09-30 0001534525 us-gaap:OtherLiabilitiesMember 2019-09-30 0001534525 xbio:PrepaidExpensesMember 2019-09-30 0001534525 xbio:PulbicOfferingMember 2019-01-01 2019-03-07 0001534525 xbio:DirectOfferingMember 2019-01-01 2019-07-19 0001534525 xbio:HesperixMember 2019-01-01 2019-07-19 0001534525 xbio:OpkoAssignmentAgrMember 2019-01-01 2019-07-19 0001534525 xbio:InstituteMember 2019-01-01 2019-07-19 0001534525 xbio:XcartTechnologyMember 2019-01-01 2019-07-19 0001534525 xbio:XcartTechnologyMember 2019-01-01 2019-09-30 0001534525 xbio:UnderwritingAgreementMember xbio:PurchaseWarrantsMember 2019-01-01 2019-07-17 0001534525 xbio:UnderwritingAgreementMember 2019-01-01 2019-07-17 0001534525 xbio:UnderwritingAgreementMember xbio:UnderwriterMember 2019-01-01 2019-07-17 0001534525 xbio:PreFundedWarrantsMember 2019-07-01 2019-09-30 0001534525 xbio:UnderwritingAgreementMember xbio:PurchaseWarrantsMember 2019-07-17 0001534525 xbio:UnderwritingAgreementMember xbio:ConsentSharesMember 2019-01-01 2019-07-16 0001534525 xbio:NonAffiliatesMember 2019-06-28 0001534525 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-03-05 0001534525 xbio:UnderwritingAgreementMember xbio:PreFundedWarrantsMember 2019-09-30 0001534525 xbio:UnderwritingAgreementMember xbio:PurchaseWarrantsMember 2019-09-30 0001534525 xbio:UnderwritingAgreementMember xbio:ConsentSharesMember 2019-01-01 2019-06-24 0001534525 xbio:UnderwritingAgreementMember xbio:ConsentSharesMember 2019-01-01 2019-09-30 0001534525 xbio:UnderwritingAgreementMember xbio:ConsentSharesMember 2019-07-01 2019-09-30 0001534525 xbio:SecuritiesPurchaseAgreementMember xbio:PreFundedWarrantsMember 2019-09-30 0001534525 us-gaap:WarrantMember xbio:DebtAndEquityFinancingMember 2019-09-30 0001534525 us-gaap:WarrantMember xbio:DebtAndEquityFinancingMember 2018-01-01 2018-09-30 0001534525 xbio:SecuritiesPurchaseAgreementMember xbio:PreFundedWarrantsMember 2019-01-01 2019-06-30 xbrli:shares iso4217:USD xbrli:pure iso4217:USD xbrli:shares

12500000

.001

10-Q Xenetic Biosciences, Inc. Non-accelerated Filer 2019-09-30 false --12-31 2019 0001534525 Q3 Yes 5755141

970

1804

970

1804

0.001

10000000

970000

1804394

970000

1804394

970000

1804394

970000

1804394

true false

5633490

783865

475000

Yes NV 001-37937

22875119

14431094

709113

705660

9243128

3283379

1590

4956

12921288

1193971

876816

555856

66510

12044472

571605

4615807

4518306

2918518

1697289

1599788

538734

665641

1158555

934147

22875119

14431094

18259312

9912788

14301459

11295510

3090

2774

754

811

5660

948

165258198

167913738

167590260

168170244

188116697

171352760

-145933137

-151594367

-149781831

-153233595

-164838373

-155938245

253734

-5281180

12784568

10390791

5281180

253734

-164838373

-153233595

188116697

168170244

5660

811

5660481

810856

-11651975

-5636816

-8946522

-1814887

3896657

3267597

2142505

1079008

1100000

64000

4471939

2369219

3520638

735879

3000000

-11604778

-5661230

-8900128

-1812536

-5661230

-1812536

-11604778

-8900128

47197

-24414

46394

2351

46930

424

46617

267

-24838

-223

2292

-16889157

-5661230

-10305060

-1812536

5284379

1404932

1861867

746629

3862936

783865

-9.07

-7.58

-2.67

-2.31

3283379

47427 52281 63536 0

683104

1123000

2000

15437

16629

3366

12540

1000

3283379

3031226

-4721652

-5423077

54171

-623992

297712

310239

2000

22500

2000

22500

12044472

638115

5599572

1678995

11406357

-3920577

16126009

1480000

13421950

13400000

599

0 316 1890 0 1 0 3031226 0 7 0

43330

13421950 13421950 1747 1747 13420203 13420203 3031226 3031226 625 625 3030601 3030601 5009 4500 492 450 4517 4050 1890 1890 -1890 -1890 63536 63536 63536 63536 5284379 1404932 5284379 1404932 3900000

5284379

1404932

5284379

1404932

683104

1123000

232437

306051

1123000

306051

683104

232437

47427

52281

15000

17427

52281

17427

47427

15000

3090742

2774394

753659

810856

5660481

949218

1746666 1746666 624995 624995 492417 450000 1889602 1889602

2699050

2698963

-7

-1

86667

570000

1730000

86667

16666

7836

1442

1480000 31 1479969

-316

290

30834

-316348

26363

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 33px">8.</td> <td style="text-align: justify">Stockholders’ Equity </td></tr> </table>   The Offering   On July 17, 2019, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Maxim Group LLC (the “Underwriter”), relating to the Company’s Offering of 1,730,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), Prefunded Warrants to purchase 570,000 shares of Common Stock (the “Prefunded Warrants”), and warrants to purchase 2,300,000 shares of the Common Stock (the “Purchase Warrants,” and together with the Shares and the Prefunded Warrants, the "Firm Securities"). Each Share was sold together with one Purchase Warrant at a combined public offering price of $6.50 per Share and Purchase Warrant. Each Pre-funded Warrant purchased was sold together with one Purchase Warrant at a combined public offering price of $6.49 per Prefunded Warrant and Purchase Warrant. The Prefunded Warrants were exercisable beginning on July 17, 2019 at an exercise price of $0.01 per share. The holders of the Prefunded Warrants will not have the right to exercise any portion of the Prefunded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Prefunded Warrants. The Prefunded Warrants had an intrinsic value of approximately $3.1 million. Pursuant to the Underwriting Agreement, the Company also granted the Underwriter a 45-day option to purchase up to an additional 345,000 shares of Common Stock and/or Purchase Warrants to purchase up to 345,000 shares of Common Stock (the "Additional Securities," and together with the Firm Securities, the "Securities"), at the public offering price less discounts and commissions.   The Securities were offered, issued, and sold pursuant to an effective Registration Statement on Form S-1 (Reg. No. 333-231508) and accompanying prospectus filed with the SEC under the Securities Act of 1933, as amended.   On the Closing Date, the Company completed the Offering resulting in gross proceeds to the Company of approximately $15.0 million before deducting the underwriting discount and offering fees and expenses payable by the Company. In addition, on the Closing Date, the Underwriter exercised its overallotment option with respect to 160,000 Purchase Warrants, resulting in additional gross proceeds of $1,600. The Company intends to use the net proceeds from the Offering of approximately $13.4 million to fund its research, development and clinical programs, including the development of the XCART technology acquired in the Transaction, and for other general corporate purposes. Prefunded Warrants to purchase 450,000 shares of Common Stock were exercised during the three and nine months ended September 30, 2019 resulting in $4,500 of net proceeds to the Company.   The Purchase Warrants are immediately exercisable at a price of $13.00 per share of Common Stock and expire five years from the date of issuance. The warrants began trading on NASDAQ on July 23, 2019 under the symbol “XBIOW.” The Purchase Warrants also provide that if the weighted-average price of Common Stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each Purchase Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $4.61 per share, for a total of approximately $11.3 million. The fair value of these warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 1.83%, an expected life of 5 years and an expected volatility of 141.89%. Purchase Warrants to purchase approximately 1.9 million shares of Common Stock were exercised on a cashless one-for-one basis during the three and nine months ended September 30, 2019.   Common Stock   On July 16, 2019, the Company, in connection with the Offering, entered into a consent agreement with certain holders of warrants to purchase shares of the Company’s Common Stock whose consent was sought in connection with the Offering. In consideration of the holders’ consent, the Company agreed to (i) issue such holders an aggregate of 16,666 shares of the Company’s Common Stock (“Consent Shares”) and (ii) adjust the exercise price of those certain warrants issued to each holder in connection with the Company’s Reverse Stock Split on June 25, 2019. The Consent Shares and incremental cost associated with the warrant modification were determined to be direct costs of the Offering and, as a result, have been included within net proceeds from the Offering.   On June 21, 2019, the Company filed a Certificate of Change to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., eastern Time, on June 25, 2019. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in 1,442 new shares of Common Stock being issued to existing holders of the Company’s common stock.   On June 19, 2019, shareholders of the Company voted to approve an amendment to the Company’s Articles of Incorporation to increase the authorized shares of Common Stock to 150,000,000 shares on a pre-Reverse Stock Split basis (the “Authorized Share Increase”). On June 24, 2019, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of the State of Nevada to effect the Authorized Share Increase as of June 25, 2019. As a result of the Authorized Share Increase and after giving effect to the Reverse Stock Split, the Company had 12,500,000 authorized shares of Common Stock.   As a result of the Reverse Stock Split, the number of outstanding shares of our Common Stock held by non-affiliates was approximately 475,000. On June 28, 2019, the Company received a notice from the Nasdaq Capital Market ("NASDAQ") that it no longer met the minimum 500,000 publicly held shares requirement for continued listing. On July 19, 2019, the Company received a notice from NASDAQ that the Company had regained compliance with the publicly held shares requirement as a result of the Offering.   On March 5, 2019, the Company entered into a Securities Purchase Agreement with certain purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of (i) 86,667 shares of Common Stock, par value $0.001 per share and (ii) prefunded warrants to purchase 42,417 shares of Common Stock. The prefunded warrants were exercisable beginning on March 7, 2019 at an exercise price of $0.012 per share. The shares were sold at a price of $24.00 per share and the prefunded warrants were sold at a price of $23.988 per prefunded warrant, which represents the per share purchase price for the shares less the $0.012 per share exercise price for each such prefunded warrant. The holders of the prefunded warrants will not have the right to exercise any portion of the prefunded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the prefunded warrants. The net proceeds to the Company from this offering were approximately $2.7 million, after deducting expenses related to the offering, including dealer-manager fees and expenses. In a concurrent private placement, the Company issued to the purchasers a warrant to purchase one share of the Company’s Common Stock for each share and prefunded warrant purchased in the offering. These warrants have an exercise price of $27.00 per share, were exercisable beginning on September 8, 2019 and expire seven years from such date. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $22.74 per share, for a total of approximately $2.9 million. The fair value of the warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 2.56%, an expected life of 7.5 years and an expected volatility of 111.3%. The prefunded warrants had an intrinsic value of approximately $1.1 million. In June 2019, the prefunded warrants were exercised in full resulting in $509 of net proceeds to the Company.   Series B Preferred Stock   As of September 30, 2019 and December 31, 2018 there were approximately 1.8 million shares of Series B Preferred Stock issued and outstanding which were convertible on a 1.625 preferred shares to one share of common stock basis. The number of shares of Common Stock that, when aggregated with any shares of Common Stock that may be issued in connection with any conversion of Series B Preferred Stock and the exercise of warrants issued in connection with the Series B Preferred Stock, is subject to an Issuable Maximum, subject to adjustment, as set forth in the Second Amended and Restated Certificate of Designation of the Company’s Series B Preferred Stock. As of September 30, 2019, the Issuable Maximum is 0.6 million shares of Common Stock that can be issued upon the conversion of the currently outstanding Series B Preferred Stock and the exercise of warrants, issued in connection with the Series B Preferred Stock, that are currently outstanding.   The March 2019 registered direct offering triggered the down-round provision in the Company’s Series B Preferred Stock resulting in an adjustment to the conversion ratio and the recording of a deemed dividend of $3.9 million increasing the net loss attributable to common shareholders for the nine months ended September 30, 2019. In addition, the Offering triggered the down-round provision in the Company’s Series B Preferred Stock, resulting in a further adjustment to the conversion ratio and the recording of a deemed dividend of $1.4 million during the third quarter increasing the net loss attributable to common shareholders for the three and nine months ended September 30, 2019. There were no Series B Preferred Stock conversions during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, the holders of Series B Preferred Stock converted approximately 316,000 shares into approximately 26,000 shares of common stock.   Warrants   On July 17, 2019, in connection with the Offering, the Company offered to the purchasers Prefunded Warrants to purchase 570,000 shares of common stock. The Prefunded Warrants were exercisable beginning on July 17, 2019 at an exercise price of $0.01 per share. The Prefunded Warrants were sold at a price of $6.49 per Prefunded Warrant, which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such Prefunded Warrant. The holders of the Prefunded Warrants did not have the right to exercise any portion of the Prefunded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Prefunded Warrants. Prefunded Warrants to purchase 450,000 shares were exercised during the three and nine months ended September 30, 2019 resulting in net proceeds to the Company of $4,500. Also in connection with the Offering, the Company issued to the purchasers the Purchase Warrants. These Purchase Warrants have an exercise price of $13.00 per share, were exercisable beginning on July 17, 2019 and expire five years from such date. The warrants began trading on NASDAQ on July 23, 2019 under the symbol “XBIOW.” The Purchase Warrants also provide that if the weighted-average price of Common Stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each Purchase Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. Purchase Warrants to purchase approximately 1.9 million shares of common stock were exercised on a cashless one-for-one basis during the three and nine months ended September 30, 2019. As of September 30, 2019, there were approximately 120,000 Prefunded Warrants and 0.6 million Purchase Warrants outstanding. Subsequent to quarter end, the remaining outstanding Prefunded Warrants were exercised resulting in $1,200 of net proceeds to the Company.   On June 24, 2019, the Company entered into a consent agreement with certain holders of warrants to purchase shares of the Company’s common stock whose consent was required to effect the Reverse Stock Split. In consideration of the holders’ consent, the Company agreed to issue the holders warrants (the “Consent Warrants”) to purchase 8,335 shares of the Company’s common stock, at an exercise price per share based on a volume weighted average price for the five trading days following the effectiveness of the Reverse Stock Split. The Consent Warrants were issued on July 3, 2019 at an exercise price of $10.63. The Company evaluated the terms of the Consent Warrants and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $7.62 per share, for a total of approximately $64,000. The fair value of the Consent Warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 1.83%, an expected life of 7 years and an expected volatility of 114.53%. The Company recorded approximately $64,000 as general and administrative expense during the three and nine months ended September 30, 2019. The Consent Warrants were subsequently modified to reflect an exercise price of $2.91 price per share in connection with the Offering. As a result of this modification, the Company recognized a $2,000 expense that was netted against the proceeds of the Offering.   In March 2019, in connection with its registered direct offering, the Company offered to the purchasers prefunded warrants to purchase 42,417 shares of common stock. The prefunded warrants were exercisable beginning on March 7, 2019 at an exercise price of $0.012 per share. The prefunded warrants were sold at a price of $23.988 per prefunded warrant, which represents the per share purchase price for the shares less the $0.012 per share exercise price for each such prefunded warrant. The holders of the prefunded warrants did not have the right to exercise any portion of the prefunded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the prefunded warrants. All of these prefunded warrants were exercised in June 2019 resulting in net proceeds to the Company of $509. In a concurrent private placement, the Company issued to the purchasers a warrant to purchase one share of the Company’s common stock for each share and prefunded warrant (129,084 shares) purchased in the offering. These warrants have an exercise price of $27.00 per share, are exercisable beginning on September 8, 2019 and expire seven years from such date. As of September 30, 2019, all of these warrants were outstanding.   In addition to the prefunded and purchase warrants issued in the March 2019 registered direct offering and the Offering, the Company has outstanding warrants to purchase an aggregate of 262,690 shares of common stock in connection with debt and equity financing arrangements as of September 30, 2019 at a weighted average exercise price of $51.97 and expiration dates ranging from July 2020 through November 2021. There were no debt and equity financing warrants granted or exercised during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, debt and equity financing warrants to purchase approximately 31,000 shares of common stock were exercised resulting in approximately $1.5 million of net proceeds to the Company.

Preparation of Interim Financial Statements   The accompanying condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 and amended on April 30, 2019.   These condensed consolidated financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As a result, the financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.   On June 25, 2019, the Company effected a reduction, on a 1 for 12 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every 12 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock were proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1 for 12 basis; and (iv) the number of shares of common stock into which each share of preferred stock could be converted were proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this Reverse Stock Split.   Certain prior period amounts have been reclassified to conform to the presentation for the current period.

Basic and Diluted Net Loss per Share   The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during each period, except where such non-participating securities would be anti-dilutive.    For the three and nine months ended September 30, 2019 and 2018, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recently Adopted Accounting Standards   In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, and that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 Revenue from Contracts with Customers. ASU 2018-07 was effective for the Company in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.    In January 2017, the FASB issued ASU 2017-04: Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment that eliminated the requirement to calculate implied fair value of goodwill to measure a goodwill impairment charge. Instead, the new guidance requires entities to take an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company no later than 2020. The Company adopted ASU 2017-04 in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.   In February 2016, FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Subsequently, in July 2018, the FASB issued ASU 2018-11, Lease (Topic 842): Targeted Improvements, which provides a number of practical expedients in transition. The Company adopted ASU 2016-02 effective January 1, 2019 and elected a package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of lease, classification of a lease or any initial direct costs. The Company has also elected to use the hindsight practical expedients. The adoption did not have a material impact on the Company’s condensed consolidated financial statements, resulted in an approximate $43,000 increase in total assets and total liabilities in our condensed consolidated balance sheet and did not have any effect on accumulated deficit at the beginning of 2019. See Note 11 for further information.

Property and equipment, net consists of the following:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2019</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Office and computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">42,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">42,289</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,841</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,263</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment – at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,393</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(55,437</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(84,437</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment – net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,590</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,956</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

A reconciliation of the change in the carrying value of goodwill is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 58%">Balance as of January 1, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">3,283,379</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">No changes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Balance as of December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,283,379</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,283,379</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">38,843</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">81,921</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">178,926</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">208,594</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">314,323</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">648,610</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">996,355</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">247,437</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">323,478</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">730,531</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,175,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Operating cash flow information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">16,629</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">43,330</td><td style="text-align: left"> </td></tr></table>

Supplemental balance sheet information related to our operating leases is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance Sheet Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2019</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: justify; padding-bottom: 1pt">Right-of-use assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Prepaid expenses and other</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 13%; border-bottom: Black 1pt solid; text-align: right">26,701</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Current lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">26,701</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Non-current lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Other liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr></table>

57027

89393

42289

26841

14738

20263

55437

84437

On June 25, 2019, the company effected a reverse stock split on a 1-for-12 basis

1442

42417 2300000 8335 2900000 11300000

5009

1480000

4500

1600

4500

1500000

509

44944

120000

600000

42417

262690

124.90

316000

26000

3100000 1100000

1400000

3900000

730531

1175281

247437

323478

38843

9155

81921

178926

208594

314323

648610

996355

200000

300000

700000

1100000

1000

36000

15000

17000

47000

52000

834

7153

375

9026

1627

0 0 0 0 December 2019 through May 2021

26200000

23500000

2900000

16629

26701

3000

52000

0.102

40000

310000 2699050 0 2700000 2700000

406246

164062

54687

4100000

15000000

1900000

160000

31000

42417

2000

Principles of Consolidation   The condensed consolidated financial statements of the Company include the accounts of Hesperix and Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">1.</td> <td style="text-align: justify">The Company </td></tr> </table>   Background   Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART™, a personalized Chimeric Antigen Receptor (“CAR”) T cell platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (the “Institute”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (“IBCH”), is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. On March 1, 2019, the Company entered into agreements with Hesperix S.A. (“Hesperix”) and Opko Pharmaceuticals LLC (“OPKO”) to acquire the XCART technology (the “Transaction”) and closed the Transaction on July 19, 2019 concurrent with the completion of an approximate $15 million public offering (the “Offering”). For additional information regarding the Transaction, see Note 4 – “Acquisitions.”   Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen™, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid (“PSA”) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics.   As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.   The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various U.S. federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated.   Going Concern and Management’s Plan   Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On March 7, 2019, the Company closed on a $3.1 million registered direct common stock offering resulting in $2.7 million of net proceeds to the Company. On July 19, 2019, the Company completed the Offering resulting in $13.4 million of net proceeds to the Company. The Company believes that these financings, coupled with the Company’s existing resources, will be adequate to fund the Company’s operations as a going concern. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives and continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

EX-101.SCH 6 xbio-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. The Company link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Significant Strategic Drug Collaborations - Related Parties link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Acquisitions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Commitments link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 13. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 5. Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 11. Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 1. The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 4. Acquisitions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 5. Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 5. Property and Equipment, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets (Details - Change in carrying value of goodwill) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 7. Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 8. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 10. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 11. Commitments (Details - Supplemental Cash Flow Info) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 11. Commitments (Details - Lease liabilities) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 11. Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 12. Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 xbio-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 xbio-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 xbio-20190930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A [Member] Series B [Member] Equity Components [Axis] Preferred Stock Common Stock [Member] Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Income Treasury Stock Property, Plant and Equipment, Type [Axis] Office and Computer Equipment [Member] Leasehold Improvements [Member] Furniture and Fixtures [Member] Indefinite-lived Intangible Assets [Axis] OncoHist [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Sale of Stock [Axis] Underwriting Agreement [Member] Prefunded Warrants [Member] Securities Purchase Agreement [Member] Series B Preferred Stock [Member] Income Statement Location [Axis] Research and Development Expenses [Member] General and Administrative Expenses [Member] Award Type [Axis] Employee Stock Options [Member] Non Employee Stock Options [Member] Common Stock Awards [Member] Derivative Instrument [Axis] Warrant [Member] Transaction Type [Axis] Collaboration Agreements [Member] Balance Sheet Location [Axis] Other Assets [Member] Accrued Expenses and other current liabilities [Member] Other Liabilities [Member] Prepaid Expenses [Member] Public Offering [Member] Direct Offering [Member] Business Acquisition [Axis] Hesperix [Member] OPKO Assignment Agreement [Member] Institute [Member] Research and Development Assets Acquired Other than Through Business Combination by Transaction [Axis] XCART Technology [Member] Purchase Warrants [Member] Counterparty Name [Axis] Underwriter [Member] Consent Shares [Member] Non-Affiliates [Member] Warrants [Member] Securities Financing Transaction [Axis] Debt and Equity Financing [Member] Document And Entity Information [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Trading Symbol Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Current reporting status Well known Seasoned Issuer Entity Voluntary Filers Entity Public Float Entity Small Business Entity Emerging Growth Entity Interactive Data Current Entity Incorporation State Country Code Entity File Number Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Restricted cash Prepaid expenses and other Total current assets Property and equipment, net Goodwill Indefinite-lived intangible assets Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Total current liabilities Deferred tax liability Total liabilities Commitments (Note 11) Stockholders' equity: Preferred stock, 10,000,000 shares authorized Common stock, $0.001 par value; 12,500,000 shares authorized as of September 30, 2019 and December 31, 2018; 5,660,481 and 810,856 shares issued as of September 30, 2019 and December 31, 2018, respectively; 5,633,490 and 783,865 shares outstanding as of September 30, 2019 and December 31, 2018, respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive income Treasury stock Total stockholders' equity Total liabilities and stockholders' equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Statement of Comprehensive Income [Abstract] Operating costs and expenses: Research and development General and administrative Goodwill impairment Loss from operations Other income (expense): Other income (expense) Interest income Total other income (expense) Net loss Deemed dividend Net loss applicable to common stockholders Basic and diluted loss per share Weighted-average shares of common stock outstanding, basic and diluted Beginning balance, shares Beginning balance, value Exercise of warrants, shares Exercise of warrants, value Issuance of common stock and warrants in registered direct offering, net of issuance costs, shares Issuance of common stock and warrants in registered direct offering, net of issuance costs, value Issuance of common stock and warrants in public offering, net of issuance costs, shares Issuance of common stock and warrants in public offering, net of issuance costs, value Issuance of common stock in connection with purchase of in-process research and development, shares Issuance of common stock in connection with purchase of in-process research and development, value Exercise of pre-funded warrants, shares Exercise of pre-funded warrant, value Exercise of purchase warrants, shares Exercise of purchase warrants, value Issuance of common stock to vendor, shares Issuance of common stock to vendor, value Issuance of warrants in connection with reverse stock split, shares Issuance of warrants in connection with reverse stock split, value Issuance of common stock to adjust for reverse split rounding, shares Issuance of common stock to adjust for reverse split rounding, value Deemed dividend related to Series B Preferred Stock down round provision Accretion of deemed dividend related to Series B Preferred Stock down round provision Conversion of Series B preferred stock to shares of common stock, shares Conversion of Series B preferred stock to shares of common stock, value Share-based expense Common stock awards to vendors Net loss Ending balance, shares Ending balance, value Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Acquired in-process research and development Goodwill impairment Depreciation Amortization of right of use asset Gain on sale of property and equipment Share-based expense Issuance of warrants in connection with reverse stock split Vendor share-based expense Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable, accrued expenses and other liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from sale of property and equipment Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of common stock and warrants in public offering Net proceeds from issuance of common stock and warrants in registered direct offering Proceeds from exercise of warrants Net cash provided by financing activities Net change in cash and restricted cash Cash and restricted cash at beginning of period Cash and restricted cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Right of use asset acquired in exchange for lease liability Issuance of common stock to vendor Issuance of common stock to acquire in-process research and development Issuance of common stock to adjust for Reverse Stock Split Issuance of common stock from cashless exercise of purchase warrants Conversion of Series B preferred stock to common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] EX-101.PRE 10 xbio-20190930_pre.xml XBRL PRESENTATION FILE XML 11 R32.htm IDEA: XBRL DOCUMENT

8. Stockholders' Equity (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended		6 Months Ended		7 Months Ended		9 Months Ended
8. Stockholders' Equity (Details Narrative) - USD ($)	Mar. 05, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Jun. 24, 2019	Jul. 17, 2019	Jul. 16, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 28, 2019	Dec. 31, 2018
Reverse stock split								On June 25, 2019, the company effected a reverse stock split on a 1-for-12 basis
Reverse stock split, shares								1,442
Net proceeds from issuance of common stock and warrants in public offering								$ 13,421,950	$ 0
Net proceeds from issuance of common stock and warrants in registered direct offering								$ 2,699,050	0
Stock outstanding		5,633,490						5,633,490			783,865
Proceeds from warrants exercised								$ 5,009	1,480,000
Deemed dividend related to Series B Preferred Stock down round provision, value		$ 1,404,932						5,284,379
General and administrative expense		$ 2,142,505	$ 1,079,008					$ 3,896,657	$ 3,267,597
Warrants [Member] \| Debt and Equity Financing [Member]
Warrants exercised, shares									31,000
Proceeds from warrants exercised									$ 1,500,000
Warrants outstanding		262,690						262,690
Non-Affiliates [Member]
Stock outstanding										475,000
Prefunded Warrants [Member]
Proceeds from warrants exercised		$ 4,500						$ 4,500
Series B Preferred Stock [Member]
Deemed dividend related to Series B Preferred Stock down round provision, value								$ 3,900,000
Stock converted, shares converted								0	316,000
Stock converted, shares issued									26,000
Deemed dividend	$ 3,900,000	1,400,000						$ 1,400,000
Underwriting Agreement [Member]
Gross proceeds form the sale of stock and warrants						$ 15,000,000
Underwriting Agreement [Member] \| Underwriter [Member]
Warrants exercised, shares						160,000
Proceeds from warrants exercised						$ 1,600
Underwriting Agreement [Member] \| Consent Shares [Member]
Stock issued new, shares							16,666
Warrants issued					8,335
General and administrative expense		$ 64,000						64,000
Fair value adjustment of warrants								$ 2,000
Underwriting Agreement [Member] \| Common Stock [Member]
Stock issued new, shares						1,730,000
Underwriting Agreement [Member] \| Prefunded Warrants [Member]
Stock issued new, shares						570,000
Warrants outstanding		120,000						120,000
Intrinsic value of warrants						$ 3,100,000
Underwriting Agreement [Member] \| Purchase Warrants [Member]
Warrants issued						2,300,000
Warrants exercised, shares						1,900,000
Warrants granted fair value						$ 11,300,000
Warrants outstanding		600,000						600,000
Securities Purchase Agreement [Member]
Net proceeds from issuance of common stock and warrants in registered direct offering	$ 2,700,000
Securities Purchase Agreement [Member] \| Common Stock [Member]
Stock issued new, shares	86,667
Securities Purchase Agreement [Member] \| Prefunded Warrants [Member]
Warrants issued	42,417
Warrants exercised, shares				42,417
Proceeds from warrants exercised				$ 509
Warrants granted fair value	$ 2,900,000
Warrants outstanding		42,417						42,417
Intrinsic value of warrants	$ 1,100,000

XML 12 R36.htm IDEA: XBRL DOCUMENT

11. Commitments (Details - Supplemental Cash Flow Info) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating cash flow information
Cash paid for amounts included in the measurement of lease liabilities	$ 16,629
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	$ 43,330	$ 0

XML 13 R15.htm IDEA: XBRL DOCUMENT

9. Share-Based Expense

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-Based Expense

9.	Share-Based Expense

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development expenses	$	38,843	$	9,155	$	81,921	$	178,926
General and administrative expenses		208,594		314,323		648,610		996,355
	$	247,437	$	323,478	$	730,531	$	1,175,281

Employee Stock Options

Non-Employee Stock Options

Common Stock Awards

Warrants

XML 14 R11.htm IDEA: XBRL DOCUMENT

5. Property and Equipment, net

9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment, net

5.	Property and Equipment, net

Property and equipment, net consists of the following:

	September 30, 2019			December 31, 2018
Office and computer equipment	$	42,289		$	42,289
Leasehold improvements		–			26,841
Furniture and fixtures		14,738			20,263
Property and equipment – at cost		57,027			89,393
Less accumulated depreciation		(55,437	)		(84,437	)
Property and equipment – net	$	1,590		$	4,956

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,604,778)	$ (5,661,230)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	3,031,226	0
Goodwill impairment	3,283,379	0
Depreciation	3,366	12,540
Amortization of right of use asset	16,629	0
Gain on sale of property and equipment	(2,000)	(15,437)
Share-based expense	683,104	1,123,000
Issuance of warrants in connection with reverse stock split	63,536	0
Vendor share-based expense	47,427	52,281
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(297,712)	(310,239)
Accounts payable, accrued expenses and other liabilities	54,171	(623,992)
Net cash used in operating activities	(4,721,652)	(5,423,077)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	2,000	22,500
Net cash provided by investing activities	2,000	22,500
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants in public offering	13,421,950	0
Net proceeds from issuance of common stock and warrants in registered direct offering	2,699,050	0
Proceeds from exercise of warrants	5,009	1,480,000
Net cash provided by financing activities	16,126,009	1,480,000
Net change in cash and restricted cash	11,406,357	(3,920,577)
Cash and restricted cash at beginning of period	638,115	5,599,572
Cash and restricted cash at end of period	12,044,472	1,678,995
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	8	599
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right of use asset acquired in exchange for lease liability	43,330	0
Issuance of common stock to vendor	7	0
Issuance of common stock to acquire in-process research and development	3,031,226	0
Issuance of common stock to adjust for Reverse Stock Split	1	0
Issuance of common stock from cashless exercise of purchase warrants	1,890	0
Conversion of Series B preferred stock to common stock	$ 0	$ 316

XML 16 R19.htm IDEA: XBRL DOCUMENT

13. Subsequent Events

9 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

13.

Subsequent Events

XML 17 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 12,044,472	$ 571,605
Restricted cash	0	66,510
Prepaid expenses and other	876,816	555,856
Total current assets	12,921,288	1,193,971
Property and equipment, net	1,590	4,956
Goodwill	0	3,283,379
Indefinite-lived intangible assets	9,243,128	9,243,128
Other assets	709,113	705,660
Total assets	22,875,119	14,431,094
Current liabilities:
Accounts payable	1,158,555	934,147
Accrued expenses and other current liabilities	538,734	665,641
Total current liabilities	1,697,289	1,599,788
Deferred tax liability	2,918,518	2,918,518
Total liabilities	4,615,807	4,518,306
Stockholders' equity:
Common stock, $0.001 par value; 12,500,000 shares authorized as of September 30, 2019 and December 31, 2018; 5,660,481 and 810,856 shares issued as of September 30, 2019 and December 31, 2018, respectively; 5,633,490 and 783,865 shares outstanding as of September 30, 2019 and December 31, 2018, respectively	5,660	811
Additional paid in capital	188,116,697	168,170,244
Accumulated deficit	(164,838,373)	(153,233,595)
Accumulated other comprehensive income	253,734	253,734
Treasury stock	(5,281,180)	(5,281,180)
Total stockholders' equity	18,259,312	9,912,788
Total liabilities and stockholders' equity	22,875,119	14,431,094
Series B [Member]
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized	1,804	1,804
Series A [Member]
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized	$ 970	$ 970

XML 18 R27.htm IDEA: XBRL DOCUMENT

5. Property and Equipment, net (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property and equipment - at cost	$ 57,027	$ 89,393
Less accumulated depreciation	(55,437)	(84,437)
Property and equipment - net	1,590	4,956
Office and Computer Equipment [Member]
Property and equipment - at cost	42,289	42,289
Leasehold Improvements [Member]
Property and equipment - at cost	0	26,841
Furniture and Fixtures [Member]
Property and equipment - at cost	$ 14,738	$ 20,263

XML 19 R23.htm IDEA: XBRL DOCUMENT

9. Share-Based Expense (Tables)

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-based expense

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development expenses	$	38,843	$	9,155	$	81,921	$	178,926
General and administrative expenses		208,594		314,323		648,610		996,355
	$	247,437	$	323,478	$	730,531	$	1,175,281

XML 20 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 22 R26.htm IDEA: XBRL DOCUMENT

4. Acquisitions (Details Narrative) - USD ($)	3 Months Ended		7 Months Ended	9 Months Ended
4. Acquisitions (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Jul. 19, 2019	Sep. 30, 2019	Sep. 30, 2018
Research and development expense	$ 3,520,638	$ 735,879		$ 4,471,939	$ 2,369,219
General and administrative expense	$ 2,142,505	$ 1,079,008		3,896,657	$ 3,267,597
XCART Technology [Member]
Payment for intellectual property			$ 4,100,000
Research and development expense				3,000,000
General and administrative expense				$ 1,100,000
Hesperix [Member]
Stock issued for acquisition, shares			406,246
OPKO Assignment Agreement [Member]
Stock issued for acquisition, shares			164,062
Institute [Member]
Stock issued for acquisition, shares			54,687

XML 23 R22.htm IDEA: XBRL DOCUMENT

6. Goodwill and Indefinite-Lived Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Reconciliation of change in carrying value of goodwill

A reconciliation of the change in the carrying value of goodwill is as follows:

Balance as of January 1, 2018	$	3,283,379
No changes		–
Balance as of December 31, 2018		3,283,379
Impairment		(3,283,379	)
Balance as of September 30, 2019	$	–

ZIP 24 0001683168-19-003653-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-19-003653-xbrl.zip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end XML 25 R33.htm IDEA: XBRL DOCUMENT v3.19.3

9. Share-Based Expense (Details - Share based compensation) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Share-based expense $ 247,437 $ 323,478 $ 730,531 $ 1,175,281

Research and Development Expenses [Member]

Share-based expense 38,843 9,155 81,921 178,926

General and Administrative Expenses [Member]

Share-based expense $ 208,594 $ 314,323 $ 648,610 $ 996,355

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R37.htm IDEA: XBRL DOCUMENT v3.19.3

11. Commitments (Details - Lease liabilities)

Sep. 30, 2019

USD ($)

Other Assets [Member]

Right-of-use assets $ 26,701

Accrued Expenses and other current liabilities [Member]

Current lease liabilities 26,701

Other Liabilities [Member]

Non-current lease liabilities $ 0

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=xbio_AccruedExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R7.htm IDEA: XBRL DOCUMENT v3.19.3

1. The Company
9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

1. The Company

Background

Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART™, a personalized Chimeric Antigen Receptor (“CAR”) T cell platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (the “Institute”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (“IBCH”), is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. On March 1, 2019, the Company entered into agreements with Hesperix S.A. (“Hesperix”) and Opko Pharmaceuticals LLC (“OPKO”) to acquire the XCART technology (the “Transaction”) and closed the Transaction on July 19, 2019 concurrent with the completion of an approximate $15 million public offering (the “Offering”). For additional information regarding the Transaction, see Note 4 – “Acquisitions.”

Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen^™, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid (“PSA”) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics.

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.

The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various U.S. federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated.

Going Concern and Management’s Plan

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On March 7, 2019, the Company closed on a $3.1 million registered direct common stock offering resulting in $2.7 million of net proceeds to the Company. On July 19, 2019, the Company completed the Offering resulting in $13.4 million of net proceeds to the Company. The Company believes that these financings, coupled with the Company’s existing resources, will be adequate to fund the Company’s operations as a going concern. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives and continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.19.3

12. Related Party Transactions
9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

Related Party Transactions
12. Related Party Transactions

The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (as well as SynBio, a wholly owned subsidiary of Pharmsynthez), each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the years ended December 31, 2018 filed with the SEC on March 29, 2019 as amended on April 30, 2019. In connection with the Offering, Serum Institute’s and Pharmsynthez’ ownership significantly changed. As of September 30, 2019, Serum Institute owned less than 1% and Pharmsynthez owned approximately 7.9% of the total outstanding common stock of the Company.

During the third quarter, the Company entered into a sponsored research agreement with Pharmsynthez related to experiments identified by the Company to support its efforts as it prepares for initial tech transfer of the XCART methods to a future academic collaborator. Under the agreement, the Company made a $350,000 payment to Pharmsynthez during the third quarter of 2019, which is refundable on pro rata basis if the project is terminated prematurely as a result of Pharmsynthez failing to perform the work. The Company expensed approximately $40,000 related to this agreement during the three months ended September 30, 2019. As of September 30, 2019, approximately $310,000 was recorded as an advanced payment and included in Prepaid expenses and other on the September 30, 2019 condensed consolidated balance sheet.

On July 19, 2019, the Company acquired the XCART technology platform from Hesperix and OPKO. Dr. Genkin is a director and significant shareholder of Hesperix. In addition, the Company agreed to repay an approximate $225,000 loan that Dr. Genkin entered into with Hesperix. Mr. Adam Logal, one of our directors, is Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer of OPKO Health, Inc., the parent company of OPKO.

Subsequent to quarter end, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company shall advance Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the August 2011 Stock Subscription and Collaborative Development of Pharmaceutical Products Agreement between the Company and SynBio. The Pharmsynthez Loan has a term of 15-months and shall accrue interest at a rate of 10% per annum. The Pharmsynthez Loan is guaranteed by SynBio and AS Kevelt, which are the operating entities of Pharmsynthez, and is secured by all of the equity interests of the Company owned by Pharmsynthez and SynBio.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R3.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares

Sep. 30, 2019

Dec. 31, 2018

Common stock, par value $ .001 $ .001

Common stock, shares authorized 12,500,000 12,500,000

Common stock, shares issued 5,660,481 810,856

Common stock, shares outstanding 5,633,490 783,865

Preferred stock, shares authorized 10,000,000 10,000,000

Series B [Member]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares issued 1,804,394 1,804,394

Preferred stock, shares outstanding 1,804,394 1,804,394

Series A [Member]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares issued 970,000 970,000

Preferred stock, shares outstanding 970,000 970,000

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.19.3

8. Stockholders' Equity
9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Stockholders' Equity
8. Stockholders’ Equity

The Offering

On July 17, 2019, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Maxim Group LLC (the “Underwriter”), relating to the Company’s Offering of 1,730,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), Prefunded Warrants to purchase 570,000 shares of Common Stock (the “Prefunded Warrants”), and warrants to purchase 2,300,000 shares of the Common Stock (the “Purchase Warrants,” and together with the Shares and the Prefunded Warrants, the "Firm Securities"). Each Share was sold together with one Purchase Warrant at a combined public offering price of $6.50 per Share and Purchase Warrant. Each Pre-funded Warrant purchased was sold together with one Purchase Warrant at a combined public offering price of $6.49 per Prefunded Warrant and Purchase Warrant. The Prefunded Warrants were exercisable beginning on July 17, 2019 at an exercise price of $0.01 per share. The holders of the Prefunded Warrants will not have the right to exercise any portion of the Prefunded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Prefunded Warrants. The Prefunded Warrants had an intrinsic value of approximately $3.1 million. Pursuant to the Underwriting Agreement, the Company also granted the Underwriter a 45-day option to purchase up to an additional 345,000 shares of Common Stock and/or Purchase Warrants to purchase up to 345,000 shares of Common Stock (the "Additional Securities," and together with the Firm Securities, the "Securities"), at the public offering price less discounts and commissions.

The Securities were offered, issued, and sold pursuant to an effective Registration Statement on Form S-1 (Reg. No. 333-231508) and accompanying prospectus filed with the SEC under the Securities Act of 1933, as amended.

On the Closing Date, the Company completed the Offering resulting in gross proceeds to the Company of approximately $15.0 million before deducting the underwriting discount and offering fees and expenses payable by the Company. In addition, on the Closing Date, the Underwriter exercised its overallotment option with respect to 160,000 Purchase Warrants, resulting in additional gross proceeds of $1,600. The Company intends to use the net proceeds from the Offering of approximately $13.4 million to fund its research, development and clinical programs, including the development of the XCART technology acquired in the Transaction, and for other general corporate purposes. Prefunded Warrants to purchase 450,000 shares of Common Stock were exercised during the three and nine months ended September 30, 2019 resulting in $4,500 of net proceeds to the Company.

The Purchase Warrants are immediately exercisable at a price of $13.00 per share of Common Stock and expire five years from the date of issuance. The warrants began trading on NASDAQ on July 23, 2019 under the symbol “XBIOW.” The Purchase Warrants also provide that if the weighted-average price of Common Stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each Purchase Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $4.61 per share, for a total of approximately $11.3 million. The fair value of these warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 1.83%, an expected life of 5 years and an expected volatility of 141.89%. Purchase Warrants to purchase approximately 1.9 million shares of Common Stock were exercised on a cashless one-for-one basis during the three and nine months ended September 30, 2019.

Common Stock

On July 16, 2019, the Company, in connection with the Offering, entered into a consent agreement with certain holders of warrants to purchase shares of the Company’s Common Stock whose consent was sought in connection with the Offering. In consideration of the holders’ consent, the Company agreed to (i) issue such holders an aggregate of 16,666 shares of the Company’s Common Stock (“Consent Shares”) and (ii) adjust the exercise price of those certain warrants issued to each holder in connection with the Company’s Reverse Stock Split on June 25, 2019. The Consent Shares and incremental cost associated with the warrant modification were determined to be direct costs of the Offering and, as a result, have been included within net proceeds from the Offering.

On June 21, 2019, the Company filed a Certificate of Change to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., eastern Time, on June 25, 2019. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in 1,442 new shares of Common Stock being issued to existing holders of the Company’s common stock.

On June 19, 2019, shareholders of the Company voted to approve an amendment to the Company’s Articles of Incorporation to increase the authorized shares of Common Stock to 150,000,000 shares on a pre-Reverse Stock Split basis (the “Authorized Share Increase”). On June 24, 2019, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of the State of Nevada to effect the Authorized Share Increase as of June 25, 2019. As a result of the Authorized Share Increase and after giving effect to the Reverse Stock Split, the Company had 12,500,000 authorized shares of Common Stock.

As a result of the Reverse Stock Split, the number of outstanding shares of our Common Stock held by non-affiliates was approximately 475,000. On June 28, 2019, the Company received a notice from the Nasdaq Capital Market ("NASDAQ") that it no longer met the minimum 500,000 publicly held shares requirement for continued listing. On July 19, 2019, the Company received a notice from NASDAQ that the Company had regained compliance with the publicly held shares requirement as a result of the Offering.

On March 5, 2019, the Company entered into a Securities Purchase Agreement with certain purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of (i) 86,667 shares of Common Stock, par value $0.001 per share and (ii) prefunded warrants to purchase 42,417 shares of Common Stock. The prefunded warrants were exercisable beginning on March 7, 2019 at an exercise price of $0.012 per share. The shares were sold at a price of $24.00 per share and the prefunded warrants were sold at a price of $23.988 per prefunded warrant, which represents the per share purchase price for the shares less the $0.012 per share exercise price for each such prefunded warrant. The holders of the prefunded warrants will not have the right to exercise any portion of the prefunded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the prefunded warrants. The net proceeds to the Company from this offering were approximately $2.7 million, after deducting expenses related to the offering, including dealer-manager fees and expenses. In a concurrent private placement, the Company issued to the purchasers a warrant to purchase one share of the Company’s Common Stock for each share and prefunded warrant purchased in the offering. These warrants have an exercise price of $27.00 per share, were exercisable beginning on September 8, 2019 and expire seven years from such date. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $22.74 per share, for a total of approximately $2.9 million. The fair value of the warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 2.56%, an expected life of 7.5 years and an expected volatility of 111.3%. The prefunded warrants had an intrinsic value of approximately $1.1 million. In June 2019, the prefunded warrants were exercised in full resulting in $509 of net proceeds to the Company.

Series B Preferred Stock

As of September 30, 2019 and December 31, 2018 there were approximately 1.8 million shares of Series B Preferred Stock issued and outstanding which were convertible on a 1.625 preferred shares to one share of common stock basis. The number of shares of Common Stock that, when aggregated with any shares of Common Stock that may be issued in connection with any conversion of Series B Preferred Stock and the exercise of warrants issued in connection with the Series B Preferred Stock, is subject to an Issuable Maximum, subject to adjustment, as set forth in the Second Amended and Restated Certificate of Designation of the Company’s Series B Preferred Stock. As of September 30, 2019, the Issuable Maximum is 0.6 million shares of Common Stock that can be issued upon the conversion of the currently outstanding Series B Preferred Stock and the exercise of warrants, issued in connection with the Series B Preferred Stock, that are currently outstanding.

The March 2019 registered direct offering triggered the down-round provision in the Company’s Series B Preferred Stock resulting in an adjustment to the conversion ratio and the recording of a deemed dividend of $3.9 million increasing the net loss attributable to common shareholders for the nine months ended September 30, 2019. In addition, the Offering triggered the down-round provision in the Company’s Series B Preferred Stock, resulting in a further adjustment to the conversion ratio and the recording of a deemed dividend of $1.4 million during the third quarter increasing the net loss attributable to common shareholders for the three and nine months ended September 30, 2019. There were no Series B Preferred Stock conversions during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, the holders of Series B Preferred Stock converted approximately 316,000 shares into approximately 26,000 shares of common stock.

Warrants

On July 17, 2019, in connection with the Offering, the Company offered to the purchasers Prefunded Warrants to purchase 570,000 shares of common stock. The Prefunded Warrants were exercisable beginning on July 17, 2019 at an exercise price of $0.01 per share. The Prefunded Warrants were sold at a price of $6.49 per Prefunded Warrant, which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such Prefunded Warrant. The holders of the Prefunded Warrants did not have the right to exercise any portion of the Prefunded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Prefunded Warrants. Prefunded Warrants to purchase 450,000 shares were exercised during the three and nine months ended September 30, 2019 resulting in net proceeds to the Company of $4,500. Also in connection with the Offering, the Company issued to the purchasers the Purchase Warrants. These Purchase Warrants have an exercise price of $13.00 per share, were exercisable beginning on July 17, 2019 and expire five years from such date. The warrants began trading on NASDAQ on July 23, 2019 under the symbol “XBIOW.” The Purchase Warrants also provide that if the weighted-average price of Common Stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each Purchase Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. Purchase Warrants to purchase approximately 1.9 million shares of common stock were exercised on a cashless one-for-one basis during the three and nine months ended September 30, 2019. As of September 30, 2019, there were approximately 120,000 Prefunded Warrants and 0.6 million Purchase Warrants outstanding. Subsequent to quarter end, the remaining outstanding Prefunded Warrants were exercised resulting in $1,200 of net proceeds to the Company.

On June 24, 2019, the Company entered into a consent agreement with certain holders of warrants to purchase shares of the Company’s common stock whose consent was required to effect the Reverse Stock Split. In consideration of the holders’ consent, the Company agreed to issue the holders warrants (the “Consent Warrants”) to purchase 8,335 shares of the Company’s common stock, at an exercise price per share based on a volume weighted average price for the five trading days following the effectiveness of the Reverse Stock Split. The Consent Warrants were issued on July 3, 2019 at an exercise price of $10.63. The Company evaluated the terms of the Consent Warrants and determined that they should be classified as equity instruments. The grant date fair value of these warrants was estimated to be $7.62 per share, for a total of approximately $64,000. The fair value of the Consent Warrants was estimated using a Black-Scholes model utilizing the following key valuation assumptions: the Company’s stock price, a risk free rate of 1.83%, an expected life of 7 years and an expected volatility of 114.53%. The Company recorded approximately $64,000 as general and administrative expense during the three and nine months ended September 30, 2019. The Consent Warrants were subsequently modified to reflect an exercise price of $2.91 price per share in connection with the Offering. As a result of this modification, the Company recognized a $2,000 expense that was netted against the proceeds of the Offering.

In March 2019, in connection with its registered direct offering, the Company offered to the purchasers prefunded warrants to purchase 42,417 shares of common stock. The prefunded warrants were exercisable beginning on March 7, 2019 at an exercise price of $0.012 per share. The prefunded warrants were sold at a price of $23.988 per prefunded warrant, which represents the per share purchase price for the shares less the $0.012 per share exercise price for each such prefunded warrant. The holders of the prefunded warrants did not have the right to exercise any portion of the prefunded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the prefunded warrants. All of these prefunded warrants were exercised in June 2019 resulting in net proceeds to the Company of $509. In a concurrent private placement, the Company issued to the purchasers a warrant to purchase one share of the Company’s common stock for each share and prefunded warrant (129,084 shares) purchased in the offering. These warrants have an exercise price of $27.00 per share, are exercisable beginning on September 8, 2019 and expire seven years from such date. As of September 30, 2019, all of these warrants were outstanding.

In addition to the prefunded and purchase warrants issued in the March 2019 registered direct offering and the Offering, the Company has outstanding warrants to purchase an aggregate of 262,690 shares of common stock in connection with debt and equity financing arrangements as of September 30, 2019 at a weighted average exercise price of $51.97 and expiration dates ranging from July 2020 through November 2021. There were no debt and equity financing warrants granted or exercised during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, debt and equity financing warrants to purchase approximately 31,000 shares of common stock were exercised resulting in approximately $1.5 million of net proceeds to the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R10.htm IDEA: XBRL DOCUMENT v3.19.3

4. Acquisitions
9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

Acquisitions
4. Acquisitions

On March 1, 2019 (the “Signing Date”) the Company entered into agreements with Hesperix and Opko to acquire the XCART technology. The Company entered into a Share Purchase Agreement, as amended (the “Share Purchase Agreement”), with Hesperix, the owners of Hesperix (each, a “Seller” and collectively, the “Sellers”), and Alexey Andreevich Vinogradov, as the representative of each Seller, pursuant to which the Company purchased from Sellers all of the issued and outstanding shares of capital stock of Hesperix.



Under the terms of the Share Purchase Agreement, the Company issued to Sellers an aggregate of Four Hundred Six Thousand Two Hundred Forty-Six (406,246) shares of the Company’s common stock (the “Transaction Shares”) at the time of the closing. In addition, the Share Purchase Agreement contains customary representations and warranties relating to each Seller and about the condition of the Company and Hesperix. The Company issued the Transaction Shares pursuant to a registration statement on Form S-4.

On the Signing Date and in connection with the Transaction, Hesperix entered into an assignment agreement (the “Hesperix Assignment Agreement”) with IBCH, Pharmsynthez, and certain other parties thereto (collectively, the “Assignors”), pursuant to which, the Assignors have agreed, among other things, to sell, assign, transfer, and convey unto Hesperix all of their individual right, title, and interest throughout the world in and to patents related to “Articles And Methods Directed To Personalized Therapy Of Cancer,” and the related know-how. Hesperix has agreed to pay each of IBCH and Pharmsynthez a royalty rate in the low single digit range based on the net sales of products in each country in which, in the absence of the Hesperix Assignment Agreement, the manufacture, use, offer for sale, sale, or importation of such product would infringe a valid claim of a patent.

Also on the Signing Date, the Company entered into an assignment agreement with OPKO (the “OPKO Assignment Agreement”), pursuant to which the Company will acquire and accept, all of OPKO’s right, title and interest in and to that certain Intellectual Property License Agreement (the “IP License Agreement”), entered into between the Institute and OPKO regarding certain patents related to “Articles And Methods Directed To Personalized Therapy Of Cancer” and in which the Institute agreed to grant an exclusive royalty-bearing license, to the patent rights owned by the Institute to OPKO, and OPKO has agreed to pay the Institute a royalty rate in the low single digit range based on the net sales of products in each country in which, in the absence of the IP License Agreement, the manufacture, use, offer for sale, sale, or importation of such product would infringe a valid claim of a patent or pending application.

Under the terms of the OPKO Assignment Agreement and the IP License Agreement, the Company issued One Hundred Sixty Four Thousand Sixty Two (164,062) shares of the Company’s common stock to OPKO and Fifty-Four Thousand Six Hundred Eighty Seven (54,687) shares of the Company’s common stock to the Institute at the time of the closing. In addition, the OPKO Assignment Agreement contains customary representations and warranties relating to OPKO and the IP License Agreement.

On July 19, 2019, the Company closed the Transaction (the “Closing Date”), acquiring in-process research and development (“IPR&D”) related to certain intellectual property rights with respect to the XCART technology. The acquisition did not meet the business combination requirements and, as a result, was accounted for as an asset acquisition. The total consideration for the IPR&D was approximately $4.1 million, which represented the value of the common shares issued of $3.0 million utilizing the market price of the Company’s stock price at the Closing Date and approximately $1.1 million of transaction costs. As there was no future alternative use for the IPR&D, the Company recorded expense of $3.0 million to Research and development expense and $1.1 million to General and administrative expense for the transaction costs in the three and nine months ended September 30, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R24.htm IDEA: XBRL DOCUMENT v3.19.3

11. Commitments (Tables)
9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Supplemental cash flow information
Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

Nine Months

Ended

September 30,

2019

Operating cash flow information:

Cash paid for amounts included in the measurement of lease liabilities $ 16,629

Non-cash activity:

Right-of-use assets obtained in exchange for lease obligations $ 43,330

Supplemental balance sheet information
Supplemental balance sheet information related to our operating leases is as follows:

Balance Sheet Classification September 30, 2019

Right-of-use assets Prepaid expenses and other $ 26,701

Current lease liabilities Accrued expenses and other current liabilities $ 26,701

Non-current lease liabilities Other liabilities $ –

X

- Definition
Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10
+ Details

Name: srt_ScheduleOfCondensedBalanceSheetTableTextBlock

Namespace Prefix: srt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of supplemental cash flow information for the periods presented.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.19.3

2. Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Preparation of Interim Financial Statements
Preparation of Interim Financial Statements

The accompanying condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 and amended on April 30, 2019.

These condensed consolidated financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As a result, the financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

On June 25, 2019, the Company effected a reduction, on a 1 for 12 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every 12 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock were proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1 for 12 basis; and (iv) the number of shares of common stock into which each share of preferred stock could be converted were proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this Reverse Stock Split.

Certain prior period amounts have been reclassified to conform to the presentation for the current period.

Principles of Consolidation

Principles of Consolidation

The condensed consolidated financial statements of the Company include the accounts of Hesperix and Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share
Basic and Diluted Net Loss per Share

The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during each period, except where such non-participating securities would be anti-dilutive.



For the three and nine months ended September 30, 2019 and 2018, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recently Adopted Accounting Standards
Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, and that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 Revenue from Contracts with Customers. ASU 2018-07 was effective for the Company in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.



In January 2017, the FASB issued ASU 2017-04: Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment that eliminated the requirement to calculate implied fair value of goodwill to measure a goodwill impairment charge. Instead, the new guidance requires entities to take an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company no later than 2020. The Company adopted ASU 2017-04 in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

In February 2016, FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Subsequently, in July 2018, the FASB issued ASU 2018-11, Lease (Topic 842): Targeted Improvements, which provides a number of practical expedients in transition. The Company adopted ASU 2016-02 effective January 1, 2019 and elected a package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of lease, classification of a lease or any initial direct costs. The Company has also elected to use the hindsight practical expedients. The adoption did not have a material impact on the Company’s condensed consolidated financial statements, resulted in an approximate $43,000 increase in total assets and total liabilities in our condensed consolidated balance sheet and did not have any effect on accumulated deficit at the beginning of 2019. See Note 11 for further information.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R28.htm IDEA: XBRL DOCUMENT v3.19.3

5. Property and Equipment, net (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2019

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Depreciation expense $ 1,000 $ 3,366 $ 12,540

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited) - USD ($)

Preferred Stock

Common Stock [Member]

Additional Paid-In Capital

Accumulated Deficit

Accumulated Other Comprehensive Income

Treasury Stock

Total

Beginning balance, shares at Dec. 31, 2017 3,090,742 753,659

Beginning balance, value at Dec. 31, 2017 $ 3,090 $ 754 $ 165,258,198 $ (145,933,137) $ 253,734 $ (5,281,180) $ 14,301,459

Exercise of warrants, shares 30,834

Exercise of warrants, value $ 31 1,479,969 1,480,000

Conversion of Series B preferred stock to shares of common stock, shares (316,348) 26,363

Conversion of Series B preferred stock to shares of common stock, value $ (316) $ 26 290

Share-based expense 1,123,000 1,123,000

Common stock awards to vendors 52,281 52,281

Net loss (5,661,230) (5,661,230)

Ending balance, shares at Sep. 30, 2018 2,774,394 810,856

Ending balance, value at Sep. 30, 2018 $ 2,774 $ 811 167,913,738 (151,594,367) 253,734 (5,281,180) 11,295,510

Beginning balance, shares at Jun. 30, 2018 2,774,394 810,856

Beginning balance, value at Jun. 30, 2018 $ 2,774 $ 811 167,590,260 (149,781,831) 253,734 (5,281,180) 12,784,568

Share-based expense 306,051 306,051

Common stock awards to vendors 17,427 17,427

Net loss (1,812,536) (1,812,536)

Ending balance, shares at Sep. 30, 2018 2,774,394 810,856

Ending balance, value at Sep. 30, 2018 $ 2,774 $ 811 167,913,738 (151,594,367) 253,734 (5,281,180) 11,295,510

Beginning balance, shares at Dec. 31, 2018 2,774,394 810,856

Beginning balance, value at Dec. 31, 2018 $ 2,774 $ 811 168,170,244 (153,233,595) 253,734 (5,281,180) 9,912,788

Issuance of common stock and warrants in registered direct offering, net of issuance costs, shares 86,667

Issuance of common stock and warrants in registered direct offering, net of issuance costs, value $ 87 2,698,963 2,699,050

Issuance of common stock and warrants in public offering, net of issuance costs, shares 1,746,666

Issuance of common stock and warrants in public offering, net of issuance costs, value $ 1,747 13,420,203 13,421,950

Issuance of common stock in connection with purchase of in-process research and development, shares 624,995

Issuance of common stock in connection with purchase of in-process research and development, value $ 625 3,030,601 3,031,226

Exercise of pre-funded warrants, shares 492,417

Exercise of pre-funded warrant, value $ 492 4,517 5,009

Exercise of purchase warrants, shares 1,889,602

Exercise of purchase warrants, value $ 1,890 (1,890)

Issuance of common stock to vendor, shares 7,836

Issuance of common stock to vendor, value $ 7 (7)

Issuance of warrants in connection with reverse stock split, shares

Issuance of warrants in connection with reverse stock split, value 63,536 63,536

Issuance of common stock to adjust for reverse split rounding, shares 1,442

Issuance of common stock to adjust for reverse split rounding, value $ 1 (1)

Deemed dividend related to Series B Preferred Stock down round provision 5,284,379 5,284,379

Accretion of deemed dividend related to Series B Preferred Stock down round provision (5,284,379) (5,284,379)

Share-based expense 683,104 683,104

Common stock awards to vendors 47,427 47,427

Net loss (11,604,778) (11,604,778)

Ending balance, shares at Sep. 30, 2019 2,774,394 5,660,481

Ending balance, value at Sep. 30, 2019 $ 2,774 $ 5,660 188,116,697 (164,838,373) 253,734 (5,281,180) 18,259,312

Beginning balance, shares at Jun. 30, 2019 2,774,394 949,218

Beginning balance, value at Jun. 30, 2019 $ 2,774 $ 948 171,352,760 (155,938,245) 253,734 (5,281,180) 10,390,791

Issuance of common stock and warrants in public offering, net of issuance costs, shares 1,746,666

Issuance of common stock and warrants in public offering, net of issuance costs, value $ 1,747 13,420,203 13,421,950

Issuance of common stock in connection with purchase of in-process research and development, shares 624,995

Issuance of common stock in connection with purchase of in-process research and development, value $ 625 3,030,601 3,031,226

Exercise of pre-funded warrants, shares 450,000

Exercise of pre-funded warrant, value $ 450 4,050 4,500

Exercise of purchase warrants, shares 1,889,602

Exercise of purchase warrants, value $ 1,890 (1,890)

Issuance of warrants in connection with reverse stock split, shares

Issuance of warrants in connection with reverse stock split, value 63,536 63,536

Deemed dividend related to Series B Preferred Stock down round provision 1,404,932 1,404,932

Accretion of deemed dividend related to Series B Preferred Stock down round provision (1,404,932) (1,404,932)

Share-based expense 232,437 232,437

Common stock awards to vendors 15,000 15,000

Net loss (8,900,128) (8,900,128)

Ending balance, shares at Sep. 30, 2019 2,774,394 5,660,481

Ending balance, value at Sep. 30, 2019 $ 2,774 $ 5,660 $ 188,116,697 $ (164,838,373) $ 253,734 $ (5,281,180) $ 18,259,312

X

- Definition
Amount of other increase (decrease) in additional paid in capital (APIC).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of preferred stock dividends and adjustments classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 7
-Subparagraph (SAB Topic 5.Q)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187283-122770
+ Details

Name: us-gaap_OtherPreferredStockDividendsAndAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Deemed dividend related to Series B Preferred Stock down round provision
+ References
No definition available.
+ Details

Name: xbio_DeemedDividendRelatedToSeriesBPreferredStockDownRoundProvision

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise of pre-funded warrant, value
+ References
No definition available.
+ Details

Name: xbio_ExerciseOfPrefundedWarrantValue

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise of pre-funded warrants, shares
+ References
No definition available.
+ Details

Name: xbio_ExerciseOfPrefundedWarrantsShares

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_ExerciseOfPurchaseWarrantsShares

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_ExerciseOfPurchaseWarrantsValue

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_IssuanceOfCommonStockAndWarrantsInPublicOfferingNetOfIssuanceCostsShares

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_IssuanceOfCommonStockAndWarrantsInPublicOfferingNetOfIssuanceCostsValue

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopmentShares

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopmentValue

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_IssuanceOfWarrantsInConnectionWithReverseStockSplitShares

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_IssuanceOfWarrantsInConnectionWithReverseStockSplitValue

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise of warrants, shares
+ References
No definition available.
+ Details

Name: xbio_StockIssuedForExerciseOfWarrantsShares

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise of warrants, value
+ References
No definition available.
+ Details

Name: xbio_StockIssuedForExerciseOfWarrantsValue

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 36 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 08, 2019

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

Entity Registrant Name Xenetic Biosciences, Inc.

Entity Central Index Key 0001534525

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Common Stock, Shares Outstanding 5,755,141

Current reporting status Yes

Entity Small Business true

Entity Emerging Growth false

Entity Interactive Data Current Yes

Entity Incorporation State Country Code NV

Entity File Number 001-37937

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: xbio_DocumentAndEntityInformationAbstract

Namespace Prefix: xbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v3.19.3

10. Income Taxes
9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes
10. Income Taxes

During the nine months ended September 30, 2019 and 2018, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $26.2 million and $23.5 million as of September 30, 2019 and December 31, 2018, respectively.

As of September 30, 2019, and December 31, 2018, the net deferred tax liability of $2.9 million on the condensed consolidated balance sheets is related to book and tax basis differences for intangible assets with indefinite lives that were acquired in the Company’s January 2012 acquisition of SymbioTec. In accordance with ASC 740-10-30-18, the deferred tax liability related to the intangible assets cannot be used to offset deferred tax assets when determining the amount of the valuation allowance for deferred tax assets which are not more-likely-than-not to be realized. This results in a net deferred tax liability, even though the Company has a full valuation allowance on its other net deferred tax assets. This net deferred tax liability will continue to be reflected on the balance sheet until the related intangible assets are no longer held by the Company.

As of September 30, 2019 and December 31, 2018, the Company did not record any unrecognized tax positions.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R9.htm IDEA: XBRL DOCUMENT v3.19.3

3. Significant Strategic Drug Collaborations - Related Parties
9 Months Ended

Sep. 30, 2019

Significant Strategic Drug Collaborations - Related Parties

Significant Strategic Drug Collaborations - Related Parties
3. Significant Strategic Collaborations – Related Parties

The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd. (“Takeda”), Serum Institute of India (“Serum Institute”), Pharmsynthez and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through September 30, 2019. No amounts were recognized as revenue related to these agreements during the three and nine months ended September 30, 2019 or 2018. The related party ownership interest in the Company materially changed in connection with the Offering.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-URI http://asc.fasb.org/topic&trid=5833765
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_CollaborativeAgreementDisclosureAbstract

Namespace Prefix: xbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R12.htm IDEA: XBRL DOCUMENT v3.19.3

6. Goodwill and Indefinite-Lived Intangible Assets
9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Indefinite-Lived Intangible Assets
6. Goodwill and Indefinite-Lived Intangible Assets

Goodwill

Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired and is not amortized. The Company assesses goodwill for impairment at least annually, or when events or changes in the business environment indicate that the carrying value may not be fully recoverable. The Company performs its annual impairment review during the fourth quarter at the reporting unit level. Goodwill may be considered impaired if the carrying value of the reporting unit, including goodwill, exceeds the reporting unit’s fair value. The Company is comprised of one reporting unit. The Company experienced a significant decline in its stock price during the three months ended September 30, 2019 resulting in a drop in its market capitalization indicating potential impairment. The Company determined the fair value of the reporting unit using its market capitalization, concluding that the fair value of the reporting unit is less than the carrying amount in excess of Goodwill, therefore fully impairing Goodwill. Goodwill impairment is presented within continuing operations in the condensed consolidated statements of operations. A reconciliation of the change in the carrying value of Goodwill is as follows:

Balance as of January 1, 2018 $ 3,283,379

No changes –

Balance as of December 31, 2018 3,283,379

Impairment (3,283,379 )

Balance as of September 30, 2019 $ –

Indefinite-Lived Intangible Assets

The Company’s indefinite-lived intangible asset, OncoHist, is IPR&D relating to the Company’s business combination with SymbioTec in 2012. The carrying value of the IPR&D was approximately $9.2 million as of September 30, 2019 and December 31, 2018, respectively. IPR&D is required to be tested annually until the project is completed or abandoned. The IPR&D is not yet commercialized and, therefore, has not yet begun to be amortized as of September 30, 2019. The Company assesses IPR&D for impairment at least annually as of October 1 or when events or changes in circumstances indicate that the carrying value may be impaired. No impairment was recorded during the nine months ended September 30, 2019 nor during the year ended December 31, 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R39.htm IDEA: XBRL DOCUMENT v3.19.3

12. Related Party Transactions (Details Narrative)
3 Months Ended

Sep. 30, 2019

USD ($)

Related party expenses $ 40,000

Prepaid Expenses [Member]

Advanced payment $ 310,000

X

- Definition
Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_RelatedPartyCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xbio_AdvancedPayment

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=xbio_PrepaidExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.3

7. Fair Value Measurements (Details Narrative)

Sep. 30, 2019

USD ($)

Fair Value, Inputs, Level 3 [Member]

Derivative instruments $ 0

X

- Definition
Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958
+ Details

Name: us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R35.htm IDEA: XBRL DOCUMENT v3.19.3

10. Income Taxes (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Provision for income taxes $ 0 $ 0

Deferred tax assets, valuation allowance 26,200,000 $ 23,500,000

Net deferred tax liability 2,900,000 2,900,000

Unrecognized tax positions $ 0 $ 0

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 43 R17.htm IDEA: XBRL DOCUMENT v3.19.3

11. Commitments
9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments
11. Commitments

Leases

The Company determines whether an arrangement is a lease at inception. In January 2019, the Company entered into a sublease and relocated its corporate headquarters from Lexington, Massachusetts to Framingham, Massachusetts. This sublease calls for total future minimum rent payments of approximately $52,000 and has a termination date of September 30, 2020, which corresponds to the underlying base lease. The Company does not have options to extend, termination options or material residual value guarantees. The Company recorded a right-of-use (“ROU”) asset and corresponding lease liability on the condensed consolidated balance sheet. The Company recognized a ROU asset and a lease liability of approximately $43,000 during the nine months ended September 30, 2019. As the sublease does not provide an implicit rate, we used our incremental borrowing rate (10.2%) based on the information available at the lease’s commencement date in determining the present value of lease payments.

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

Nine Months

Ended

September 30,

2019

Operating cash flow information:

Cash paid for amounts included in the measurement of lease liabilities $ 16,629

Non-cash activity:

Right-of-use assets obtained in exchange for lease obligations $ 43,330

Supplemental balance sheet information related to our operating leases is as follows:

Balance Sheet Classification September 30, 2019

Right-of-use assets Prepaid expenses and other $ 26,701

Current lease liabilities Accrued expenses and other current liabilities $ 26,701

Non-current lease liabilities Other liabilities $ –

The Company did not apply the provisions of ASU 2016-02 to the lease of its former headquarters in Lexington, Massachusetts or its office space lease in Miami, Florida as they did not have a material impact on our condensed consolidated financial statements. The leases would have resulted in a combined increase in total assets of approximately $3,000 and a combined increase in total liabilities of approximately $3,000 in our September 30, 2019 condensed consolidated balance sheet, respectively, and would not have a material impact on our accumulated deficit as of the beginning of 2019. The lease of the Company’s former headquarters expired on January 31, 2019 and the Miami office space lease expires in November 2019. As of September 30, 2019, total minimum lease payments on these leases were approximately $3,000.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R8.htm IDEA: XBRL DOCUMENT v3.19.3

2. Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies

Preparation of Interim Financial Statements

The accompanying condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 and amended on April 30, 2019.

These condensed consolidated financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As a result, the financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

On June 25, 2019, the Company effected a reduction, on a 1 for 12 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every 12 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock were proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1 for 12 basis; and (iv) the number of shares of common stock into which each share of preferred stock could be converted were proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this Reverse Stock Split.

Certain prior period amounts have been reclassified to conform to the presentation for the current period.



Principles of Consolidation

The condensed consolidated financial statements of the Company include the accounts of Hesperix and Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share

The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during each period, except where such non-participating securities would be anti-dilutive.



For the three and nine months ended September 30, 2019 and 2018, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, and that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 Revenue from Contracts with Customers. ASU 2018-07 was effective for the Company in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.



In January 2017, the FASB issued ASU 2017-04: Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment that eliminated the requirement to calculate implied fair value of goodwill to measure a goodwill impairment charge. Instead, the new guidance requires entities to take an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company no later than 2020. The Company adopted ASU 2017-04 in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

In February 2016, FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Subsequently, in July 2018, the FASB issued ASU 2018-11, Lease (Topic 842): Targeted Improvements, which provides a number of practical expedients in transition. The Company adopted ASU 2016-02 effective January 1, 2019 and elected a package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of lease, classification of a lease or any initial direct costs. The Company has also elected to use the hindsight practical expedients. The adoption did not have a material impact on the Company’s condensed consolidated financial statements, resulted in an approximate $43,000 increase in total assets and total liabilities in our condensed consolidated balance sheet and did not have any effect on accumulated deficit at the beginning of 2019. See Note 11 for further information.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R13.htm IDEA: XBRL DOCUMENT v3.19.3

7. Fair Value Measurements
9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements
7. Fair Value Measurements

Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. The carrying amounts of certain of the Company’s financial instruments approximates fair value due to their short maturities.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Operating costs and expenses:

Research and development $ (3,520,638) $ (735,879) $ (4,471,939) $ (2,369,219)

General and administrative (2,142,505) (1,079,008) (3,896,657) (3,267,597)

Goodwill impairment (3,283,379) 0 (3,283,379) 0

Loss from operations (8,946,522) (1,814,887) (11,651,975) (5,636,816)

Other income (expense):

Other income (expense) (223) 2,292 267 (24,838)

Interest income 46,617 59 46,930 424

Total other income (expense) 46,394 2,351 47,197 (24,414)

Net loss (8,900,128) (1,812,536) (11,604,778) (5,661,230)

Deemed dividend (1,404,932) 0 (5,284,379) 0

Net loss applicable to common stockholders $ (10,305,060) $ (1,812,536) $ (16,889,157) $ (5,661,230)

Basic and diluted loss per share $ (2.67) $ (2.31) $ (9.07) $ (7.58)

Weighted-average shares of common stock outstanding, basic and diluted 3,862,936 783,865 1,861,867 746,629

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetImpairment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R30.htm IDEA: XBRL DOCUMENT v3.19.3

6. Goodwill and Indefinite-Lived Intangible Assets (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Indefinite-lived intangible assets $ 9,243,128 $ 9,243,128

OncoHist [Member]

Indefinite-lived intangible assets 9,243,128 $ 9,243,128

Impaiment of intangible assets $ 0

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=xbio_OncoHistMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.19.3

9. Share-Based Expense (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Share based compensation $ 247,437 $ 323,478 $ 730,531 $ 1,175,281

Warrant [Member] | Collaboration Agreements [Member]

Warrants outstanding 44,944 44,944 44,944

Weighted average exercise price $ 124.90 $ 124.90

Warrants issued 0 0

Warrants exercised 0 0

Warrants expiration dates December 2019 through May 2021

Employee Stock Options [Member]

Options granted 0 0

Options exercised 0 0

Share based compensation $ 200,000 300,000 $ 700,000 $ 1,100,000

Non Employee Stock Options [Member]

Options granted 0 834

Options exercised 0 0

Share based compensation $ 0 $ 1,000 $ 0 $ 36,000

Common Stock Awards [Member]

Other than options granted 7,153 375 9,026 1,627

Share based compensation $ 15,000 $ 17,000 $ 47,000 $ 52,000

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants exercised
+ References
No definition available.
+ Details

Name: xbio_WarrantsExercised

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants expiration dates
+ References
No definition available.
+ Details

Name: xbio_WarrantsExpirationDates

Namespace Prefix: xbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants issued
+ References
No definition available.
+ Details

Name: xbio_WarrantsIssued

Namespace Prefix: xbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=xbio_CollaborationAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=xbio_NonEmployeeStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=xbio_CommonStockAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.19.3

11. Commitments (Details Narrative)

Sep. 30, 2019

USD ($)

Commitments and Contingencies Disclosure [Abstract]

Future minimum lease payment $ 3,000

Future minimim sublease rent payment $ 52,000

Incremental borrowing rate (10.20%)

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 40
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77914019&loc=d3e50824-112756
+ Details

Name: us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Discount rate used by lessee to determine present value of operating lease payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 148 253 1 false 41 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://xeneticbio.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://xeneticbio.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://xeneticbio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://xeneticbio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited) Sheet http://xeneticbio.com/role/StatementsOfChangesInStockholdersEquity Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://xeneticbio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - 1. The Company Sheet http://xeneticbio.com/role/Company 1. The Company Notes 7 false false R8.htm 00000008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - 3. Significant Strategic Drug Collaborations - Related Parties Sheet http://xeneticbio.com/role/SignificantStrategicDrugCollaborations-RelatedParties 3. Significant Strategic Drug Collaborations - Related Parties Notes 9 false false R10.htm 00000010 - Disclosure - 4. Acquisitions Sheet http://xeneticbio.com/role/Acquisitions 4. Acquisitions Notes 10 false false R11.htm 00000011 - Disclosure - 5. Property and Equipment, net Sheet http://xeneticbio.com/role/PropertyAndEquipmentNet 5. Property and Equipment, net Notes 11 false false R12.htm 00000012 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets Sheet http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssets 6. Goodwill and Indefinite-Lived Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - 7. Fair Value Measurements Sheet http://xeneticbio.com/role/FairValueMeasurements 7. Fair Value Measurements Notes 13 false false R14.htm 00000014 - Disclosure - 8. Stockholders' Equity Sheet http://xeneticbio.com/role/StockholdersEquity 8. Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - 9. Share-Based Expense Sheet http://xeneticbio.com/role/Share-basedExpense 9. Share-Based Expense Notes 15 false false R16.htm 00000016 - Disclosure - 10. Income Taxes Sheet http://xeneticbio.com/role/IncomeTaxes 10. Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - 11. Commitments Sheet http://xeneticbio.com/role/Commitments 11. Commitments Notes 17 false false R18.htm 00000018 - Disclosure - 12. Related Party Transactions Sheet http://xeneticbio.com/role/RelatedPartyTransactions 12. Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - 13. Subsequent Events Sheet http://xeneticbio.com/role/SubsequentEvents 13. Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - 5. Property and Equipment, net (Tables) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetTables 5. Property and Equipment, net (Tables) Tables http://xeneticbio.com/role/PropertyAndEquipmentNet 21 false false R22.htm 00000022 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets (Tables) Sheet http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssetsTables 6. Goodwill and Indefinite-Lived Intangible Assets (Tables) Tables http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssets 22 false false R23.htm 00000023 - Disclosure - 9. Share-Based Expense (Tables) Sheet http://xeneticbio.com/role/Share-basedExpenseTables 9. Share-Based Expense (Tables) Tables http://xeneticbio.com/role/Share-basedExpense 23 false false R24.htm 00000024 - Disclosure - 11. Commitments (Tables) Sheet http://xeneticbio.com/role/CommitmentsTables 11. Commitments (Tables) Tables http://xeneticbio.com/role/Commitments 24 false false R25.htm 00000025 - Disclosure - 1. The Company (Details Narrative) Sheet http://xeneticbio.com/role/CompanyDetailsNarrative 1. The Company (Details Narrative) Details http://xeneticbio.com/role/Company 25 false false R26.htm 00000026 - Disclosure - 4. Acquisitions (Details Narrative) Sheet http://xeneticbio.com/role/AcquisitionsDetailsNarrative 4. Acquisitions (Details Narrative) Details http://xeneticbio.com/role/Acquisitions 26 false false R27.htm 00000027 - Disclosure - 5. Property and Equipment, net (Details) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetDetails 5. Property and Equipment, net (Details) Details http://xeneticbio.com/role/PropertyAndEquipmentNetTables 27 false false R28.htm 00000028 - Disclosure - 5. Property and Equipment, net (Details Narrative) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetDetailsNarrative 5. Property and Equipment, net (Details Narrative) Details http://xeneticbio.com/role/PropertyAndEquipmentNetTables 28 false false R29.htm 00000029 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets (Details - Change in carrying value of goodwill) Sheet http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssetsDetails-ChangeInCarryingValueOfGoodwill 6. Goodwill and Indefinite-Lived Intangible Assets (Details - Change in carrying value of goodwill) Details http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - 6. Goodwill and Indefinite-Lived Intangible Assets (Details Narrative) Sheet http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssetsDetailsNarrative 6. Goodwill and Indefinite-Lived Intangible Assets (Details Narrative) Details http://xeneticbio.com/role/GoodwillAndIndefinite-livedIntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - 7. Fair Value Measurements (Details Narrative) Sheet http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative 7. Fair Value Measurements (Details Narrative) Details http://xeneticbio.com/role/FairValueMeasurements 31 false false R32.htm 00000032 - Disclosure - 8. Stockholders' Equity (Details Narrative) Sheet http://xeneticbio.com/role/StockholdersEquityDetailsNarrative 8. Stockholders' Equity (Details Narrative) Details http://xeneticbio.com/role/StockholdersEquity 32 false false R33.htm 00000033 - Disclosure - 9. Share-Based Expense (Details - Share based compensation) Sheet http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedCompensation 9. Share-Based Expense (Details - Share based compensation) Details http://xeneticbio.com/role/Share-basedExpenseTables 33 false false R34.htm 00000034 - Disclosure - 9. Share-Based Expense (Details Narrative) Sheet http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative 9. Share-Based Expense (Details Narrative) Details http://xeneticbio.com/role/Share-basedExpenseTables 34 false false R35.htm 00000035 - Disclosure - 10. Income Taxes (Details Narrative) Sheet http://xeneticbio.com/role/IncomeTaxesDetailsNarrative 10. Income Taxes (Details Narrative) Details http://xeneticbio.com/role/IncomeTaxes 35 false false R36.htm 00000036 - Disclosure - 11. Commitments (Details - Supplemental Cash Flow Info) Sheet http://xeneticbio.com/role/CommitmentsDetails-SupplementalCashFlowInfo 11. Commitments (Details - Supplemental Cash Flow Info) Details http://xeneticbio.com/role/CommitmentsTables 36 false false R37.htm 00000037 - Disclosure - 11. Commitments (Details - Lease liabilities) Sheet http://xeneticbio.com/role/CommitmentsDetails-LeaseLiabilities 11. Commitments (Details - Lease liabilities) Details http://xeneticbio.com/role/CommitmentsTables 37 false false R38.htm 00000038 - Disclosure - 11. Commitments (Details Narrative) Sheet http://xeneticbio.com/role/CommitmentsDetailsNarrative 11. Commitments (Details Narrative) Details http://xeneticbio.com/role/CommitmentsTables 38 false false R39.htm 00000039 - Disclosure - 12. Related Party Transactions (Details Narrative) Sheet http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative 12. Related Party Transactions (Details Narrative) Details http://xeneticbio.com/role/RelatedPartyTransactions 39 false false All Reports Book All Reports xbio-20190930.xml xbio-20190930.xsd xbio-20190930_cal.xml xbio-20190930_def.xml xbio-20190930_lab.xml xbio-20190930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 51 R29.htm IDEA: XBRL DOCUMENT v3.19.3

6. Goodwill and Indefinite-Lived Intangible Assets (Details - Change in carrying value of goodwill) - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill, beginning balance $ 3,283,379 $ 3,283,379 $ 3,283,379

Goodwill increase (decrease) for the period 0 0

Impairment (3,283,379) $ 0

Goodwill, ending balance $ 0 $ 3,283,379

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "6+;D\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ )8MN3R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " EBVY/'K(*#>\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*$[+1DWJR\9.&PQ6V.C-V&IK&L?&UDCZ]G.R M-J5L#["CI=^?/H$:'83V$=^B#QC)8KH;7-LEH<.:'8B" $CZ@$ZE,B>ZW-SY MZ!3E9]Q#4/JH]@AU5=V#0U)&D8(16(29R&1CM- 1%?EXQAL]X\-7;">8T8 M M.NPH 2\Y,#E.#*>A;> *&&&$T:6? IJ9.%7_Q$X=8.?DD.R"K[:C MZXW?5=AY8W?V'QM?!&4#O^Y"?@-02P,$% @ )8MN3YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " EBVY/>_'[-94" *"@ & 'AL+W=O"E*2J6JF5HJO:_G:($] !IK83 MKF]?VW"4VDO_!-O,['B]3+SYP/BKJ"B5WEO;=&+G5U+VST$@RHJV1#RQGG;J MS97QED@UY;= ])R2BR&U38##, U:4G=^D9NU$R]R=I=-W=$3]\2];0G_?: - M&W8^\M\77NI;)?5"4.0]N=%O5'[O3US-@CG*I6YI)VK6>9Q>=_X>/1_15A,, MXD=-![$8>SJ5,V.O>O+YLO-#O2/:T%+J$$0]'O1(FT9'4OOX-07U9TU-7([? MHW\TR:MDSD30(VM^UA=9[?R-[UWHE=P;^<*&3W1**/&]*?LO]$$;!=<[41HE M:X3Y]0[CFSB::# !3P0\$W#Z7T(T$:*9@&*3_+@S MD^H'(DF1 B4 @K9*!"YO*1)0% ,"RQ 24V+C^R) #(2J6W MH,36Y=NE!B KM48A;*?0C6"7&\*L%!RMF!:Y$>R: QB\4G0$.G>/L!O!+CN$ M6:D[@NV+(C>"5?GCA$D,IAM-FB4)BE?^B1!L=>0Z&<=V0@ F65&!_8Y<.^/4 M5@$PV8H*;'KD>AIO;!47L_:=P;Y'KJNQ\YT!F+4#@ZV/7&-'SB4$8-:*#[L? MN=Z.L*T"8.R[*%CO M$[((/.-CWY '_F/_QQ[_XF1^:MKOW<[[?O:CK@[=(MOU_?$AS[OGG:_+[G-S M](?PS[9IZ[(/E^U+WAU;7V[&H+K*L2AT7I?[0[:V^6\>>VK_<$_MK/N MM:[+]K^5KYK3(H/L_<:W_#(5_ZY'YHHP^'-KWU5 M#2T%'_].C6:7/H? Z_/WUK^.R8=DGLK.KYOJG_VFWRTRF\TV?EN^5OVWYO2K MGQ)2V6S*_G?_YJL@'YR$/IZ;JAM_9\^O7=_44RO!2EW^.!_WA_%XFMI_#^,# M< K 2P#(GP:(*4!$ ?G9V9CJE[(OE_.V.;HYC-_X7 MLNW"W;>ED//\;6AGDJS.$KR2X*UB315"721YZ/]B ED3.,:+ZWC-QPLV7HSQ M\CK>1$F<)7J4'$8)8"&E-'$N5*@,Z"*1CV3]2.K'1G[.$G7531$9H0JM%12\ M#\7Z4-2'BWPHTHLUVH*.S%"94LJJQ"QIUHTF;F24\TJ3;@ = MIH^-:,$)QP M!GA#AC5DJ"&(#!G:CW+Q3%&1=*FAL:P32YU$=;FR=PN&*@1:(8SCG3C6B:-. M1.3$D7X<2A$F*?)S7W?C!PH>4 5U1 A5D*Y,X0!$S"E.I[1.+"I((!.H(Q4[ M M(3HC4J5&GLB2I!AF$JG$RXXAD*%*(R48/ 4Q0H1F6,T4ESN_ "")2*TZ)" M)R1<-7AKB0*0"9:J,F0J4EJ"=04OF MGA$JYXQ-+1$>K$#)JF*R B4F.K *XE7[ >&M)YZM0.&J8K@" TX=JJDPL2=& M& R)(E7@/&7!DB6B,-$"3T>@>%0Q'H%R[P8Q4TI492%1BLB3$2D954Q&I,0# M&SK2H1XC1YPT[ 1,@3)!(N3YB)2/,1Y62*GW";2TP@H34YO5*H%"*)?:9B;V MF4B=Z=@9TOI7@N+DON[6$<]$<$C2% $D1&9 M--=O>L[$*^J.Z.PEOWK9'KY^_%&V+_M#-WMJ^O#>/KY=;YNF]Z'!XG,8VYTO M-Y>+RF_[X=2$\_;\U>%\T3?'Z8M*?OFLL_P?4$L#!!0 ( "6+;D\?HWKG MA@( +0) 8 >&PO=V]R:W-H965T&ULC99OKYL@%,:_ MBO$#5/"_C359NRQ;LB7-77;WFK:TFJOB@-:[;S] KU&@:_NB C[/X0='C^0] MH6^LQ)@[[TW=LHU;JDO)Y8!7Y!VZX)^8 M_^KV5/2\*XWL%0&I3BM<(]F[4=N90#(6^R\^VT<8$D MPC4^D=.F2K0_*A@.M ;.91 M#JJ]4_?$:ID8O15QD'LW&6>4; >)/Y/X2\7.5 31)/'$_!.$;X7PE3^<0X0: MA$42:13_E2PH BM%8/ICC6*01$K2*@GT(R!_&LL3P@51:"4*3:)$(PJ-B:(X M!F$*-2!3ET*01K$=)[+B1"9.JN%$%IP@"#-]?TQ=D@;IO7S%5IS8Q,DTG-A, M P"V?#TA7! E5J+$)+KC3ZW^U/ G&NAVD"0S4+ "0,_V(]6");.R9":+-LLV M,S_N[K%NP0.!O5(!D\C72Q5X$ND)X9+I3O6$9L;].Q'LI0^:58=F=;,3/=0-1-[L M\RG/,S\0O50M">%8Q 0K$:T41ZBI4^,SE\U$M.EPCA@ZG'3C M&FQL,# !]#P & 'AL+W=OVM6<[= MN2N/M7UKHO9<547S7V9+=UG$-/[6\.FX/W1]0[*&O^67+UL MCY6MVZ.KH\;N%O$K?5E3U1L,Q#]'>VEOGJ->RKMSG_N7W[>+F/01V=)NNMY% MX7\^;&[+LO?DX_@R.8VO??:&M\_?O/\ZB/=BWHO6YJ[\][CM#HM8Q]'6[HIS MV7URE]_L)$C&T:3^#_MA2X_WD?@^-JYLA__1YMQVKIJ\^%"JXNOX>ZR'W\OX M):63&6[ )@-V-?!]/S/@DP'_;B">&HC)0/QL#W(RD*"'9-0^#.:JZ(KEO'&7 MJ!G7PZGHEQU]D7ZZ-GWC,#O#-S^>K6_]6*9\GGST?B8D&Q%VBXA[9!4B]$HD MOO]K$ P+(F.!.;OO( ^)5((8?NAD_=3)79@<'2L^V/-;>X7;"]1>#/;BUCX% M8STB:D#J ?F%2T84UV! $##E4J<&C K""9%2PP&X1D#&E6'4X!(E*E&&$D'D MV8C(NXZH8)* ")^UM7ZF:L[52FJ*@U4:1!*EH:A:".49'"W(B#55&@-)F2%@51) M:N#N7B.D5%QI^F ':E2D#G:P?I"H#&IOPD$"VC.#+&\&4FH>0HP9X&F%0 JN M:*PWH6^RQ9TH2O S@(2R@D. !#T)I2B()T M*!CI-RV37$&1&$D5$2G,]6L,E7[9,/X@-U'\Y*4\E*J@5(Z$)8@P'*8GA(19 M%W,FF19AVGWJ[%X;?BN@X;4 YLF,(J12_&-#P9J#AS8"& MQS37BADX.SD"ICZQ*WCM13BJE?\+)"(.?0IG\'Z7W)0.E6WV0QW71AMWKKO^ M[+QIO=:*KZPO/4![1E]RBK2O^MIR*%6^NQ\+TS^+9G^LV^C==;[@&&3F0_\X&OAZTMI=UW_F/KG9BP(QY?.G:9B-[E6W,O_ 5!+ P04 " E MBVY/I?%=KKH) !L1 & 'AL+W=O/^_O;[NMQL]ZU M'_>SP]?M=K7_;]ENNK>[N9I__\.G]9>7X_"'Q?WMZ^I+^WM[_./UX[Y_M3CW M\K3>MKO#NMO-]NWSW?QG]:'Q9FAP(OY;J;)T-$ M[:9]/ Y=K/H?W]J'=K,9>NKC^&?L='X>GR(I!_CL=L<3O_.'K\> MCMUV[*4/9;OZ]_WG>G?Z^3;V_[T9;J#'!OK<0/FK#!T""W>I^,TO\7J MN+J_W7=OL_W[(?JZ&LX$]2'KCZ#'X8^G ^;T?_T4'_J_?KO/D]O%MZ&?$5F^ M(_H242'R ! =(@5 3(B4 +$A4@'$A4@-$!\B#4#2,[+H\W5.FH9)TZ?V]K)] M1I+VCK@3LCLA)LF3U)*T/' N=<:['(=C8#B&AY.3<-X13\(AL7 H=60""LXH M[[3+%,U R)@?#P8BJ\O2LX%NC/+&DN/V@7/:&V]P."D,)P7AD(-Y MF?*#N0^'Q,(A39 BY>'2$[M$\="Y$C#-=29(3 83DX$.R/J]1 P]C@5,D?$# M2VF3T%.X%/15"9A:P#33,05)S&$2 \ S%22.1^)"2N:XH[6=T)CTGQ][6.B 7&JEPXZ MR5SDE$_SWG4,%2. WBBG7&Z-IV8$6*A&J$_L1BA0I7/G5&S2L70J;ITJH=HY M0H))Y^#52:(]O M=-!G9-)!H#K-K/-9),'80Q4R.K9R2DQ4 A6*RZ%)?.+8XBF140E42Z!F.JPP ME]A9%9)6>AV'$,NE "H4]UK5WXZF-)6"OBH)5$N@9C*J,)-8MQ7W4GXY%_CM M@P0J)%"IN);?J$SUI[&GN11T5TN@1C)FF$XLZ0J9++N<R< BL[U\SHY9RC\-(!>&W2-?9*#;Q2T;+'"$U,.J#XI&MNGLIG*DVT)?V5 .TGW6AC'"U(5H"% MDX[ZQ),.R#P?+NB1J[F.E#&!(RM:-D$06S@UE\K,>Q\KJF*CU, H%2V;((B' MPPN 64HG&ZBIS[/6WSBX4LC =;F :.HMBVB$3#-"][>NWH_'+;,7B.(9Y,+F,VU5;'%&0N8!@*FZ:TU@G@\ MW+\LVRW47&NLHT=W*1FODD"U!&I 4"Y)8EMUV+,,\"Q-/0M!+(^&.Y;*^NO7 MQ<90&!"6+ ,D2U/)0A /B#N6RNA>1&&0.3&LE(Q82:!: C434)A(;%,&B)*F M-H4@GDBP*9S%;N),9$\8N(:F,H4@'@W8%J9SRIWEAIZKDK$J"51+H&8""E.( M% JO0V$P6)\,4 NZ%[A$$ ]&4GDS7%*\8<6+4M)7)8%J"=1, M1A5F$GN3 4I$RV!+!/%,@N*5M;'E%UN3 4ZAJ34AB$?#K8G-*JH0T2F5Z)($ MJB50,P&%*<2J9( %:?8 C$25)%!AN$_U=^G6I/0)"4EOE02J)5 CB"O,)A8] M TR([D$N$<2S*=E@-KC2A=(ID3T)5$N@1A)8^! 1%CZ+7(Y>12#$GB.2;#9; M;H4^,^SQDU+2626!:@G43(<5YA*[JD661B^"$&*Y%$"%Y:IJP9:)I*]* M42 MJ)F,*LPDEE7+/91MF0 &)%( %1*HM&A;7/G$IFE&DRGHKY9 C6C0,*'8MRWP M3;JQN[32[7 .M]'%7O.Q6*#M< [#;VW&Z&) CJ@AHCH1(-:89;U"?4Y.VLX M>J.\S4QF4D/GF[.P@H[ZQ!5T&*AVN5$1?;-8RRW05D-O^BS7ULBT=43A^8+"S:PU7&Z90]!0'0&^7ZM&?:TFT3P.))!WU& M)AT$FI@\2?/8:86=W:)*)UL])D-(X)X-H&+N?C#ZP[+F$.5 M0WK+A2 >#W]4T3IZD7;<>6Q"J5(R7B6!:@G4H*!<-(_8P1RJ>5('0Q#/(_>O MJ[5UA_W+H0HB^]R&I(+HN'Z!VKI#3L5KZY(1*PE42Z!F @H3B37+H>HGO>(B MB"?R.A0&@_W*H0(BO=HBB 7#/@=U94(J5]%5)H%H"-9-1A9G$(N50\9,M MQ!*1DD"% [9E$YO36Z)2TELE@6H)U CB"K.)+= !0V*5.P3Q;$KJH(Z[UDTD MG1()E$"U!&HD@87YQ!+HD-^Q14FLDD"U!&JFPPH_ MGX<%UB.]HVLFA&@N)5#AP=ZXXQ_]DO152:!: C634869Q/+JN9>RRAU@0"(E M)5 )5'JPI=];1\(VLBI)=[4$:B1CANG$[NV!G+*ZG0>?PH$%' !>K=MY++(> M%1.I-WKPJ6E>P0$4J-L!*E:W VBT;H="1"49^8PZ(LMT8?#,S3Y\;(X-^VW;N]]/_M> M5\=N.=_W_>D^2;KMWM=E]Z4Y^6/XY;EIZ[(/K^U+TIU:7^[&2G654)JZI"X/ MQ_EJ,98]MJM%\]I7AZ-_;&?=:UV7[;]K7S7GY5S-WPN^'E[V_5"0K!:G\L7_ MX?L_3X]M>$NN47:'VA^[0W.#(U_Y;3^$*,/7F]_XJAHB!1__3$'GUS:'BK?/[]%_'I,/R3R5G=\T MU=^'7;]?SO/Y;.>?R]>J_]JA:(;3]604]5= _*I@Q^8NS,=6?RKY< M+=KF/&LO_]:I' :%NM>A,[=#X=AWXV\AVRZ4OJV4MHOD;0@T:=87#=UJKHHD M1+\V0:B)-8GJ]+&!C51D%K>@81)ZK*\_).%P ,#F#& N0F0\TZX2-PH.8Z2 M.Z5<:K(L9]D I75.D4ZQ)0LM69!3A@,X&,")G)1F5M<7C;VQJE.MB!Q+2>HB MN6302B:L9 5SDDDGE&O-=1NIBSC)H9,<= JWDDLKVO$>D2)%UD2\%-!+(;W< M!+AX*60SSA'O%*F*&%$IAD *K"A.@52T6"^9X@V3*FMC851$L*>DH%5Q2 MHBF7:Y4:;DGJU# =TU@O08X]* *]1-P324_::CY\@"QF!B-/:6!&LB G\:=;, R++%-\44'",#CH9KY_-(4Q MJ@!'C>.F)""M49GBEJ3LS@5#!44L89PJR5-E,FY)DO+.9*2<%1T%E-:$^9'% MYBQFJ\K!",@C(3 2%6(BY[.2N$,< BJRL2E/&(P$P&@YHTD2#_A!JD_\8"R2 MDEUL8YLQ3#$"%.-#8DT23TH;4@5/?@.4L90PR B S'*0D204N:)(I1TIC-G! M&".Y%0RK%[=CY'1/4[XJ U68#VETV2%,10)4M)R*)&&GPI;3 5= ^:DKC$4" M6+0)RR(? D"RCM=4&IC#"*,1@)HY(VM20+/Z5PIRTU)G;5%8;,( MK@ESD<"FT_*=.*$-96J,R<1A"2A=E@=?$5<8M50 E$261HWIJ $=':>CEMSC M!R8@"=TTUAQ#0!:97CIRH@54=)R*6L*. MSRL@B1G!/-2 AX[S4$O2X7,D$,;L8!AJ $/'8:@!XK@1*8D9P?S3@'_\D+C6 M@']Y(0;+_SY=:PP]#:#G./0FD8.M3$:D1"M^CY+#OUW#2]#Q[3 M+Z&;]K[<75\J_]P/CUEX;B^W=I>7OCE--Y+)]5IT]1]02P,$% @ )8MN M3PS 0 T@, !@ !X;"]W;W)K$K M3/U\HF1J_CN<0?KTH,37*%':^"5E;QVJB<5+4?QM/(6.YS#Q7V#K@'0"I%< M-A:*RC]SQXO,X$#,./N.ARO>[%,_FS($XRCB/R_>^NBYV-S>9^P>=M,Z[9Z#CLIA?$YF=I:E;S)Z0TD)E>B5?S+#(TSU7%(R M%?\3SJ P/"C!'(51+JZDZ)TW>F)!*5J\C;MLXSZ,-\G5!%L'\ G 9\!-S,/& M1%'YO? B3ZT9B!U[WXGPQ-L]Q]X4P1E;$>]0O$/O.=]>\Y2= ]$4(UG.X[9:'C333^(S=\X_P]02P,$% @ )8MN3X%#0(2V 0 MT@, !@ !X;"]W;W)K2X^_OIXKINY[U((L5S>$A1V:#-LVT! M''J50MDWZ>-J&^!CPF\-@9V<4*KEH_1R,;U6.5T$0""A=8&!^N\(="!&( MO(R7D1-/*0-P?GYC_QIK][5("QGB\8C<5_ MARL('QZ4^!RE%C:NJ.RMTW)D\5(D>TT[5W$?TLUN,\*6 70$T EPB'E(2A25 MWS/'BLSH 9G4^XZ%)UX?J>]-&9RQ%?'.B[?>>RW6^UU&KH%HC#FE&#J/F2*( M9Y]2T*44)_H/G"[#-XL*-Q&^^:!POTRP72381H+M?PB2QJ68PZ0]/T_Z#F88KBR[:^9>-_:^U=N"EK&[\"+7^@TV& M@-J%X]Z?31JS9#C=C3^(3-^X^ M02P,$% @ )8MN3^Y71QNV 0 T@, M !D !X;"]W;W)K&UL;5/;;MP@$/T5Q <$&V^: M[6;ML8W"Q0&\3O^^@!W'3?T"S##GS)EAR$=M7FP'X-"; M%,H6N'.N/Q!BJPXDLU>Z!^5O&FTD<]XT+;&] 59'D!2$)LD7(AE7N,RC[V3* M7 ].< 4G@^P@)3-_CB#T6. 4OSL>>=NYX"!EWK,6?H'[W9^,M\C"4G,)RG*M MD(&FP+?IX;@+\3'@B<-H5V<4*CEK_1*,[W6!DR (!%0N,#"_7> .A A$7L;K MS(F7E &X/K^S?XNU^UK.S,*=%L^\=EV!]QC5T+!!N$<]/L!EA8TKJ@;KM)Q9O!3)WJ:=J[B/TTV6S;!M )T!= 'L8QXR)8K*[YEC M96[TB,S4^YZ%)TX/U/>F"L[8BGCGQ5OOO93IS=><7 +1''.<8N@Z9HD@GGU) M0;=2'.E_<+H-SS859A&>K;/ODVV"W2;!+A+L_B%(/Y6X%?-9)5GU5()IXS19 M5.E!Q4E>>9>!O:7Q33["IVG_R4S+E45G[?S+QOXW6COP4I(K/T*=_V"+(:!Q MX7CCSV8:L\EPNI]_$%F^&PO=V]R:W-H965TVT-]J#]38-&<>=-TS+;&^!U!"G)TMWNCBDN-"WSZ#N;,L?! M2:'A;(@=E.+FSPDDC@5-Z)OC6;2="PY6YCUOX3NX'_W9>(LM++50H*U 30PT M!;U/CJ GP)&NSJ34,D%\2487^J"[H(@D%"YP,#]=H4'D#(0>1F_9TZZ MI S ]?F-_3'6[FNY< L/*'^)VG4%/5!20\,'Z9YQ?(*YGEM*YN*_PA6D#P]* M?(X*I8TKJ0;K4,TL7HKBK],N=-S'Z29+9M@V()T!Z0(XQ#QL2A25?^:.E[G! MD9BI]ST/3YP<4]^;*CAC*^*=%V^]]UHFAWW.KH%HCCE-,>DZ9HE@GGU)D6ZE M.*7_P=-M^'Y3X3["]^\49ML$V29!%@FR=P2W'TKJK M'&:+*EP MT'&25]YE8._3^";_PJ=I_\9-*[0E%W3^96/_&T0'7LKNQH]0YS_88DAH7#A^ M\F1'+=[@! #2 P &0 M 'AL+W=O_=N^/(!C1/M@5PY$5);7/: M.M<=&+-E"XK;*^Q ^YL:C>+.FZ9AMC/ JPA2DJ5) M;P['78B/ 7\$#'9Q)J&2,^)3,+Y7.4V"()!0NL# _7:!!Y R$'D9SQ,GG5,& MX/+\SOXUUNYK.7,+#RC_BLJU.=U34D'->^D>E/@< M)4H;5U+VUJ&:6+P4Q5_&7>BX#^/-]7:"K0/2"9#.@'W,P\9$4?D7[GB1&1R( M&7O?\?#$FT/J>U,&9VQ%O//BK?=>BLW^-F.70#3%',>8=!DS1S#//J=(UU(< MT__@Z3I\NZIP&^';#PKWZP2[58)=)-A](+C[5.)*S%WR*0E;]%2!:>(T65)B MK^,D+[SSP-ZG\4W^A8_3_I.;1FA+SNC\R\;^UX@.O)3DRH]0ZS_8;$BH73C> M^K,9QVPT'';3#V+S-R[> %!+ P04 " EBVY/:H74$K8! #2 P &0 M 'AL+W=OML8I[-&W'W&"!-Q&D)$L/A[=,<:%I543?V5:%&;T4 M&LZ6N%$I;G^?0)JII E]=CR(KO?!P:IBX!U\ _]].%NTV,K2" 7:":.)A;:D M=\GQE(?X&/!#P.0V9Q(JN1CS&(S/34D/01!(J'U@X+A=X1ZD#$0HX]?"2=>4 M ;@]/[-_C+5C+1?NX-[(GZ+Q?4EO*6F@Y:/T#V;Z!$L];RA9BO\"5Y 8'I1@ MCMI(%U=2C\X;M;"@%,6?YEWHN$_S398OL'U N@#2%7 ;\[ Y453^@7M>%=9, MQ,Z]'WAXXN288F_JX(RMB'Q]1M7?P!02P,$% @ )8MN3R^@,3RV 0 T@, !D !X M;"]W;W)K&UL;5-A;]L@$/TKB!]0$N*V661;:CI- MG;1*4:=MGXE]ME'!YP*.VW\_P*[G=OX"W''OW;OC2 MO*C1:.&^:FMG.@"@C2"O&-YL;IH5L:9Y&W\GD*?9.R19. MAMA>:V'>CJ!PR.B6OCN>9-VXX&!YVHD:?H+[U9V,M]C,4DH-K978$@-51N^V MAV,2XF/ ;PF#79Q)J.2,^!R,[V5&-T$0*"A<8!!^N\ ]*!6(O(R7B9/.*0-P M>7YG_Q9K][6! MRL:5%+UUJ"<6+T6+UW&7;=R'\88G$VP=P"< GP'[F(>-B:+RK\*)/#4X$#/V MOA/AB;<'[GM3!&=L1;SSXJWW7O+ME^N470+1%',<8_@R9HY@GGU.P==2'/E_ M<+X.WZTJW$7X[H/"FW6"9)4@B03)!X+;3R6NQ>P_)6&+GFHP=9PF2PKLVSC) M"^\\L'<\OLF_\'':'X6I96O)&9U_V=C_"M&!E[*Y\B/4^ \V&PHJ%XZW_FS& M,1L-A]WT@]C\C?._4$L#!!0 ( "6+;D^PCO7KM0$ -(# 9 >&PO M=V]R:W-H965T3L<^N!_#D14GM2MI[/QP9 M]+>DM) RT?I7\TTV=8ZGE'R5+\5[B"Q/"@!'/41KJX MDGITWJB%!:4H_C+O0L=]FF_RPP+;!V0+(%L!MS$/FQ-%Y1^YYU5AS43LW/N! MAR=.CQGVI@[.V(IXA^(=>J]5>G=7L&L@6F).JF2;GBJP79PF1VHSZCC)&^\Z ML/=9?)._X?.T?^.V$]J1B_'XLK'_K3$>4$IR@R/4XP=;#0FM#\+;SF,V& M-\/R@]CZC:L_4$L#!!0 ( "6+;D]4?$,-M@$ -(# 9 >&PO=V]R M:W-H965T(,R*7[]P.29FF7+X"-W_.S,?F$YMEV (Z\:-7;@G;.#4?&;-6! M%O8&!^C]38-&"^=-TS([&!!U!&G%>)+<,2UD3\L\^LZFS'%T2O9P-L2.6@OS MYP0*IX(>Z*OC2;:="PY6YH-HX3NX'\/9>(NM++74T%N)/3'0%/3A<#QE(3X& M_)0PV0:E Y&7\7CCIFC( M^=7]D^Q M=E_+15AX1/5+UJXKZ#TE-31B5.X)I\^PU'-+R5+\5[B"\N%!B<]1H;)Q)=5H M'>J%Q4O1XF7>91_W:;Y)TP6V#^ +@*^ ^YB'S8FB\H_"B3(W.!$S]WX0X8D/ M1^Y[4P5G;$6\\^*M]UY+GJ0YNP:B)>8TQ_!-S&&-8)Y]3<'W4ISX?W"^#T]W M%:81GKY1F.T39+L$623(WA#PMN:#S+QO[WR Z\%*2&S]"G?]@JZ&@<>'XP9_-/&:SX7!8 M?A!;OW'Y%U!+ P04 " EBVY/X2$9UK3DFD7J=IDS;IU&G= M9RYQ$E2(,R"7[M\/2)JE7;X -G[/S\9D(YIGVP(X\J)59W/:.M-)\H%I(3M:9-%W-D6&@U.R@[,A=M!:F#\G M4#CF-*6OCD?9M"XX6)'UHH$?X'[V9^,MMK!44D-G)7;$0)W3^_1XVH?X&/ D M8;2K,PF57!"?@_&URFD2!(&"T@4&X;X@O+A08G/4:*R<27E8!WJ MF<5+T>)EVF47]W&ZN>4S;!O 9P!? (>8ATV)HO)/PHDB,S@2,_6^%^&)TR/W MO2F#,[8BWGGQUGNO!4_N,G8-1'/,:8KAJYATB6">?4G!MU*<^']PO@W?;2K< M1?CNC<+#-L%^DV ?"?9O"#Z^*W$C)DW>)6&KGFHP39PF2TH&PO=V]R:W-H M965T?2=3)GKP0FNX&20':1DYO4( M0H\%3O";XY&WG0L.4N8]:^$GN%_]R7B++"PUEZ LUPH9: I\DQR.68B/ ;\Y MC'9U1J&2L]9/P;BO"[P+@D! Y0(#\]L%;D&(0.1E/,^<>$D9@.OS&_M=K-W7 MU,%9VQ%O//BK?=>2IHD.;D$HCGF.,705)(_X'3;7BZJ3"- M\/2#PO\09)L$623(/A"DGTKH\Q]L,00T+AR_^K.9QFPRG.[G'T26 M;US^!5!+ P04 " EBVY/J!4[%[_=N^-(!S3/M@%PY%6KUF:T<:X[,&:+!K2P5]A! MZV\J-%HX;YJ:V0I]D[)%DZ&V%YK8=Z.H'#( M:$+?'4^R;EQPL#SM1 T_P?WJ3L9;;&8II8;62FR)@2JC=\GAN OQ,>"WA,$N MSB14QLO$2>>4 ;@\O[-_B[7[6L[" MPCVJ/[)T34;WE)10B5ZY)QP>8*KGFI*I^!]P >7#@Q*?HT!EXTJ*WCK4$XN7 MHL7KN,LV[L-XP[],L'4 GP!\!NQC'C8FBLJ_"B?RU.! S-C[3H0G3@[<]Z8( MSMB*>.?%6^^]Y#RY3MDE$$TQQS&&+V*2.8)Y]CD%7TMQY/_!^3I\NZIP&^'; M#PIOU@EVJP2[2+#[0'#[J<2UF/VG)&S14PVFCM-D28%]&R=YX9T']H['-_D7 M/D[[HS"U;"TYH_,O&_M?(3KP4C97?H0:_\%F0T'EPO'6G\TX9J/AL)M^$)N_ M&PO=V]R:W-H965T MX-68X$J++%@33=W* MWI[44@EFK*D:H@<%K/)!@A,:1036\Z^&LD+X*P=2?$W Y MYCC&[XZ7KFF-YDCQ34.7Z(CZ?4X3W@9P>C M7NV1J^0BY:LSOE0YCEQ"P*$TCH'9Y0:/P+DCLFG\GCGQ(ND"U_MW]F=?NZWE MPC0\2OZKJTR;XWN,*JC9E9L7.7Z&N9X$H[GXKW #;N$N$ZM12J[]%Y57;:28 M66PJ@KU-:]?[=9Q.DG0."P?0.8 N ?=>ATQ"/O,G9EB1*3DB-=W]P-POCH_4 MWDWIG/XJ_)E-7EOOK:#QIXS<'-&,.4T8NL+$"X)8]D6"AB1.]+]P&@[?!3/< M^?#=6CW=A0GV08*])]BO]6FT*3&$^:#()"B2! CH1B2$^:"20U#D$"#8;T1" MF"0LD@9%T@#!82,2PJ0;$;)Z@@)4XYM/HU)>>]_X*^_2WP_4/^%_\&DX?&.J MZ7J-+M+81O#/M9;2@$TENK.WVMIYM!@<:N.VJ=VKJ2LGP\AA'CADF7K%7U!+ M P04 " EBVY//WJG,;UM8Q)4_;>_M.>=^]#:?C'UR'8 GSUKUKJ"=]\.),5=UH(6[,P/T>-,8JX5' MT[;,#19$'4E:,9XD;YD6LJ=E'GT76^9F]$KV<+'$C5H+^_L,RDP%3>F+XU&V MG0\.5N:#:.$;^._#Q:+%5I5::NB=-#VQT!3T/CV=LX"/@!\2)KX@4)XR 1C5$:YN))J=-[H1053T>)YWF4? M]VF^R=*%MD_@"X&OA&.,P^9 ,?,/PHLRMV8B=N[](,(3IR>.O:F",[8BWF'R M#KVWDO-CSFY!:,&<9PS?8-(5P5!]#<'W0ISY?W2^3S_L9GB(],,V^C';%\AV M!;(HD/U3XOM7)>Y@#LFK(&S34PVVC=/D2&7&/D[RQKL.[#V/;_(7/D_[5V%; MV3MR-1Y?-O:_,<8#II+&PO=V]R:W-H965T:9M<<7A8L#>)W^ M?0?L==S4+\ ,YYRY,*2#L:^N ?#D74GM,MIXWQT8R>6IZ+UL-)TM;0_'7F; MC.XI*:$2O?3/9GB$J9XOE$S%?X<+2(2'3#!&8:2+*REZYXV:5# 5)=['O=5Q M'\:;VRMMG< G I\)^TA@8Z"8^3?A19Y:,Q []KX3X8FW!XZ]*8(SMB+>8?(. MO9><)]N478+0A#F.&+[ ?" 8JL\A^%J((_^/SM?IR6J&2:0GR^C[_;K ;E5@ M%P5V_Y3(/Y6XADD^!6&+GBJP=9PF1PK3ZSC)"^\\L'<\OLD'?)SV'\+6K7;D M;#R^;.Q_98P'3&5S@R/4X >;#0F5#\>O>+;CF(V&-]WT@]C\C?._4$L#!!0 M ( "6+;D_6F.%CN0$ -(# 9 >&PO=V]R:W-H965T("7J=_WP$[ MKI7X!9AASIDSPY!/QCZ[#L"3%R6U*VCG_7!BS%4=*.'NS :;QICE?!HVI:Y MP8*H(TA)QI/D U.BU[3,H^]BR]R,7O8:+I:X42EA_YY!FJF@!_KJ>.K;S@<' M*_-!M/ #_,_A8M%B*TO=*]"N-YI8: KZ<#B=LQ ? W[U,+G-F81*KL8\!^-K M7= D" ()E0\, K<;/(*4@0AE_%DXZ9HR +?G5_;/L7:LY2H)EWGL=]VF^ MR=(%M@_@"X"O@/N8A\V)HO)/PHLRMV8B=N[](,(3'TX<>U,%9VQ%O$/Q#KVW MDJ=9SFZ!:(DYSS%\$W-8(QBRKRGX7HHS?P?G^_!T5V$:X>D6GB3[!-DN018) MLJW\Y/BFQ/V[;4C M5^/Q96/_&V,\H)3D#D>HPP^V&A(:'XX?\6SG,9L-;X;E!['U&Y?_ %!+ P04 M " EBVY/5\%I(<4! W! &0 'AL+W=OX+A]^P%V M/2]C?PPMM?V!$%.V()BY43U(MU,K+9AU2]T0 MTVM@52 )3FB2W!+!.HF++,1.NLC48'DGX:21&81@^OT(7(TYWN"/P$O7M-8' M2)'UK(%O8+_W)^U69%&I.@'2=$HB#76.[S>'8^KQ ?"C@]&LYLA7 MJQPG/B'@4%JOP-QP@0?@W NY-'[-FGBQ],3U_$/]2ZC=U7)F!AX4_]E5MLWQ M'J,*:C9P^Z+&KS#7DV(T%_\$%^ .[C-Q'J7B)GQ1.1BKQ*SB4A'L;1H[&<9Q MVDGI3(L3Z$R@"V$??,AD%#+_S"PK,JU&I*>S[YF_XLV!NK,I?3 <1=ASR1L7 MO11T>YN1BQ>:,<<)0U>8S8(@3GVQH#&+(_V'3N/T;33#;:!OU_1D'Q?8105V M06#W5XEW5R7&,/\Q2:,F:43@TY5)!+-+KDS(ZN($Z"8\68-*-&ULC57;CILP$/T5Q 4_;**P#AO#6DY0NW$J*;>QXO M*V@P?Z =M/+-GK(&"SEE!X]W#/!.DQKB(=]/O ;7K5OD.K9A14Z/@M0M;)C# MCTV#V=\E$-HOW,!]#[S4ATJH@%?D'3[ #Q _NPV3,V]4V=4-M+RFK<-@OW ? M@_E3IO :\*N&GE^,'57)EM)7-?FZ6[B^,@0$2J$4L'R<8 6$*"%IX\^@Z8XI M%?%R_*[^K&N7M6PQAQ4EO^N=J!9NYCH[V.,C$2^T_P)#/;'K#,5_@Q,0"5=. M9(Z2$J[_G?+(!6T&%6FEP6_F6;?ZV9LW43S0[ 0T$-!("#XFA ,AO)<0#83H M7D(\$.(S(=++:VK7B[G& AC562SND26%-&-#1LFOK%AP5PC MGJ:(-+8[#:V+&FI^=.4BN7%A,(G&M&8QP@@%L]B_,3,%^G8OD=5+=(>7:)(" M);.9/[$RQ?W'2FRU$ENLI':!Q"J0?%[+,IG6DOKJ9T^46A.EED2972"S"F2? M.UUEMA-@L^I=?,P-L(/NK-PIZ;$5ZIA>1,?F_8A4,[B)KV53-SWX+&-NA.^8 M'>J6.ULJ9*O1#6%/J0#ITW^0^U;)2VB<$-@+-4SEF)E6;":"=L,MXXU77?$/ M4$L#!!0 ( "6+;D^OU7=2U0( #@* 9 >&PO=V]R:W-H965TNSL,W/3,^*O84RJ#MZ9NQ2S<2WF81)%8[VE#Q!T[ MT%:]V3+>$*FF?!>) Z=D8YR:.H)QC*.&5&TXGQK;(Y]/V5'654L?>2".34/X MOP6MV7D6@O#=\%3M]E(;HOGT0';T%Y7/AT>N9M' LJD:VHJ*M0&GVUEX#R8K M@+2#0?RNZ%F,QH%.Y86Q5SWYOIF%L8Z(UG0M-051CQ-=TKK63"J.OSUI.&AJ MQ_'XG7UEDE?)O!!!EZS^4VWD?A;F8;"A6W*LY1,[?Z-]0FD8]-G_H"=:*[B. M1&FL62W,?[ ^"LF:GD6%TI"W[EFUYGGNWB#E?7 A$"67F-+%@ $1J2"'2*$OT@5T M)2X%EBXB2ZTX/23(PI2?"JUN"EVDDGB+GAA_-%9(8ZOH'08;3&LP20ICG.16 MTBXN2](\L]:P=&$(9:!(+-S*Q<$$%Q 4_OR0-S_DR0]8^2%7""!5!FLUEBX. MQ%D1QU8=R@Z7CNN5%QBGF96@RY= G*5%YD\P]2:8>A*$?@+L)< > FN_/&!W MR4"L?WZAS"N4??ZIE9E;NOB&4.X5RC]?\S)WU_)61H57J/ ((3\!B/UG7NRA ML$^*'C2N"HHQ1/B*U)7C%7BDKE%XS[U[ +\2+72B!5C'>T7*?RX!W\%T96, M_]8'OKWO1.MNUA3AW%:*1I=80_G.M" B6+-C*_71.K(.;@95^ R1)X M[*5NB\RE^4'?]50_"=]5K0A>F%17K[D@MXQ)JJ*/[U3<>]7 .:;J4>9FK, MNUZFFTAVZ/NT:&@6Y_\!4$L#!!0 ( "6+;D^RU!8(. ( !@' 9 M>&PO=V]R:W-H965T@1FEP.30N= M;'CG"3AN_??AI@H#$V 5/QJXREG?,ZGL.'\Q@\^'K1\8(F"P5\:"ZN8"%3!F MG#3'K]'4G_8T@?/^F_M'F[Q.9D&&ZKI^:C"#>1/LR]F;1G9]=TME+/7DI,L@)= MC-&H>1PT>*ZY551K140F"=( $P5V4F ;']]0Y N*09-836.09?%<=H,3.W%B!TZXP(E7^X0D7S!7 M:U&PVT"7760:".W(91?,_5QBG4;8L!FL9#M9' MBV8ERKP97ZDX-9WT=ESI:F=KTI%S!=HR>-#'4^MG:AHP."K3375?#+5Z&"C> MC^\0FA[#\@]02P,$% @ )8MN3[.$Z3_V 0 4 !D !X;"]W;W)K M&ULC53K;ILP%'X5Q /4!!Q218#4)*HV:9.B3EM_ M.W"XJ#9FM@G=V\\72BE!6_]@G^/O^\X%'R<#%R^R!E#>*Z.M3/U:J6Z/D,QK M8$3>\0Y:?5)RP8C2IJB0[ 20PI(816$0Q(B1IO6SQ/K.(DMXKVC3PEEXLF>, MB#\'H'Q(_8W_YGAJJEH9!\J2CE3P ]3/[BRTA2:5HF'0RH:WGH R]1\V^Q,V M> OXU< @9WO/5'+A_,487XO4#TQ"0"%71H'HY0I'H-0(Z31^CYK^%-(0Y_LW M]4=;NZ[E0B0<.7UN"E6G_KWO%5"2GJHG/GR!L9ZM[XW%?X,K4 TWF>@8.:?2 M?KV\EXJS446GPLBK6YO6KH,[B3\! 5';&I)?S MOE6F63/O-,8/H;E'"_]1C[>;QG<9]S9\)Z)J6NE=N-*WU-ZEDG,%.LG@3@]< MK9^CR:!0*K/=Z;UP0^D,Q;OQO4'3HY?]!5!+ P04 " EBVY/UON4=C4" M "F!@ &0 'AL+W=O]<)US0B2$NBJI5:*=JJ[;-#)@&MP=1VPO;OZPLA7+QI7\ >SCES9O E:2E[ MY06 <-XJ4O.-6PC1K!'B>0$5YD^T@5I^.5%682&G[(QXPP ?-:DBR%LL(E3A MLG;31,?V+$WH19"RACUS^*6J,/N3 :'MQEVZM\!+>2Z$"J T:? 9OH/XT>R9 MG*%>Y5A64/.2U@Z#T\9]7JYWL<)KP,\26CX8.ZJ2 Z6O:O+EN'$7RA 0R(52 MP/)UA2T0HH2DC=^=IMNG5,3A^*;^2=LL( M7D^0N1\1_([@WPG!0T+0$8([(=+=,J7HWNRPP&G":.LP\W<;K!;1 +,<(W9SA!>M>@R2#GH;GLU&YLT%QBFV M^%KOC^L<_5.%8%5(- "P:@-'R?--)A(8VICTEOY?CS! M;?\3M_LW;F0\M!H/Y\;CQ<2XP82#1!/$[A%B9"*RFH@L)B8++8MF*3[8VQ?- MVO*.E]CJ);9XF:S(+'Z0PC1DCK#_&S38K16PLSX)N9/32RW4@AY$^\/VV5.[ M?1+/ENNM.3/O,N8$_X;9N:RYAAK$< M,W-TFHF@37&PO=V]R:W-H965TN=I1Y*GI- M6PY'Z:F>,2+_[(&*(?,W_J7PW-:-M@64IQVIX3OH']U1FAV:5MX)Z$ M*O.?-KM#8O$.\+.%02W6GDUR$N+%;KZ4F1]80T"AT%:!F,<9#D"I%3(V?D^: M_MS2$I?KB_HGE]UD.1$%!T%_M:5N,O_1]TJH2$_ULQ@^PY0G]KTI_%J4%FU2,%49>QV?+W7.8]"^T=0*>"'@FF-[_(H03(7PC1"[\ MZ,Q%_4@TR5,I!D^.?U9'[)G8[$+S,0M;=-_.O3-IE:F><[P-4W2V0A-F/V+P M K.9$N]FQJ,XCX@F[0_T&'^?+-R+KEBOO)+2Y&NX 5T)H,$:" M!Q.Y,2-MWE"HM%UNS5J.%WO<:-%-,PO-@S/_"U!+ P04 " EBVY/L^L^ M$9D! !8 P &0 'AL+W=O%!NF MA32T+E/NX.K2GH.2!@Z.^+/6PKWM0=FQHBOZGGB2IS[$!*O+09S@-X0_P\%A MQ&:65FHP7EI#''05_;;:[=<1GP!_)8S^RB=QDJ.USS'XV5:TB() 01,B@T!S M@7M0*A*AC)>)D\XM8^&U_\[^(\V.LQR%AWNK_LDV]!6]HZ2%3IQ5>++C TSS M?*%D&OX77$ A/"K!'HU5/GU)<_;!ZHD%I6CQFJTTR8[YY'8[E2T7\*F SP4\ MSY(;)>7?11!UZ>Q(7-[](.(5KW8<=]/$9%I%.D/Q'K.7FF\W);M$H@FSSQC^ M ;.=,0SYYR9\L0E/!+ 9 >&PO=V]R:W-H965T8A8.6TNB7U.2U9TT-1_JHVQM2CWWFVJV[&F[K>3X*@>MV8/*V^ M%7NSL_]Y*\H\K>UC^1Y4^]*DZ]8HSP+!6!CDZ78WGDW;MN=R-BT^ZFR[,\_E MJ/K(\[3\;VZRXG SYN-CP\_M^Z9N&H+9=)^^FS]-_=?^N;1/P:F7]38WNVI; M[$:E>;L9W_+)D]:-08OX>VL.U=GO43.4EZ+XU3RLUC=CUD1D,O-:-UVD]NO3 M+$R6-3W9./YUG8Y//AO#\]_'WN_;P=O!O*256139/]MUO;D9Q^/1VKRE'UG] MLS@\&#<@/1ZYT3^93Y-9>!.)]?%:9%7[=_3Z4=5%[GJQH>3I[^Y[NVN_#Z[_ MHQEN()R!.!EP?=% .@,YU$ Y _5EH"X::&>@AWH(G4$XU$/D#**A'F)G$ _U MD#B#9.@Z<'9<.3;4!S\M-A]L CO:TY %.N2Y0.+PAX-@^H@[B(BT-V#,D3>8>PSC3=P2PWB^ M'C!,Z$WB<"\*]I!X MN;_J,+K%[+ID4V?)WW.C<3<:N.':F_A5APG/W4@E>**]>!XAD.'!A'@P(1*, M3[ 0^!!ADC 02PCFAH@EPF.)D/GW!&$1 1\ZE%*!=1J(>X*X*)9Q2*1GC <> M(X'[*QJ#2=2,)=X,QDAVQW7"!]:#]@ 19&>68 MOH9^#D"!%:&5&Y_?UW']F @MYE",!;GFA(1RJ*% MWYP*(XJTO0<$A+),8V, MB3X(M>(#Y&K!H5XIS< J7$'UXR'DBF-Z1>B+(/1%(/KB:]Y*("1/+B2R($@N M(,DEF!H'PJNAVUU!B.0A'0ZA%P+JA63<]P7U0EQP1>B%@'KA[RKG LJ%/\MN M3RV1:H< 5TB//K ?/2% @J09,3>31""(:!@2.8EVE(@V[=.,:F("6D14%HD M(\J)("1#8)*A_8CA/JC-1"I>0EK$ &E9"B@:C2_"$R$: HJ&9-2A@A -"45# M,B^='QRH/S/V0[@B)$-BDN%M0NXEU(-8DB"X!(C.%%))$%PB1'<2XJE _62(I(T7R3!;XGP MFU-]$/R6D-](P,AY*+H0+\%OB?';W\))Y!0C$%F_CNO'1"B!1)2 ^^^1)#SO MM-MERIDB)$,ADL&)$J((+5 #M&"IH!8(>2E@0@[4@,/$4D&>\TL;(T4P72%, MYWYQ5$@UYQ>'1KVN&7*>4/"<$&)[C.NX?DR$>BA$/3A1L!4A"FK .YFY0E[* M1)<")M1#(>K!B9*C"%504!6 LT59'MLRRAQUE($V15&=J(6:X+#&BO['O_F M&I9])10GPM4$U37V.L!_+:PAU2^Y(HBN,:(+WQ6L^YHJD)H@N1Y \KE&RODE M1=$$Q_40CFO(W?X$NG>JUV#]B*BWMQC#N3]\Y " EIO@[&(F-^5[>P59C5Z+ MCUW=A'K6>KKFO!7-Q8[7ON"3.XZT?^>3>ZQ]R27M']%84M;'C9=_L>#,O-6-S\C^[OL[CZ[A[K8NWO= MX'2Y//L?4$L#!!0 ( "6+;D_NRSC)< ( ) ' 9 >&PO=V]R:W-H M965T"]*FLY"X]*-9,HDMLC MJZA\X@VK]9<]%Q55>BH.D6P$HSM+JLHHB>,TJFA1A_.IC:W%?,I/JBQJMA:! M/%45%7\6K.2760C":^"U.!R5"43S:4,/[#M3/YJUT+.H5]D5%:MEP>M L/TL M? :3%V+P%O"S8!A4*OK>OHO:OB_M%W*EC1.2CI#T!+WV/0+L"/"# M@.X24$= CZZ .P)V5HA:[[:8*ZKH?"KX)1#M<6BH.75@@O5V;4W0[H[]INLI M=?0\AX!,H[,1ZC"+%I,,, 3=0E8^!/2(2"?09Y&,9;%(/'IRN\#21Q#LY/!? MD9>[(C=IPM%B0QD\6BQ:064[=9((*@4].E#X,)1"1S//DP F,,@6/, MAP% <)+]8Q/0J#ODN8,@&Q? HP+X@?*T&#STG64(.M7Q43G [G[[H SDB5L: M'P5(EB?IN+%TU%@Z4IE\7(","I '*D/\@Q-G.'?^M*4/@P#IL^,4QX>E*$M! M[%3'A^5Y"K'[5T2#ZZ1BXF#O=AEL^:E6YF<91/OV\9R8Z\B)+\!D"4;B*]UN MVN[P(=_VJF]4'(I:!ANN]"5HKZH]YXKI[.,GO:U'W1[[2?2J<\F2?1V49Q[V_T^-)J %O,3LG1_:+B9?S4RGOO#;+ M/LU94:6\<$IVF+N/:+K%O@JHB=\INU6=:T>5\LKYF[KYOI^[OE+$,K83*D4B M/ZYLQ;),99(Z_NJD;CNG"NQ>?V3?UL7+8EZ3BJUX]B?=B]/6\^TZ+^O#5/0J+# MX "L W ;(.<>"R Z@'P&!*,!@0X(V@""1@-"'1!^=89(!T1&@-S?B87H)*CUP7!_LR[JD2:638,[C TZ"-K M&T$MX4D!K0H,J5AB*QSW)UC9! T-#7>3;.XGV=H(">%*"-A/4L<'O7XBHY\- M$]5,T0@-:$"H4;*-$4P"&AMEVQ@E?DB,23& M@F*H+<8W]LV:6C4;7^C-&-$3$8,B8J CYO+$=T6,$3T1$U#$!!!A.@+$1/ D MR(?MT0=2T($4 PZ+@!3FEUA#8_T:1?I"0)-]1!@08NY1#8T*&4/Z0F"/1%\Q M202XI*_^#)?47%<- ;@UD(\"W ;@$.J#_1IAIT2 59*A%+!7(MLL@8UC.YQ5 MD8W$9, "$>R!"#)!:^M$]Z6,(7TAL/\AP #MK4.M);1VC8T@8,_<3;0!$!(- M;Q;84!'@J&3@AQG!=H@ KR/8;,S$:C]%(3%[8U/$>MD"H(F/([,[-H6B(?_$ ML 5CR(+-)==0;SU#VRP@C-KK#F"!C6T +,3VVGN==_&8*HW_,/G LF MU?L/&PO=V]R:W-H965TF^4M*+P:RF[-4*BJH%B\< Z:-6=$^,42[7E9R0Z#OAH M2)2@, A21''3^F5N8GM>YNPB2=/"GGOB0BGF_S9 6%_X*_\]\-R<:ZD#J,P[ M?(9?(']W>ZYV:%0Y-A1:T;#6XW J_,?5>I=IO '\:: 7D[6G*SDP]J(WWX^% M'VA#0*"26@&KRQ6V0(@64C9>!TU_3*F)T_6[^I.I7=5RP *VC/QMCK(N_"^^ M=X03OA#YS/IO,-23^-Y0_ ^X E%P[43EJ!@1YM^K+D(R.J@H*Q2_V6O3FFMO M[\390',3PH$0C@25^QXA&@C1!R&^2X@'0KP@(%N*ZMT^WP_HE M6JUCU?U*!TVSS3W5'J&BUS**HAQ=M=" V5A,.,&L1@12ZF.*T)5B$][0PWF" M[2TB2^:0W2TD2MPF(F>=D>%'4Q-![!:(G0*Q$8AGC8H7C;*8U&!:@PD6E=Y# MS$PD3A.)P\2B4QN+228IPE2- ?5;M#2Y\1)&R1PXLY0Z+:4.2^G"4GIKZ:O+ MT>>XF:',:2AS&,H6AK+/'M3N'L*:0),C1H&?S?@27L4NK=1OZB0Z3LC'4!_1 M17RS6F_MH/N0L6/W)^;GIA7>@4DU ,PQ/3$F01D,'E2;:C7IQPV!D]3+3*VY MG7=V(UDWC'(T?D_*_U!+ P04 " EBVY/@CP0I_D! *!0 &0 'AL M+W=O&BV)C:9DG_OKX00G9)7[ ]/N?,G,%V,G'Q+%L Y;TPVLO4;Y4: MC@C)L@5&Y!T?H-<[-1>,*+T4#9*# %)9$J,H#((8,=+U?I;8V$ED"1\5[7HX M"4^.C!'Q-P?*I]3?^:^!QZYIE0F@+!E( S]!_1I.0J_0HE)U#'K9\=X34*?^ MP^Y8Q 9O 4\=3'(U]XR3,^?/9O&M2OW % 042F44B!XN4 "E1DB7\6?6])>4 MAKB>OZI_L=ZUES.14'#ZNZM4F_KWOE=!34:J'OGT%68_>]^;S7^'"U --Y7H M'"6GTGZ]"3)]S/&H@Y$[LCULTL3=#VSNYIMU)'+QG&]PFZ&*$9DSM,N,+L M%@32ZDN*<"M%'M[0P_<)BEO$8;^= 6^:P):/WYGXM"T0;0I$5B!:"T3!51<< M)K:8WG4ACL,/TNPWT^QOZXP^:&6\*1!OU'G5S#R^J3/"&%^Y*6Y1P54A:'6$ M&(C&WC;IE7SLE?E9J^ARH1]"OLFX5^('$4W72^_,E3[@]AC6 MG"O0!09WNEFM?IB6!85:F>E!SX6[GFZA^#"_/&AY_K)_4$L#!!0 ( "6+ M;D\[TM;FS0$ *@$ 9 >&PO=V]R:W-H965T*@D;25_'QZ*X+I\Z(O( M7<[.S%(DZUFJ%ST"F.25,Z$;-!HS[3#6W0B@SYT2][8')N4$;])%XIJ?1N 1NZXF< MX >8G]-!V0BO+#WE(#25(E$P-.C39K>O'-X#?E&8]=4\<9T^0:DS M! PZXQB('2[P"(PY(FOCS\*)5DE7>#W_8/_B>[>]'(F&1\E^T]Z,#;I'20\# M.3/S+.>OL/13H&1I_CM<@%FX=$A;V?B/O%FUUF]Z9S2;\5?LV:US9[:;?Y MML871[1@]@&376&RJEHQV/*O(EE4)/,$^5\B>9Q@&R781@B*&Y,$192@B!!4-SX#IO@_GV54IHS(W,<)JBA!%2%XN/%9_;.? MZ8T$OCID[@X_$76B0B=':>QY]:=JD-* 94OO;,.C?3;6@,%@W+2R&PO=V]R M:W-H965T0'J(F!IHH J6E5;=(F19VV M_G;@$JS:F-E.Z-Y^_J"(INX?['M][CGG^H-RDNI5]P F>1-\T!7JC1EW&.NF M!T'UC1QAL"N=5((:&ZH3UJ,"VOHBP3%)TULL*!M07?K<0=6E/!O.!CBH1)^% MH.K?'KB<*K1![XEG=NJ-2^"Z'.D)?H'Y/1Z4C?#"TC(!@V9R2!1T%;K?[/:% MPWO 'P:37LT3U\E1RE<7?&\KE#I#P*$QCH':X0(/P+DCLC;^SIQHD72%Z_D[ M^Y/OW?9RI!H>)']AK>DK=(>2%CIZYN993M]@[J= R=S\#[@ MW#GQ&HTDFO_ M39JS-E+,+-:*H&]A9(,?I[!2D+DL7D#F K(4D-!+$/+.'ZFA=:GDE*BP]R-U M1[S9$;LWC4OZK?!KUKRVV4N=%6F)+XYHQNP#AJPP9+M=,-CR+R(D*D(\0;8F M2._B!%F4(/,$^0>7FRN7 7/K,4/ I&D:5\FC*GE$A5RIY)]4"O*E3!&5*2(R MV95,#)-?B>#5&;LG]).J$QMTF,)>_MJEX!#9]QT:^K$;\X! _! &0 'AL M+W=OL!P* 7SH2N\&#, M="1$-P-PJN_D!,*>=%)Q:JRI>J(G!;3U09R1+$GVA--1X+KTOK.J2WDU;!1P M5DA?.:?J]PF8G"NVPHD3! P:XQBH76[P"(PY(BOCU\*)UY0N M<+M_9?_H:[>U7*B&1\E^CJT9*GR/40L=O3+S).=/L-138+04_P5NP"S<*;$Y M&LFT_T?-51O)%Q8KA=.7L(["KW,X*=(E+!Z0+0'9&I"%6D(BK_P#-;0NE9R1 M"G<_4??$Z3&S=],XI[\*?V;%:^N]U;NB*,G-$2V84\!D&\PA7R'$TJ\YLEB. M4_8N/CL)H^FR2-I_J.SB!(4$8+[ M-SJ+=SIW:40HV3P@!]7[UM6HD5?AQV;C7:?C(?,-\!<>1NLK5?TH-+I(8]O( M/W8GI0&K)KFS<@8[S:O!H#-N>[![%7HZ&$9.R[B2]9M1_P%02P,$% @ M)8MN3]&_V1-]0@ -@L! !0 !X;"]S:&%R9613=')I;F=S+GAM;.U]VW+; M2)+H\ZFOJ/!Q[\H1()LWW=PS'2'+4K>V;(!*4, 8!-D!*UL;Y M^).7N@)5)&6[Y[SLP_3(!%"5E965]\SZ2].LY+K,_UAGI]6Z7/WUQ7C_^(7\ MLBC*YJ\O[E>KY>L??VRF]]DB;?K5,BOAR;RJ%^D*_EG?_=@LZRR=-?=9MEH4 M/XX&@X,?%VE>OOCY+TW^\U]6/[^MINM%5JYD6L[D6;G*5T_RHN01\JJ4/=G< MIW76_.7'U<]_^1&_X>^.Y?NJ7-TW\,TLF[6?7F?+OAP/$CD:#(_;#R^KA[X< M'(4?&GA.PO#\U\EMLZK3Z>K_1+^\>5IF[8?#0>]O[=].X.T9?7%>I'?MI_.T M:#K#F#D^9'5>(8 S^39===[3ZQ?_ZW]M7.1YWDS30OYGEM;R''[LH'F7KQ4L MP>__-F[_HG#Z,;O+$9$PS&6ZZ"S@'UF9K?*I?)-7S33/RFG6)+ /TWYDN%. MIP98+H :OLC?LJ?V>X/!8+@_GNR/]MM/3M=UW<9%#*^]WG#4&P\C0)SG15;+ M4_CNKJH[$%Q692^=3C-X!]Z8\=NQY52+!1#;]:J:?D[D-9T >;5>-2LX)GG9 M(1:]ACI;5O4*7I#PYJJ['?_9/4AJQNM%6A3RS;K)RZSIO+2JUQU/J_O(6Q?E*L-3DS]DB-A4*HBCKT^K&I;"9^X:UI))8C\UXF;6@>7R M]PU;(B_7B]LNJH$@>N/#X_%A!YD5$%'9P!;!7TU5Y#/:KS=ID0(=PFX +VOD MWJ/(*F-2GZ[=R[^6KSE')IG .A\1JCF*;EC8-#/BZ\SAM.MC\F,&9 MR:<(SC3P^ /L?YK/9/9EB0MHB*E6J_ONXF^J%=#ZU(.@.QKP\QJ0B*-D?ZSS M)9[Z1,+);+_Z2U7-'O.B:/^.QW&>EX"E7@%;/Y-Y"11\E]_"KH0GO4)H(\\8 MZ/ SCC)],ITE CE^E3"B $G@.=A]!G,.4,OQFE&UY\F\TS M>&DF5^D7\UZ'7?!P&X8AYG!?%;.L;OZ=]F?UU"4B9B0-,Y*7@SY0/2R_E@]I MLXG!P>#9'(TI!>.AH/D:/] CYLWS?K98R; T9IE1GRC>*(9QN-DH;+\\9NFZ9#%#(XY\"'8#CI=>0F';YG#]@0(:+U8%\0ND/"G>>>D MN*\HTJH6H"/= \4A<\R!\W7%X0TH4D^XZZ@_P'L462MB&Q)9A4DK,OI)=/3G\^2]#RD>Q'M4(](">?1+^6-$ MF?1/B3D>[==>2CP^FS_>NM3@ZWPX=GJUBFL!G2W8"DSGB^C:8V.'(8^]O0'X MR Z3[$>Y0P?Z:IFQ3K"C_!WO;"5TI+.:"GC)M&I6?%"T8.BP69#+H#9.[^FM M609P*O0R+#-3"B3-<1?!] \/4 H-/M@N_M=L''Y';J";Z+S8(ON JBN,Y.@V59 MEGAP;UDZ6#ZXDJY"WE'\ U\2+]SZX=F7K)[F38;4\9C6:-4V25C6H.?D=;-, MI]E?7\#JFZQ^R%[\+'<;,7&#R] J)->U>9VR-HT.:(>7),7)ZN)9=>@0,,70!W$#,%, MQ.]S/1:)T1BQ_9DS!LEPYPF7ZUN0-'_ZNG:=YGF+05.E*DNT;."WQWQU#Q.! MGI(R9\G+WK*NIAD(PCJBP3Q[8=]CRN B798(3*@W7Z-.MXW?;OELE[DT],^: MJ?O1\W;.\+MG;X#SY=8I70IL[UJ=(?O/U*@-Z%L[$<.SAWPV7M+9/]>@A,ZK MV@Z(0\FZ6BM%[/DHVV'0(* MA14^9A4'AC0BLZ6+R5GU6/*X0)'50XXR-N2+ MRE9*^,[^I$EV$YV= ,!.HK/SU5Y43WN:%.>GES_ M*L_?7?W]6IY_O'HOKSZ?&98)VDUNY+B7/>*;;ON=$]C.J*=Y@\?W_GUUO(]?!DIB.RAK;Y\ V(>L>2:DYQ>7)Y>G6R#%V98>M/E7JES?<>2XDKH9 MT5G ZML)O?.\!, VHY<^)+)G#W;#W*'>'%(ZC;R'O/?6\&4D#HH"/^=SE&31 M#Z\_??CP[NS]V>7-R3MI* .H]_SJXWM@MU>7P8 9>^A1BN?*6;5QX.O37\_> M?GIW)J_.Y>7598\F_+JJCNGH#9 M *_*D"4+H(E56M\A>X>M@TWJ8>POG\,LJS4H/:"'52E/U_C[D"-W!^::%@4( MP=F#XKDXJ5(W4(2G2UIYHV;!-Q"KG$0EW_3P=5'K=50*Y^MZGO(124N8A73] M-84<"49;-,+ X&N!^KO9Y560TWF5[,#I+<517JKY<;GZD'8<1'S#Y?O#G]U2'; M!J1/D6=T_L8=<_VH0CQ!<+3]7\H-W^!KY M[MVI^>KJPV]7Y@LK'<1*4X5[8MR-O@$>W*2DC'LS3L%T8:J7SBM(T_^Q!I3C M0BGJCM:.2HPP!(%LH2 35S#1ITM@"U_R!3*?E\-]N8%?J1PU5 M7Y[#MJ4V<)$[N7N@EJ7U3)]'!^!$-%DF+X%VY(1&'@Y_TC.0>=70<$U?32-M M9*2 XZ,XK@"B+#(*%^$<.2K\H# )&\"1G]?H.3AKFP<"_-(]*Y(>J>((1 MI&*!\J0Q^OWJ'H;\VSJM@3Z*)_&1LKL0N^?(W3"GT&RM>4OR6_:HK$N2KF1= M/*)X1>8R17X/W!:(FR0F"1();V0X;25]69)H8=*5)/J1_OE1\P()^Z!^6S?Z M-YH+QX^+,20K1-WC?85Y8B3U>:5BXRKU/_=_ZK^2[?(%^@;:4E9]^,Y@6Q 4 MNATR&/LAPD, MNJR^P-;?Z%.'[[1G4B_9#>U"F3@)RK#!=BA>-I(&,* &6.:U^A>&,9J#.22+/,,OQ M'X01I3/ #!>+M?.3>+S/4<,%S7?-#(J(H8+9_#.E3DM?GA2%DX^#PCYES]EL M#>9;F2XR%+U/('6DLS;83]QPFSVDOH9]%,3H& YXYXF 7VI0G=+-NO+7RI$ M &B5TZQF??)]6J9WQ/NUM!Z3IC,#%_V0T.#!9YDH-GCU@ M1.1VAE^!_I1\(6C3NSODA*L,#PG8876*7 'I=)6R[)Q5ZUNP8&X97^:P&:B4 MZ<+:-7Q2HB\.E;^[BA,F>$V( ?((9?()LVK3^8H!ENB'X\GQ7W.C-S=6;\85 M<7*)KX.!52!REB8S#VCTH@%>0*<$0LO)$$<52ROKZ&J9LO?-P Q_TU".(T6- MHE!5 M@] 'I!, "60$<#I:T1FW&&L^^&(W]M2J5IY"A>+OJ*,_8,JZPS) MK0+["&A,,[DE0$U)E5I6UD"Z^0-BF=.YC/1L4-L#0(W'@$A$L0Y?=VL2XVA> MINCVF6M/.*JM2'=BD8$,W;I$H_TT>;!K+T?]0S,"',_2]>*@YF]G)L \/:4%&"LH2K_1FH;TIQN.^Q.QZWSQ MO5XQ=7F;LH;99U9?:AU"(.B49GQ<8+$/LV7Q(& /I$C@E4U*T"5)QG+9]#Z.^O%XO%JBRHF?% MVE!2^;'Q8Q#&0 ==)V/@E0T>D*^?YUE 2O+8UP:3E,>6+T307Q.G,.%26%AH M/:(L-L2EC&E]=HCXR7!7!+,N%,D#I\/,*!;=K%)<9R"7;(KNF?(@"LR- ;&( M*S$JW=FI:Y0E^N152SA:O.*%T2 22\[ *DJTC0H% \I4HDJ'QLL,A0^B&4\O M^[O$/,U1=5*:#]"?@3IGS"J?;H-T^0BG]C2K5Q@;5:L2K:Y9WJ 8 M6&,TD&$JGC2@I+>$L"T,HN$%W+)Z1@8^<4Q29-E4)V?-%'4!9%26/$!"PI!+ MW 3+&2P_02$'2BF)/V?GFC4(,D Y;Y]H;5_?4=:Z+-Y;YR*=L=[F,NM%^CE3 MF+2H4G@'0) =P?8768J"F-BAT%N@/4#M/< I\#N]E3FAEDQ 5%@QLM<:8;X& MTD"-C?EMF,7:+1'. 4!& SL-CY4MJ3C3+9)*.E-QO7^NRZGO'=I^M!#12"L- M:[RLNA%]"$7O;?EV4I;H0.M:S;^9E9):FE%"2*:4UF=&QK2<0 MZ8*'@*F$KX C,B]?"E>D:% M(Q15^3:)26&:V\RR-=&5G')GR+8M%.V]F8:+DE0)3SHN0&]BHDS104>3="*U'.A#%>J!"0?V"R; MUA1TTIM,]7"(H59M#@;DG"(:U]$6"/-8G]L5C\L+!J8B9BJ @+\&ODSD7OX* M+520*X"$2&HU"5/"'"M9:$?2J]U,4\8#QAAJ]N@!5]*T07$3&&&]] ;Y"6 M((+XZ.:TP9=LRFAH+W]X);X* MN6:+V[&\J98D4XK](:*W8$YLQUQ??MKB'U5DS&#Q:G0*H"04*_^7"5_RC\3( M!3%R9H X'J$+A%==J5I8=?Z)8\\+M'')/Q4X,U:+@O'1OB?Q;JC MJW>"CMA/O[7^:81[U#W\6BB'Z79'*>^;\8BR$Y#4)^T#5/EF+&!6-F#@XCM# MWV5)ZV?MQN*J+VW9R5NN"!&8AO%.EYY0,KSG%L"9X;U&<"V)20\SA2IH55!P M$ ]RN7,]C#9&'MMU+?'S*3H5+G*VKG7X1)-*"'A38Q, GYV =[ "EJ3DG$PU M$V(E&3Y&*<+RA$!C2):,>Y+EQ"2ZH!$+8=@2S+L K1]=I77&BGM9E3UT9K$3 M@PKEK:'UJ!D,>CEZ&@P.*5%L];[.,E9$02<2"RXM8]TO4FK*U:6=NJ @8NK, M+)(#;9C 8B;53BB+Q=*XQ8 M15I,M;6#@;OXBA+%;_.:!R&C-89CC.M3F/9D5I&A9NUX<8U[3%4@%UKA(K0B M.,:&%X[A;S]X4\'_&4OY_.3ZC0U5L](3_.S3DC08_=W)]2?S&4[=&QS*A*@> MF""A0NBH(7-L]Y'O7LN+!>9M9283]!(4DL6RJ)ZRC+E![PT) MU@_I$["A4$!-%+-FD">33T5%B4]!P%0+/.>(HA0,'U"ML%2)55)DAQ90IR*"6,-X?P!*N
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end XML 53 R25.htm IDEA: XBRL DOCUMENT v3.19.3

1. The Company (Details Narrative) - USD ($)
2 Months Ended 7 Months Ended 9 Months Ended

Mar. 07, 2019

Jul. 19, 2019

Sep. 30, 2019

Sep. 30, 2018

Proceeds from stock offering $ 13,421,950 $ 0

Proceeds from stock offering $ 2,699,050 $ 0

Public Offering [Member]

Proceeds from stock offering $ 2,700,000

Direct Offering [Member]

Proceeds from stock offering $ 13,400,000

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
No definition available.
+ Details

Name: xbio_ProceedsFromIssuanceOrSaleOfEquity2

Namespace Prefix: xbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=xbio_PulbicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=xbio_DirectOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R21.htm IDEA: XBRL DOCUMENT v3.19.3

5. Property and Equipment, net (Tables)
9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net
Property and equipment, net consists of the following:

September 30,
2019 December 31,
2018

Office and computer equipment $ 42,289 $ 42,289

Leasehold improvements – 26,841

Furniture and fixtures 14,738 20,263

Property and equipment – at cost 57,027 89,393

Less accumulated depreciation (55,437 ) (84,437 )

Property and equipment – net $ 1,590 $ 4,956

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }

11. Commitments (Details - Lease liabilities)	Sep. 30, 2019 USD ($)
Other Assets [Member]
Right-of-use assets	$ 26,701
Accrued Expenses and other current liabilities [Member]
Current lease liabilities	26,701
Other Liabilities [Member]
Non-current lease liabilities	$ 0

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Common stock, par value	$ .001	$ .001
Common stock, shares authorized	12,500,000	12,500,000
Common stock, shares issued	5,660,481	810,856
Common stock, shares outstanding	5,633,490	783,865
Preferred stock, shares authorized	10,000,000	10,000,000
Series B [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,804,394	1,804,394
Preferred stock, shares outstanding	1,804,394	1,804,394
Series A [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	970,000	970,000
Preferred stock, shares outstanding	970,000	970,000

2. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Preparation of Interim Financial Statements	*Preparation of Interim Financial Statements* The accompanying condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 29, 2019 and amended on April 30, 2019. These condensed consolidated financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As a result, the financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On June 25, 2019, the Company effected a reduction, on a 1 for 12 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every 12 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock were proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1 for 12 basis; and (iv) the number of shares of common stock into which each share of preferred stock could be converted were proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this Reverse Stock Split. Certain prior period amounts have been reclassified to conform to the presentation for the current period.
Principles of Consolidation	*Principles of Consolidation* The condensed consolidated financial statements of the Company include the accounts of Hesperix and Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.
Basic and Diluted Net Loss per Share	*Basic and Diluted Net Loss per Share* The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during each period, except where such non-participating securities would be anti-dilutive. For the three and nine months ended September 30, 2019 and 2018, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.
Recently Adopted Accounting Standards	*Recently Adopted Accounting Standards* In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, and that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 Revenue from Contracts with Customers. ASU 2018-07 was effective for the Company in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-04: Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment that eliminated the requirement to calculate implied fair value of goodwill to measure a goodwill impairment charge. Instead, the new guidance requires entities to take an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company no later than 2020. The Company adopted ASU 2017-04 in the first quarter of fiscal 2019. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Subsequently, in July 2018, the FASB issued ASU 2018-11, Lease (Topic 842): Targeted Improvements, which provides a number of practical expedients in transition. The Company adopted ASU 2016-02 effective January 1, 2019 and elected a package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of lease, classification of a lease or any initial direct costs. The Company has also elected to use the hindsight practical expedients. The adoption did not have a material impact on the Company’s condensed consolidated financial statements, resulted in an approximate $43,000 increase in total assets and total liabilities in our condensed consolidated balance sheet and did not have any effect on accumulated deficit at the beginning of 2019. See Note 11 for further information.

Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock [Member]	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Treasury Stock	Total
Beginning balance, shares at Dec. 31, 2017	3,090,742	753,659
Beginning balance, value at Dec. 31, 2017	$ 3,090	$ 754	$ 165,258,198	$ (145,933,137)	$ 253,734	$ (5,281,180)	$ 14,301,459
Exercise of warrants, shares		30,834
Exercise of warrants, value		$ 31	1,479,969				1,480,000
Conversion of Series B preferred stock to shares of common stock, shares	(316,348)	26,363
Conversion of Series B preferred stock to shares of common stock, value	$ (316)	$ 26	290
Share-based expense			1,123,000				1,123,000
Common stock awards to vendors			52,281				52,281
Net loss				(5,661,230)			(5,661,230)
Ending balance, shares at Sep. 30, 2018	2,774,394	810,856
Ending balance, value at Sep. 30, 2018	$ 2,774	$ 811	167,913,738	(151,594,367)	253,734	(5,281,180)	11,295,510
Beginning balance, shares at Jun. 30, 2018	2,774,394	810,856
Beginning balance, value at Jun. 30, 2018	$ 2,774	$ 811	167,590,260	(149,781,831)	253,734	(5,281,180)	12,784,568
Share-based expense			306,051				306,051
Common stock awards to vendors			17,427				17,427
Net loss				(1,812,536)			(1,812,536)
Ending balance, shares at Sep. 30, 2018	2,774,394	810,856
Ending balance, value at Sep. 30, 2018	$ 2,774	$ 811	167,913,738	(151,594,367)	253,734	(5,281,180)	11,295,510
Beginning balance, shares at Dec. 31, 2018	2,774,394	810,856
Beginning balance, value at Dec. 31, 2018	$ 2,774	$ 811	168,170,244	(153,233,595)	253,734	(5,281,180)	9,912,788
Issuance of common stock and warrants in registered direct offering, net of issuance costs, shares		86,667
Issuance of common stock and warrants in registered direct offering, net of issuance costs, value		$ 87	2,698,963				2,699,050
Issuance of common stock and warrants in public offering, net of issuance costs, shares		1,746,666
Issuance of common stock and warrants in public offering, net of issuance costs, value		$ 1,747	13,420,203				13,421,950
Issuance of common stock in connection with purchase of in-process research and development, shares		624,995
Issuance of common stock in connection with purchase of in-process research and development, value		$ 625	3,030,601				3,031,226
Exercise of pre-funded warrants, shares		492,417
Exercise of pre-funded warrant, value		$ 492	4,517				5,009
Exercise of purchase warrants, shares		1,889,602
Exercise of purchase warrants, value		$ 1,890	(1,890)
Issuance of common stock to vendor, shares		7,836
Issuance of common stock to vendor, value		$ 7	(7)
Issuance of warrants in connection with reverse stock split, shares
Issuance of warrants in connection with reverse stock split, value			63,536				63,536
Issuance of common stock to adjust for reverse split rounding, shares		1,442
Issuance of common stock to adjust for reverse split rounding, value		$ 1	(1)
Deemed dividend related to Series B Preferred Stock down round provision			5,284,379				5,284,379
Accretion of deemed dividend related to Series B Preferred Stock down round provision			(5,284,379)				(5,284,379)
Share-based expense			683,104				683,104
Common stock awards to vendors			47,427				47,427
Net loss				(11,604,778)			(11,604,778)
Ending balance, shares at Sep. 30, 2019	2,774,394	5,660,481
Ending balance, value at Sep. 30, 2019	$ 2,774	$ 5,660	188,116,697	(164,838,373)	253,734	(5,281,180)	18,259,312
Beginning balance, shares at Jun. 30, 2019	2,774,394	949,218
Beginning balance, value at Jun. 30, 2019	$ 2,774	$ 948	171,352,760	(155,938,245)	253,734	(5,281,180)	10,390,791
Issuance of common stock and warrants in public offering, net of issuance costs, shares		1,746,666
Issuance of common stock and warrants in public offering, net of issuance costs, value		$ 1,747	13,420,203				13,421,950
Issuance of common stock in connection with purchase of in-process research and development, shares		624,995
Issuance of common stock in connection with purchase of in-process research and development, value		$ 625	3,030,601				3,031,226
Exercise of pre-funded warrants, shares		450,000
Exercise of pre-funded warrant, value		$ 450	4,050				4,500
Exercise of purchase warrants, shares		1,889,602
Exercise of purchase warrants, value		$ 1,890	(1,890)
Issuance of warrants in connection with reverse stock split, shares
Issuance of warrants in connection with reverse stock split, value			63,536				63,536
Deemed dividend related to Series B Preferred Stock down round provision			1,404,932				1,404,932
Accretion of deemed dividend related to Series B Preferred Stock down round provision			(1,404,932)				(1,404,932)
Share-based expense			232,437				232,437
Common stock awards to vendors			15,000				15,000
Net loss				(8,900,128)			(8,900,128)
Ending balance, shares at Sep. 30, 2019	2,774,394	5,660,481
Ending balance, value at Sep. 30, 2019	$ 2,774	$ 5,660	$ 188,116,697	$ (164,838,373)	$ 253,734	$ (5,281,180)	$ 18,259,312

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 08, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	Xenetic Biosciences, Inc.
Entity Central Index Key	0001534525
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		5,755,141
Current reporting status	Yes
Entity Small Business	true
Entity Emerging Growth	false
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV
Entity File Number	001-37937

12. Related Party Transactions (Details Narrative)	3 Months Ended
12. Related Party Transactions (Details Narrative)	Sep. 30, 2019 USD ($)
Related party expenses	$ 40,000
Prepaid Expenses [Member]
Advanced payment	$ 310,000

7. Fair Value Measurements (Details Narrative)	Sep. 30, 2019 USD ($)
Fair Value, Inputs, Level 3 [Member]
Derivative instruments	$ 0

10. Income Taxes (Details Narrative) - USD ($)	9 Months Ended
10. Income Taxes (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0
Deferred tax assets, valuation allowance	26,200,000		$ 23,500,000
Net deferred tax liability	2,900,000		2,900,000
Unrecognized tax positions	$ 0		$ 0

9. Share-Based Expense (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
9. Share-Based Expense (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Share based compensation	$ 247,437	$ 323,478	$ 730,531	$ 1,175,281
Warrant [Member] \| Collaboration Agreements [Member]
Warrants outstanding	44,944		44,944		44,944
Weighted average exercise price	$ 124.90		$ 124.90
Warrants issued			0	0
Warrants exercised			0	0
Warrants expiration dates			December 2019 through May 2021
Employee Stock Options [Member]
Options granted			0	0
Options exercised			0	0
Share based compensation	$ 200,000	300,000	$ 700,000	$ 1,100,000
Non Employee Stock Options [Member]
Options granted			0	834
Options exercised			0	0
Share based compensation	$ 0	$ 1,000	$ 0	$ 36,000
Common Stock Awards [Member]
Other than options granted	7,153	375	9,026	1,627
Share based compensation	$ 15,000	$ 17,000	$ 47,000	$ 52,000

11. Commitments (Details Narrative)	Sep. 30, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payment	$ 3,000
Future minimim sublease rent payment	$ 52,000
Incremental borrowing rate	(10.20%)

1. The Company (Details Narrative) - USD ($)	2 Months Ended	7 Months Ended	9 Months Ended
1. The Company (Details Narrative) - USD ($)	Mar. 07, 2019	Jul. 19, 2019	Sep. 30, 2019	Sep. 30, 2018
Proceeds from stock offering			$ 13,421,950	$ 0
Proceeds from stock offering			$ 2,699,050	$ 0
Public Offering [Member]
Proceeds from stock offering	$ 2,700,000
Direct Offering [Member]
Proceeds from stock offering		$ 13,400,000